INVACARE (IVCRQ) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

DEI_Document

DEI Document	6 Months Ended
	Jun. 30, 2014	Aug. 04, 2014	Aug. 04, 2014
		Common Class B (Authorized 12,000 shares; 1,086 and 1,086, issued and outstanding in 2014 and 2013, respectively - no par	Common Class A [Member]
Document Information [Line Items]	'	'	'
Entity Registrant Name	'INVACARE CORPORATION	'	'
Entity Central Index Key	'0000742112	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Accelerated Filer	'	'
Document Type	'10-Q	'	'
Document Period End Date	30-Jun-14	'	'
Document Fiscal Year Focus	'2014	'	'
Document Fiscal Period Focus	'Q2	'	'
Amendment Flag	'false	'	'
Entity Common Stock, Shares Outstanding	'	1,084,747	31,058,292

Consolidated_Statement_Of_Comp

Consolidated Statement Of Comprehensive Income (USD $)	3 Months Ended		6 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Net sales	$331,312,000	$344,760,000	$640,381,000	$676,197,000
Cost of Goods Sold	237,379,000	251,203,000	461,200,000	489,056,000
Gross Profit	93,933,000	93,557,000	179,181,000	187,141,000
Selling, general and administrative expense	101,545,000	104,088,000	199,566,000	207,323,000
Charge related to restructuring activities	2,090,000	2,592,000	4,330,000	5,114,000
Interest expense	1,158,000	815,000	1,964,000	1,932,000
Interest income	-323,000	-74,000	-391,000	-181,000
Income (Loss) from Continuing Operations before Income Taxes	-10,537,000	-13,864,000	-26,288,000	-27,047,000
Income tax provision	3,075,000	10,625,000	5,300,000	3,150,000
Income (Loss) from Continuing Operations	-13,612,000	-24,489,000	-31,588,000	-30,197,000
Net Earnings from Discontinued Operations (net of tax of $50 and $60)	0	1,448,000	0	3,015,000
Gain on Sale of Discontinued Operations (net of tax of ($10,580) and $9,500)	0	10,580,000	0	49,902,000
Total Net Earnings from Discontinued Operations	0	12,028,000	0	52,917,000
Net Earnings (loss)	-13,612,000	-12,461,000	-31,588,000	22,720,000
Dividends Declared per Common Share	$0.01	$0.01	$0.03	$0.03
Income (Loss) from Continuing Operations	($0.43)	($0.77)	($0.99)	($0.95)
Income (Loss) from Discontinued Operations	$0	$0.38	$0	$1.66
Net Earnings (loss) per Share - Basic	($0.43)	($0.39)	($0.99)	$0.71
Weighted Average Shares Outstanding - Basic	32,017	31,902	32,015	31,902
Income (Loss) from Continuing Operations	($0.43)	($0.77)	($0.99)	($0.95)
Income (Loss) from Discontinued Operations	$0	$0.38	$0	$1.65
Net Earnings (loss) per Share - Assuming Dilution	($0.43)	($0.39)	($0.99)	$0.71
Weighted Average Shares Outstanding - Assuming Dilution	32,216	32,024	32,244	31,980
Other Comprehensive Income (Loss), Net of Tax	'	'	'	'
Foreign currency translation adjustments	-4,936,000	-7,738,000	1,712,000	-9,236,000
Defined Benefit Plans	'	'	'	'
Amortization of prior service costs and unrecognized gains (losses)	15,000	236,000	723,000	536,000
Amounts arising during the year, primarily due to the addition of new participants	0	0	0	-166,000
Deferred tax adjustment resulting from defined benefit plan activity	-7,000	-80,000	-187,000	-128,000
Valuation reserve (reversal) associated with defined benefit plan activity	9,000	74,000	23,000	124,000
Current period unrealized gain (loss) on cash flow hedges	483,000	-694,000	-101,000	883,000
Deferred tax benefit (loss) related to unrealized gain (loss) on cash flow hedges	159,000	39,000	243,000	-42,000
Other Comprehensive Income (Loss)	-4,277,000	-8,163,000	2,413,000	-8,029,000
Comprehensive Income (Loss)	($17,889,000)	($20,624,000)	($29,175,000)	$14,691,000

Consolidated_Statement_Of_Comp1

Consolidated Statement Of Comprehensive Income (Parentheticals) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Discontinued Operation, Tax Effect of Discontinued Operation	$0	$50	$0	$60
Discontinued Operation, Tax Effect of Income (Loss) from Disposal of Discontinued Operation	$0	$10,580	$0	$9,500

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current Assets	'	'
Cash and cash equivalents	$23,001	$29,785
Trade receivables, net	188,046	188,622
Installment receivables, net	1,508	1,562
Inventories, net	165,013	155,637
Deferred income taxes	2,246	2,761
Other current assets	38,601	41,172
Total Current Assets	418,415	419,539
Other Assets	39,489	45,936
Other Intangibles	58,627	62,584
Property and Equipment, net	99,586	106,149
Goodwill	463,703	462,226
Total Assets	1,079,820	1,096,434
Current Liabilities	'	'
Accounts payable	123,064	116,704
Accrued expenses	128,736	133,100
Accrued income taxes	13,583	12,259
Short-term debt and current maturities of long-term obligations	2,456	14,102
Total Current Liabilities	267,839	276,165
Long-Term Debt	53,660	31,184
Other Long-Term Obligations	114,939	118,276
Shareholders' Equity	'	'
Preferred Shares (Authorized 300 shares; none outstanding)	0	0
Additional paid-in-capital	237,212	234,620
Retained earnings	363,636	396,016
Accumulated other comprehensive earnings	127,569	125,156
Treasury shares	-93,885	-93,794
Total Shareholders' Equity	643,382	670,809
Total Liabilities and Shareholders' Equity	1,079,820	1,096,434
Common Class A [Member]	'	'
Common Stock, Shares, Issued	34,220	34,084
Common Shares (Authorized 100,000 shares; 34,220 and 34,084 issued in 2014 and 2013, respectively) - no par	'	'
Shareholders' Equity	'	'
Common Shares	8,578	8,539
Common Class B (Authorized 12,000 shares; 1,086 and 1,086, issued and outstanding in 2014 and 2013, respectively - no par	'	'
Common Stock, Shares, Issued	1,086	1,086
Shareholders' Equity	'	'
Common Shares	$272	$272

Balance_Sheet_Parentheticals

Balance Sheet Parentheticals (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Preferred Stock, Shares Authorized	300	300
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	3,164	3,158
Common Class A [Member]	'	'
Common Stock, Shares Authorized	100,000	100,000
Common Stock, Shares, Issued	34,220	34,084
Common Stock, Par or Stated Value Per Share	0	0
Common Class B [Member]	'	'
Common Stock, Shares Authorized	12,000	12,000
Common Stock, Shares, Issued	1,086	1,086
Common Stock, Par or Stated Value Per Share	0	0

Consolidated_Statement_Of_Cash

Consolidated Statement Of Cash Flows (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Operating Activities	'	'
Net Earnings (loss)	($31,588)	$22,720
Adjustments to reconcile net earnings to net cash provided by operating activities:	'	'
Gain on sale of businesses (pre-tax)	0	-59,402
Depreciation and amortization	18,221	18,929
Provision for losses on trade and installment receivables	1,143	1,603
(Benefit) provision for deferred income taxes	-33	-163
Provision for other deferred liabilities	297	126
Allocated Share-based Compensation Expense	2,470	2,574
Loss on disposals of property and equipment	82	135
Asset write-downs related to restructuring activities	1,163	0
Amortization of convertible debt discount	345	307
Changes in operating assets and liabilities:	'	'
Trade receivables	916	-8,429
Installment sales contracts, net	-644	-134
Inventories	-8,705	3,405
Other current assets	2,969	4,009
Accounts payable	5,989	-18,852
Accrued expenses	-3,089	3,004
Other long-term liabilities	-3,435	204
Net Cash Provided (Used) by Operating Activities	-13,899	-29,964
Investing Activities	'	'
Purchases of property and equipment	-6,898	-7,666
Proceeds from sale of property and equipment	3	9
Proceeds from Divestiture of Business, net	0	144,681
(Increase) Decrease in other long-term assets	4,944	-422
Other	24	-30
Net Cash Used for Investing Activities	-1,927	136,572
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	135,734	196,399
Payments on revolving lines of credit and long-term borrowings	-127,402	-318,963
Proceeds from Stock Options Exercised	132	0
Payment of dividends	-792	-791
Net Cash Provided (Used) by Financing Activities	7,672	-123,355
Effect of exchange rate changes on cash	1,370	-597
Increase (decrease) in cash and cash equivalents	-6,784	-17,344
Cash and cash equivalents at beginning of year	29,785	38,791
Cash and cash equivalents at end of year	$23,001	$21,447

Accounting_Policies

Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Accounting Policies	'
	Accounting Policies
	Nature of Operations: Invacare Corporation is a leading manufacturer and distributor of medical equipment used in the home or institutional setting based upon the Company’s distribution channels, breadth of product line and net sales. The Company designs, manufactures and distributes an extensive line of health care products for the non-acute care environment, including the home health care, retail and extended care markets.
	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the Company as of June 30, 2014, the results of its operations for the six months ended June 30, 2014 and changes in its cash flow for the six months ended June 30, 2014 and 2013, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a May 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the Company's financial statements. All significant intercompany transactions are eliminated.  The results of operations for the six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the full year.
	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
	Recent Accounting Pronouncements: In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-04, Liabilities (Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. This update requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, as the sum of a) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and b) any additional amount the reporting entity expects to pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. The Company adopted ASU No. 2013-04 in the first quarter of 2014 with no impact on the Company’s Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows.
	In July 2013, the FASB issued ASU No. 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists." ASU 2013-11 requires an entity to present an unrecognized tax benefit in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward, with limited exceptions. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. ASU 2013-11 was adopted by the Company on January 1, 2014 and did not have a significant impact on the Company's financial statements.
	In April 2014, the FASB issued ASU 2014-08 changing the presentation of discontinued operations on the statements of income and other requirements for reporting discontinued operations. Under the new standard, a disposal of a component or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the component meets the criteria to be classified as held for sale or is disposed. The amendments in this update also require additional disclosures about discontinued operations and disposal of an individually significant component of an entity that does not qualify for discontinued operations. This standard must be prospectively applied to all reporting periods presented in financial reports issued after the effective date. Early adoption is permitted for disposals that have not been reported in financial statements previously issued or available for issuance. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2014. If applicable, this standard will change the presentation of the Company's financial statements but will not affect the calculation of net income, comprehensive income or earnings per share. The Company plans to adopt ASU 2014-08 effective January 1, 2015.
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers." ASU 2014-09 requires a company to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. The guidance requires five steps to be applied: 1) identify the contract(s) with customers, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocated the transaction price to the performance obligation in the contract and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also requires both quantitative and qualitative disclosures, which are more comprehensive than existing revenue standards. The disclosures are intended to enable financial statement users to understand the nature, timing and uncertainty of revenue and the related cash flow. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospective with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new accounting guidance is effective for annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently reviewing the impact of the adoption of ASU 2014-09 on the Company's financial statements.

Discontinued_Operations_Discon

Discontinued Operations Discontinued Operations	6 Months Ended
	Jun. 30, 2014
Discontinued Operations [Abstract]	'
Discontinuted Operations	'
	Discontinued Operations
	On December 21, 2012, as part of the Company's globalization strategy, and to allow it to focus on its core equipment product lines, the Company entered into an agreement to sell Invacare Supply Group (ISG) and accordingly, the Company determined on that date that the "held for sale" criteria of ASC 360-10-45-9 were met. On January 18, 2013, the Company completed the sale of the ISG medical supplies business to AssuraMed, Inc. for a purchase price of $150,800,000 in cash. ISG had been operated on a stand-alone basis and reported as a reportable segment of the Company. The Company recorded a gain of $59,402,000 pre-tax in the first quarter of 2013 which represented the excess of the net sales price over the book value of the assets and liabilities of ISG, excluding cash. The sale of this business was dilutive to the Company's results. The Company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the first quarter of 2013. The Company recorded expenses related to the sale of $5,350,000, of which $5,227,000 were paid as of June 30, 2014. The net sales and earnings before income taxes of the ISG discontinued operation were $18,498,000 and $402,000, retrospectively, for the six months ended June 30, 2013.
	On August 6, 2013, the Company sold Champion Manufacturing, Inc. (Champion), its domestic medical recliner business for dialysis clinics, to Champion Equity Holdings, LLC for $45,000,000 in cash, which is subject to final post-closing adjustments. Champion had been operated on a stand-alone basis and reported as part of the IPG segment of the Company. The Company recorded a gain of $22,761,000 pre-tax in the third quarter of 2013, which represented the excess of the net sales price over the book value of the assets and liabilities of Champion. The sale of this business was dilutive to the Company's results. The Company utilized the proceeds from the sale to reduce debt outstanding under its revolving credit facility in the third quarter of 2013. The Company recorded expenses related to the sale of $2,130,000, of which $1,542,000 were paid as of June 30, 2014. The gain recorded by the Company reflects the Company's estimated final purchase adjustments.
	The net sales and earnings before income taxes of the Champion discontinued operation were $13,214,000 and $2,672,000 for the six months ended June 30, 2013, respectively. Results for Champion include an interest expense allocation from continuing operations to discontinued operations of $371,000 for the six months ended June 30, 2013 as proceeds from the sale were required to be utilized to pay down debt. The interest allocation was based on the net proceeds assumed to pay down debt applying the Company's average interest rates for the periods presented.
	The Company recorded an incremental intra-period tax allocation expense to discontinued operations for the six months ended June 30, 2013 representing the cumulative intra-period allocation expense to discontinued operations based on the Company's June 30, 2013 estimate of the projected domestic taxable loss related to continuing operations for 2013.
	The Company has classified ISG and Champion as discontinued operations for all periods presented.

Receivables

Receivables	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Receivables	'
	Receivables
	Accounts receivable are reduced by an allowance for amounts that may become uncollectible in the future. Substantially all of the Company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to providers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid in the U.S. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. The estimated allowance for uncollectible amounts ($16,022,000 at June 30, 2014 and $17,715,000 at December 31, 2013) is based primarily on management’s evaluation of the financial condition of specific customers. In addition, as a result of the financing arrangement with De Lage Landen, Inc. ("DLL"), a third party financing company which the Company has worked with since 2000, management monitors the collection status of these contracts in accordance with the Company’s limited recourse obligations and provides amounts necessary for estimated losses in the allowance for doubtful accounts and establishing reserves for specific customers as needed. The Company charges off uncollectible trade accounts receivable after such receivables are moved to collection status and legal remedies are exhausted. See Concentration of Credit Risk in the Notes to the Consolidated Financial Statements for a description of the financing arrangement. Long-term installment receivables are included in “Other Assets” on the consolidated balance sheet.
	The Company’s U.S. customers electing to finance their purchases can do so using DLL. In addition, the Company often provides financing directly for its Canadian customers for which DLL is not an option, as DLL typically provides financing to Canadian customers only on a limited basis. The installment receivables recorded on the books of the Company represent a single portfolio segment of finance receivables to the independent provider channel and long-term care customers. The portfolio segment is comprised of two classes of receivables distinguished by geography and credit quality. The U.S. installment receivables are the first class and represent installment receivables re-purchased from DLL because the customers were in default. Default with DLL is defined as a customer being delinquent by 3 payments. The Canadian installment receivables represent the second class of installment receivables which were originally financed by the Company because third party financing was not available to the HME providers. The Canadian installment receivables are typically financed for 12 months and historically have had a very low risk of default.
	The estimated allowance for uncollectible amounts and evaluation for impairment for both classes of installment receivables is based on the Company’s quarterly review of the financial condition of each individual customer with the allowance for doubtful accounts adjusted accordingly. Installments are individually and not collectively reviewed for impairment. The Company assesses the bad debt reserve levels based upon the status of the customer’s adherence to a legally negotiated payment schedule and the Company’s ability to enforce judgments, liens, etc.
	For purposes of granting or extending credit, the Company utilizes a scoring model to generate a composite score that considers each customer’s consumer credit score and/or D&B credit rating, payment history, security collateral and time in business. Additional analysis is performed for customers desiring credit greater than $250,000, which generally includes a detailed review of the customer’s financials as well as consideration of other factors such as exposure to changing reimbursement laws.
	Interest income is recognized on installment receivables based on the terms of the installment agreements. Installment accounts are monitored and if a customer defaults on payments and is moved to collection, interest income is no longer recognized. Subsequent payments received once an account is put on non-accrual status are generally first applied to the principal balance and then to the interest. Accruing of interest on collection accounts would only be restarted if the account became current again. All installment accounts are accounted for using the same methodology regardless of the duration of the installment agreements. When an account is placed in collection status, the Company goes through a legal process of adjudication which typically approximates eighteen months. Any write-offs are made after the legal process has been completed. The Company has not made any changes to either its accounting policies or methodology to estimation allowances for doubtful accounts in the last twelve months.
	Installment receivables consist of the following (in thousands):
		June 30, 2014									December 31, 2013
		Current			Long-			Total			Current			Long-			Total
					Term									Term
	Installment receivables	$	3,184		$	6,104		$	9,288		$	3,242		$	5,677		$	8,919
	Less: Unearned interest	(58		)	—			(58		)	(61		)	—			(61		)
		3,126			6,104			9,230			3,181			5,677			8,858
	Allowance for doubtful accounts	(1,618		)	(4,861		)	(6,479		)	(1,619		)	(4,420		)	(6,039		)
		$	1,508		$	1,243		$	2,751		$	1,562		$	1,257		$	2,819
	Installment receivables purchased from DLL during the six months ended June 30, 2014 increased the gross installment receivables balance by $1,688,000. No sales of installment receivables were made by the Company during the quarter.
	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):
		Six Months Ended June 30, 2014			Year Ended December 31, 2013
	Balance as of beginning of period	$	6,039		$	3,823
	Current period provision	705			3,457
	Direct write-offs charged against the allowance	(265		)	(1,241		)
	Balance as of end of period	$	6,479		$	6,039
	Installment receivables by class as of June 30, 2014 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	7,918		$	7,918		$	6,380		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,271			1,213			—			41
	Impaired Installment receivables with a related allowance recorded	99			99			99			—
	Total Canadian Installment Receivables	$	1,370		$	1,312		$	99		$	41
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,271			1,213			—			41
	Impaired Installment receivables with a related allowance recorded	8,017			8,017			6,479			—
	Total Installment Receivables	$	9,288		$	9,230		$	6,479		$	41
	Installment receivables by class as of December 31, 2013 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	7,464		$	7,464		$	5,951		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,367			1,306			—			101
	Impaired Installment receivables with a related allowance recorded	88			88			88			—
	Total Canadian Installment Receivables	$	1,455		$	1,394		$	88		$	101
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,367			1,306			—			101
	Impaired Installment receivables with a related allowance recorded	7,552			7,552			6,039			—
	Total Installment Receivables	$	8,919		$	8,858		$	6,039		$	101
	Installment receivables with a related allowance recorded as noted in the table above represent those installment receivables on a non-accrual basis in accordance with ASU 2010-20. As of June 30, 2014, the Company had no U.S. installment receivables past due of 90 days or more for which the Company is still accruing interest. Individually, all U.S. installment receivables are assigned a specific allowance for doubtful accounts based on management’s review when the Company does not expect to receive both the contractual principal and interest payments as specified in the loan agreement.
	In Canada, the Company had an immaterial amount of Canadian installment receivables which were past due of 90 days or more as of June 30, 2014 and December 31, 2013 for which the Company is still accruing interest.
	The aging of the Company’s installment receivables was as follows (in thousands):
		June 30, 2014									31-Dec-13
		Total			U.S.			Canada			Total			U.S.			Canada
	Current	$	1,235		$	—		$	1,235		$	1,338		$	—		$	1,338
	0-30 Days Past Due	4			—			4			7			—			7
	31-60 Days Past Due	5			—			5			—			—			—
	61-90 Days Past Due	—			—			—			—			—			—
90+ Days Past Due	8,044			7,918			126			7,574			7,464			110
	$	9,288		$	7,918		$	1,370		$	8,919		$	7,464		$	1,455

Inventories

Inventories	6 Months Ended
	Jun. 30, 2014
Inventory, Net [Abstract]	'
Inventories	'
	Inventories
	Inventories consist of the following (in thousands):
		30-Jun-14		31-Dec-13
	Finished goods	$	89,439	$	77,909
	Raw materials	62,635		63,123
	Work in process	12,939		14,605
		$	165,013	$	155,637

Other_Current_Assets_Other_Cur

Other Current Assets Other Current Assets	6 Months Ended
	Jun. 30, 2014
Other Current Assets [Abstract]	'
Other Assets Disclosure [Text Block]	'
	Other Current Assets
	Other current assets consist of the following (in thousands):
		June 30, 2014		December 31, 2013
	Value added tax receivables	$	19,044	$	19,699
	Recoverable income taxes	2,375		2,465
	Derivatives (foreign currency forward contracts)	780		789
	Prepaid insurance	1,258		4,556
	Prepaids and other current assets	15,144		13,663
		$	38,601	$	41,172

Other_LongTerm_Assets_Other_Lo

Other Long-Term Assets Other Long-Term Assets	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Investments and Other Noncurrent Assets [Text Block]	'
	Other Long-Term Assets
	Other long-term assets consist of the following (in thousands):
		June 30, 2014		December 31, 2013
	Cash surrender value of life insurance policies	$	31,861	$	36,522
	Deferred Financing Fees	451		1,096
	Investments	799		998
	Long-term installment receivables	1,243		1,257
	Long-term deferred taxes	3,894		4,741
	Other	1,241		1,322
		$	39,489	$	45,936

Property_And_Equipment

Property And Equipment	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property And Equipment	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		June 30, 2014			December 31, 2013
	Machinery and equipment	$	360,402		$	358,061
	Land, buildings and improvements	91,570			91,389
	Furniture and fixtures	13,013			12,774
	Leasehold improvements	15,616			14,931
		480,601			477,155
	Less allowance for depreciation	(381,015		)	(371,006		)
		$	99,586		$	106,149

Goodwill_Goodwill

Goodwill Goodwill	6 Months Ended
	Jun. 30, 2014
Goodwill Disclosure [Abstract]	'
Goodwill Disclosure [Text Block]	'
	Goodwill
	The goodwill change reflected on the balance sheet from December 31, 2013 to June 30, 2014 was due to foreign currency translation.

Other_Intangibles

Other Intangibles	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets Disclosure [Text Block]	'
	Other Intangibles
	All of the Company’s other intangible assets have been assigned definite lives and continue to be amortized over their useful lives, except for $31,783,000 related to trademarks, which have indefinite lives. The changes in intangible balances reflected on the balance sheet from December 31, 2013 to June 30, 2014 were the result of foreign currency translation and amortization. The Company's intangibles consist of the following (in thousands):
		June 30, 2014				December 31, 2013
		Historical		Accumulated		Historical		Accumulated
		Cost		Amortization		Cost		Amortization
	Customer Lists	$	92,050	$	68,206	$	92,637	$	65,158
	Trademarks	31,783		—		31,649		—
	License Agreements	1,419		1,419		1,393		1,393
	Developed Technology	9,944		7,510		9,916		7,191
	Patents	6,286		5,781		6,107		5,568
	Other	7,541		7,480		7,702		7,510
		$	149,023	$	90,396	$	149,404	$	86,820
	Amortization expense related to other intangibles was $4,353,000 in the first six months of 2014 and is estimated to be $8,519,000 in 2014, $7,091,000 in 2015, $5,682,000 in 2016, $2,289,000 in 2017, $2,276,000 in 2018 and $2,266,000 in 2019. Amortized intangibles are being amortized on a straight-line basis over remaining lives of 1 to 11 years with the majority of the intangibles being amortized over an average remaining life of approximately 6 years.

Current_Liabilities_Current_Li

Current Liabilities Current Liabilities	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Current Liabilities Disclosure [Text Block]	'
	Current Liabilities
	Accrued expenses consist of accruals for the following (in thousands):
		June 30, 2014		December 31, 2013
	Salaries and wages	$	34,778	$	40,252
	Taxes other than income taxes, primarily Value Added Taxes	24,863		24,525
	Warranty cost	26,084		27,393
	Freight	7,356		7,636
	Professional	8,166		6,516
	Product liability, current portion	3,410		3,183
	Rebates	2,133		1,681
	Insurance	2,502		2,549
	Interest	1,431		1,041
	Derivative liabilities	1,592		1,212
	Severance	3,491		3,986
	Other items, principally trade accruals	12,930		13,126
		$	128,736	$	133,100
	Accrued rebates relate to several volume incentive programs the Company offers its customers. The Company accounts for these rebates as a reduction of revenue when the products are sold in accordance with the guidance in ASC 605-50, Customer Payments and Incentives.

Warrany_Costs

Warrany Costs	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Current Liabilities	'
	Generally, the Company's products are covered by warranties against defects in material and workmanship for various periods depending on the product from the date of sales to the customer. Certain components carry a lifetime warranty. A provision for estimated warranty cost is recorded at the time of sale based upon actual experience. The Company continuously assesses the adequacy of its product warranty accrual and makes adjustments as needed. Historical analysis is primarily used to determine the Company's warranty reserves. Claims history is reviewed and provisions are adjusted as needed. However, the Company does consider other events, such as a product recall, which could warrant additional warranty reserve provision. The increase in the liability for pre-existing warranties in 2014 is primarily the result of product recalls. The warranty accrual as of June 30, 2014 includes additional warranty expense related to the power wheelchair joystick recall of $2,237,000 ($2,100,000 after-tax) provided for during the first quarter of 2014, which impacted the North America/HME segment by $1,171,000 after-tax and the Asia/Pacific segment by $929,000 after-tax. The increase in the Company's estimate of total cost related to this matter is attributable to higher than previously anticipated response rates from larger customers in United States and Canada. As previously indicated, the reserve is subject to adjustments as new developments change the Company's estimate of the total cost of this matter.
	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):
	Balance as of January 1, 2014	$	27,393
	Warranties provided during the period	6,964
	Settlements made during the period	(11,171		)
	Changes in liability for pre-existing warranties during the period, including expirations	2,898
	Balance as of June 30, 2014	$	26,084

LongTerm_Debt

Long-Term Debt	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Long-Term Debt	'
	Long-Term Debt
	Debt consists of the following (in thousands):
		June 30, 2014				December 31, 2013
	Senior secured revolving credit facility, due in October 2015	$	38,571			$	28,109
	Convertible senior subordinated debentures at 4.125%, due in February 2027	10,986				10,641
	Other notes and lease obligations	6,559				6,536
		56,116				45,286
	Less current maturities of long-term debt	(2,456		)		(14,102		)
		$	53,660			$	31,184
	On January 31, 2014, the Company entered into an Amended and Restated Credit Agreement ("the Amended and Restated Credit Agreement") by and among the Company, the other Borrowers party thereto, the Guarantors party thereto, the Lenders party thereto and PNC Bank, National Association, as administrative agent, which amended and restated the Credit Agreement, dated as of October 28, 2010, by and among the Company and the other parties named therein, as amended (the “Prior Credit Agreement”). The Amended and Restated Credit Agreement, among other things, provides for the following:
	•	An increase in the maximum leverage ratio for the first three quarters of 2014, with quarterly ratios as described in the following table:
	Fiscal Quarter Ending	Maximum Leverage Ratio
	31-Mar-14	4.75		to	1
	30-Jun-14	4.5		to	1
	30-Sep-14	4		to	1
	December 31, 2014 and thereafter	3.5		to	1
	The quarterly minimum interest coverage ratio remains 3.50 to 1.00 in the Amended and Restated Credit Agreement.
	•	In calculating the Company’s EBITDA for purposes of determining the leverage and interest coverage ratios, the Amended and Restated Credit Agreement allows the Company to add back to EBITDA up to $20,000,000 for one-time cash restructuring charges incurred after May 30, 2013, which is an incremental increase of $5,000,000 from the terms of the Prior Credit Agreement.
	•	A decrease in the aggregate principal amount of the revolving credit facility to $100,000,000 from $250,000,000 through the maturity date of the facility in October 2015, as well as reductions in the facility’s swing line loan, optional currency and foreign borrower sublimits.
	•	Reductions in the allowances under the facility for capital expenditures (down to $25,000,000 annually), dividends, other indebtedness and liens.
	•	Further restrictions on acquisitions, share repurchases, certain investments and repurchases of convertible debt until after the Company confirms compliance with the Amended and Restated Credit Agreement following the quarter ending December 31, 2014.
	•	An increase of 25 basis points in the margin applicable to determining the interest rate on borrowings under the revolving credit facility.
	As a result of the amendment, the Company incurred $351,000 in fees in the first quarter of 2014 which were capitalized and are being amortized through October, 2015. In addition, as a result of reducing the capacity of the facility from $250,000,000 to $100,000,000, the Company wrote-off $1,070,000 in previously capitalized fees in the first quarter of 2014, which is reflected in the expense of the North America / HME segment.
	In 2007, the Company issued $135,000,000 principal amount of Convertible Senior Subordinated Debentures due 2027. The debentures are unsecured senior subordinated obligations of the Company guaranteed by substantially all of the Company’s domestic subsidiaries, pay interest at 4.125% per annum on each February 1 and August 1, and are convertible upon satisfaction of certain conditions into cash, common shares of the Company, or a combination of cash and common shares of the Company, subject to certain conditions. The debentures allow the Company to satisfy the conversion using any combination of cash or stock, and at the Company’s discretion. The Company intends to satisfy the accreted value of the debentures using cash. Assuming adequate cash on hand at the time of conversion, the Company also intends to satisfy the conversion spread using cash, as opposed to stock.
	The Company may from time to time seek to retire or purchase its 4.125% Convertible Senior Subordinated Debentures due 2027, in privately negotiated transactions or otherwise. Such purchases or exchanges, if any, will depend on prevailing market conditions, the Company's liquidity requirements, contractual restrictions and other factors. The amounts involved in any such transactions, individually or in the aggregate, may be material.
	The liability components of the Company’s convertible debt consist of the following (in thousands):
		June 30, 2014				December 31, 2013
	Principal amount of liability component	$	13,350			$	13,350
	Unamortized discount	(2,364		)		(2,709		)
	Net carrying amount of liability component	$	10,986			$	10,641
	As of June 30, 2014, the weighted average floating interest rate on revolving credit borrowings was 2.28% compared to 2.39% as of December 31, 2013.

Other_LongTerm_Obligations_Not

Other Long-Term Obligations (Notes)	6 Months Ended
	Jun. 30, 2014
Other Long-Term Obligations [Abstract]	'
Other Liabilities Disclosure [Text Block]	'
	Other Long-Term Obligations
	Other long-term obligations consist of the following (in thousands):
		June 30, 2014		December 31, 2013
	Supplemental Executive Retirement Plan liability	$	26,984	$	27,049
	Product liability	17,292		17,185
	Deferred income taxes	35,393		36,328
	Deferred compensation	9,664		11,679
	Uncertain tax obligation including interest	15,897		15,524
	Other	9,709		10,511
	Total long-term obligations	$	114,939	$	118,276

Shareholders_Equity_Transactio

Shareholders' Equity Transactions	6 Months Ended
	Jun. 30, 2014
Stockholders' Equity Note [Abstract]	'
Shareholders' Equity Transactions	'
	Shareholders’ Equity Transactions
	On May 16, 2013, the shareholders of the Company approved the Invacare Corporation 2013 Equity Compensation Plan (the “2013 Plan”), which was adopted on March 27, 2013 by the Company's Board of Directors (the “Board”). The Board adopted the 2013 Plan because the ten-year term of the Company's prior equity plan, the Invacare Corporation Amended and Restated 2003 Performance Plan (the “2003 Plan”), expired on May 21, 2013. No new awards will be granted under the 2003 Plan following its expiration, but awards granted prior to its expiration will remain in effect under their original terms.
	The 2013 Plan uses a fungible share-counting method, under which each common share underlying an award of stock options or stock appreciation rights (“SAR”) will count against the number of total shares available under the 2013 Plan as one share; and each common share underlying any award other than a stock option or a SAR will count against the number of total shares available under the 2013 Plan as two shares. Any common shares that are added back to the 2013 Plan as the result of the cancellation or forfeiture of an award granted under the 2013 Plan will be added back in the same manner such shares were originally counted against the total number of shares available under the 2013 Plan. Each common share that is added back to the 2013 Plan due to a cancellation or forfeiture of an award granted under the 2003 Plan will be added back as one common share.
	The Compensation and Management Development Committee of the Board (the “Compensation Committee”), in its discretion, may grant an award under the 2013 Plan to any director or employee of the Company or an affiliate. The 2013 Plan initially allows the Compensation Committee to grant up to 4,460,337 common shares in connection with the following types of awards with respect to shares of the Company's common shares: incentive stock options, nonqualified stock options, SARs, restricted stock, restricted stock units, unrestricted stock, and performance shares. The Compensation Committee also may grant performance units that are payable in cash. The Committee has the authority to determine which participants will receive awards, the amount of the awards and the other terms and conditions of the awards.
	As of June 30, 2014, there was $15,415,000 of total unrecognized compensation cost from stock-based compensation arrangements granted under the Company's 2013 Plan and previous plans, which is related to non-vested options and shares, and includes $6,490,000 related to restricted stock awards, $6,148,000 related to non-qualified stock options and $2,777,000 related to performance share awards. Total unrecognized compensation cost will be adjusted for future changes in actual and estimated forfeitures and for updated vesting assumptions for the performance share awards (see "Performance Shares and Performance Share Units" below). No tax benefit for share-based compensation was realized during 2014 or 2013 as a result of a valuation allowance against deferred tax assets.
	The amount of amount of stock-based compensation expense recognized under the provisions of Compensation-Stock Compensation, ASC 718 was as follows (in thousands):
		For the Three Months Ended June 30,							For the Six Months Ended June 30,
		2014				2013			2014			2013
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	1,771			$	1,414		$	2,470		$	2,574
	Stock Options
	During the six months ended June 30, 2014, the Compensation Committee granted 8,977 non-qualified stock options. Generally, non-qualified stock option awards typically have a term of ten years and are granted at the fair market value of the Company’s Common Shares on the date of grant. Compensation expense of $1,356,000 was recognized during the six months ended June 30, 2014 related to stock options previously awarded. The Company expects the compensation expense to be recognized over a weighted-average period of approximately 2 years.
	The following table summarizes information about stock option activity for the six months ended June 30, 2014:
		June 30, 2014				Weighted
						Average
						Exercise
						Price
	Options outstanding at January 1, 2014	4,533,782				$	23.86
	Granted	8,977				16.71
	Exercised	(8,810		)		14.93
	Canceled	(179,241		)		19.98
	Options outstanding at June 30, 2014	4,354,708				$	24.02
	Options exercise price range at June 30, 2014	$ 12.42 to
		$	47.8
	Options exercisable at June 30, 2014	3,095,001
	Shares available for grant at June 30, 2014*	3,622,692
	________________________
	*	Shares available for grant as of June 30, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 387,068 shares and 440,600 shares, respectively during the quarter.
	The following table summarizes information about stock options outstanding at June 30, 2014:
		Options Outstanding									Options Exercisable
	Exercise Prices	Number			Weighted Average		Weighted Average				Number		Weighted Average
		Outstanding			Remaining		Exercise Price				Exercisable		Exercise Price
		At 6/30/14			Contractual Life (Years)						At 6/30/14
	$ 12.42 – $15.00	1,222,011			8.4		$	13.95			307,617		$	13.97
	$ 15.01 – $25.00	1,548,349			4.9		22.47				1,314,501		22.2
	$ 25.01 – $35.00	898,383			5		25.72				786,918		25.77
	$ 35.01 – $47.80	685,965			0.7		43.23				685,965		43.23
	Total	4,354,708			5.2		$	24.02			3,095,001		$	26.95
	When stock options have been awarded, they generally become exercisable over a four -year vesting period whereby options vest in equal installments each year. Options granted with graded vesting are accounted for as single options. The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model with assumptions for expected dividend yield, expected stock price volatility, risk-free interest rate and expected life. The assumed expected life is based on the Company's historical analysis of option history. The expected stock price volatility is also based on actual historical volatility, and expected dividend yield is based on historical dividends as the Company has no current intention of changing its dividend policy.
	The 2013 Plan provides that shares granted come from the Company's authorized but unissued common shares or treasury shares. In addition, the Company's stock-based compensation plans allow employee participants to exchange shares for minimum withholding taxes, which results in the Company acquiring treasury shares.
	Restricted Stock and Restricted Stock Units
	During the six months ended June 30, 2014, an aggregate of 193,534 restricted shares and restricted share units (for non-U.S. recipients) were granted without cost to the recipients, 25,016 restricted shares were forfeited, and 27,925 restricted shares vested. The awards granted during the first quarter are subject to three year cliff vesting and thus vest in their entirety on May 15, 2017. The awards of restricted shares/units are classified as equity awards as they are issued as common shares, or will be settled in common shares upon vesting. The fair value of the awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The fair value of the awards granted during the six months ended June 30, 2014 was $20.01 per share. Compensation expense is recognized ratably over the service period and $867,000 was recognized during the six months ended June 30, 2014 related to restricted shares/units and there were shares/units outstanding totaling 558,271 shares that were not vested. The Company expects the compensation expense to be recognized over a weighted-average period of approximately 1.5 years.
	Performance Shares and Performance Share Units
	During the six months ended June 30, 2014, an aggregate of 152,800 performance shares and performance share units (for non-U.S. recipients) were granted as performance awards with a 3 year performance period with payouts based on achievement of certain performance goals. There was no vesting of performance awards during the period and 7,400 awards were cancelled. The awards are classified as equity awards as they will be settled in common shares upon vesting. The number of shares earned will be determined at the end of the performance period based on achievement of performance criteria for January 1, 2016 through December 31, 2016 established by the Compensation Committee at the time of grant. Recipients will be entitled to receive a number of common shares equal to the number of performance shares that vest based upon the levels of achievement which may range between 0% and 150% of the target number of shares with the target being 100% of the initial grant.
	The fair value of the performance awards is based on the stock price on the date of grant discounted for the estimated value of dividends foregone as the awards are not eligible for dividends except to the extent vested. The fair value of the awards granted during the six months ended June 30, 2014 was $20.05 per share. The Company assesses the probability that the performance targets will be met with expense recognized whenever it is probable that at least the minimum performance criteria will be achieved. Depending upon the Company's assessment of the probability of achievement of the goals, the Company may not recognize any expense associated with performance awards in a given period, may reverse prior expense recorded or record additional expense to make up for expense not recorded in a prior period. Compensation expense of $247,000 was recognized during the six months ended June 30, 2014 related to performance awards. The Company expects the compensation expense to be recognized over 3.0 years.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income Accumulated Other Comprehensive Income	6 Months Ended
	Jun. 30, 2014
Accumulated Other Comprehensive Income (Loss) [Abstract]	'
Comprehensive Income (Loss) Note [Text Block]	'
	Accumulated Other Comprehensive Income (Loss) by Component
	Changes in accumulated other comprehensive income ("OCI") for the three and six months ended June 30, 2014 and June 30, 2013, respectively, were as follows (in thousands):
		Foreign Currency			Long-Term Notes			Defined Benefit Plans			Derivatives			Total
	31-Mar-14	$	149,948		$	(12,021	)	$	(4,872	)	$	(1,209	)	$	131,846
	OCI before reclassifications	(12,596		)	7,660			(48		)	302			(4,682		)
	Amount reclassified from accumulated OCI	—			—			65			340			405
	Net current-period OCI	(12,596		)	7,660			17			642			(4,277		)
	30-Jun-14	$	137,352		$	(4,361	)	$	(4,855	)	$	(567	)	$	127,569
	31-Dec-13	$	143,845		$	(12,566	)	$	(5,414	)	$	(709	)	$	125,156
	OCI before reclassifications	(6,493		)	8,205			436			(324		)	1,824
	Amount reclassified from accumulated OCI	—			—			123			466			589
	Net current-period OCI	(6,493		)	8,205			559			142			2,413
	30-Jun-14	$	137,352		$	(4,361	)	$	(4,855	)	$	(567	)	$	127,569
	31-Mar-13	$	117,659		$	1,153		$	(6,649	)	$	714		$	112,877
	OCI before reclassifications	158			(7,896		)	362			(396		)	(7,772		)
	Amount reclassified from accumulated OCI	—			—			(132		)	(259		)	(391		)
	Net current-period OCI	158			(7,896		)	230			(655		)	(8,163		)
	30-Jun-13	$	117,817		$	(6,743	)	$	(6,419	)	$	59		$	104,714
	December 31, 2012	$	117,465		$	2,845		$	(6,785	)	$	(782	)	$	112,743
	OCI before reclassifications	352			(9,588		)	485			847			(7,904		)
	Amount reclassified from accumulated OCI	—			—			(119		)	(6		)	(125		)
	Net current-period OCI	352			(9,588		)	366			841			(8,029		)
	June 30, 2013	$	117,817		$	(6,743	)	$	(6,419	)	$	59		$	104,714
	Reclassifications out of accumulated OCI for the six months ended June 30, 2014 and June 30, 2013 were as follows (in thousands):
		Amount reclassified from OCI												Affected line item in the Statement of Comprehensive (Income) Loss
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014			2013
	Defined Benefit Plans
	Service and interest costs	65			(138		)	$	123		$	(123	)	Selling, General and Administrative
	Tax	—			6			—			4			Income Taxes
	Total after tax	$	65		$	(132	)	$	123		$	(119	)
	Derivatives
	Foreign currency forward contracts hedging sales	$	138		$	(306	)	$	148		$	(442	)	Net Sales
	Foreign currency forward contracts hedging purchases	251			(31		)	384			325			Cost of Products Sold
	Interest rate swaps	12			59			12			126			Interest Expense
	Total before tax	401			(278		)	544			9
	Tax	(61		)	19			(78		)	(15		)	Income Taxes
	Total after tax	$	340		$	(259	)	$	466		$	(6	)

Charges_Related_To_Restructuri

Charges Related To Restructuring Activities	6 Months Ended
	Jun. 30, 2014
Restructuring and Related Activities [Abstract]	'
Charges Related To Restructuring Activities	'
	Charges Related to Restructuring Activities
	The Company's restructuring charges recorded since 2011 were necessitated primarily by continued declines in Medicare and Medicaid reimbursement by the U.S. government, as well as similar healthcare reimbursement pressures abroad, which negatively affect the Company's customers (e.g. home health care providers) and continued pricing pressures faced by the Company as a result of outsourcing by competitors to lower cost locations. In addition, restructuring decisions were also the result of reduced profitability in the North America/HME segment impacted by the FDA consent decree. While the Company's restructuring efforts have been executed on a timely basis resulting in operating cost savings, the savings have been more than offset by continued margin decline, principally as a result of product mix, reduced volumes and regulatory and compliance costs related to quality system improvements which are unrelated to the restructuring actions. The Company expects any near-term cost savings from restructuring will be offset by the continued investment in regulatory and compliance costs related to quality system improvements at least until the Company has completed its quality systems remediation efforts, and reduced net sales in the North America/HME segment at least until the Company has successfully completed the previously described third-party expert certification audit and FDA inspection and has received written notification from the FDA that the Company may resume full operations.
	The Company's restructuring commenced in the second quarter of 2011 with the Company's decision to close the Hong, Denmark assembly facility as part of the Company's ongoing globalization initiative to reduce complexity in the Company's supply chain, which is intended to reduce expenses to help offset pricing pressures. In the third quarter of 2011, the Company continued to execute on the closure of the Hong, Denmark assembly facility and initiated the closure of a smaller facility in the U.S. Charges for the quarter ended December 31, 2011 were primarily incurred at the Company's corporate headquarters for severance, with additional costs incurred as a result of the closure of the Hong, Denmark facility. The facility closures were completed in 2012 in addition to the elimination of various positions principally in the North America/Home Medical Equipment (HME) and Asia/Pacific segments.
	Charges for the year ended December 31, 2011 totaled $10,534,000 including charges for severance ($8,352,000), contract exit costs primarily related to the closure of the Hong, Denmark assembly facility ($1,788,000) and inventory write-offs ($277,000) recorded in cost of products sold and other miscellaneous costs ($117,000). The majority of the 2011 North America/HME charges were incurred for severance, primarily at the corporate headquarters as the result of the elimination of various positions principally in sales and administration in Elyria, Ohio. These eliminations were permanent reductions in workforce which primarily resulted in reduced selling, general and administrative expenses. In Europe, the charges were the result of the closure of the Company's Hong, Denmark facility. The assembly activities were transferred to other Company facilities or outsourced to third parties. This closure enabled the Company to reduce fixed operating costs related to the facility and reduce headcount with the transfer of a portion of the production to other Company facilities. The 2011 charges have now been paid out and were funded with operating cash flows.
	Charges for the year ended December 31, 2012 totaled $11,395,000 including charges for severance ($6,775,000), lease termination costs ($1,725,000), building and asset write-downs, primarily related to the closure of the Hong, Denmark assembly facility, and other miscellaneous charges in Europe and Asia/Pacific ($2,404,000) and inventory write-offs ($491,000) in Asia/Pacific recorded in cost of products sold. Severance charges were primarily incurred in the North America/HME segment ($4,242,000), Asia/Pacific segment ($1,681,000) and Europe segment ($817,000). The charges were incurred as a result of the elimination of various positions as part of the Company's globalization initiatives. In addition, a portion of the North America/HME segment severance was related to positions eliminated, principally in sales and marketing as well as manufacturing, at the Company's Taylor Street facility as a result of the FDA consent decree. The savings from these charges have been reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the Company. In Europe, positions were eliminated as a result of finalizing the exit from the manufacturing facility in Denmark and an elimination of a senior management position in Switzerland. In Asia/Pacific, at the end of October 2012, the Company's management approved a plan to restructure the Company's operations in this segment. In Australia, the Company consolidated offices / warehouses, decreased staffing and exited various activities while returning to a focus on distribution. At the Company's subsidiary, which produces microprocessor controllers, the Company decided to cease the contract manufacturing business for companies outside of the healthcare industry. Payments for the year ended December 31, 2012 were $9,381,000 and were funded with operating cash flows. The majority of the 2012 charges have now been paid out.
	Charges for the year ended December 31, 2013 totaled $9,336,000 including charges for severance ($8,282,000), lease termination costs ($698,000) and other miscellaneous charges principally in North America/HME ($356,000). Severance charges were primarily incurred in the North America/HME segment ($5,405,000), Europe segment ($1,640,000) and Asia/Pacific segment ($970,000). The charges were incurred as a result of the elimination of various positions as part of the Company's globalization initiatives. North America/HME segment severance was principally related to positions eliminated due to lost sales volumes resulting from the impact of the FDA consent decree. The savings from these charges have been reflected primarily in reduced selling, general and administrative expenses and manufacturing expenses for the Company. In Europe, severance was incurred for the elimination of certain sales and supply chain positions. In Asia/Pacific, severance was principally incurred at the Company's microprocessor controller production subsidiary as a result of the Company's decision in 2012 to cease the contract manufacturing business for companies outside of the healthcare industry. The lease termination costs were principally related to Australia as a result of the restructuring announced in 2012. Payments for the year ended December 31, 2013 were $11,844,000 and were funded with operating cash flows and cash on hand. The majority of the 2013 charges are expected to be paid out in 2014.
	Restructuring continued during 2014 resulting in restructuring charges of $4,330,000 in the first six months of 2014 related to severance costs ($2,818,000) and other costs ($1,512,000), which principally included building write-downs in the Europe and IPG segments. The severance costs were incurred principally in the NA/HME segment, and to a lesser extent the Europe and IPG segments. The building write-down in the IPG segment was associated with the previously announced closure of the London, Canada facility. The building write-down in the European segment was associated with a facility in Sweden, which the Company exited in 2011. Payments for the six months ended June 30, 2014 were $4,975,000 and were funded with the Company's credit facility. The majority of the outstanding charge accruals at June 30, 2014 are expected to be paid out within the next twelve months.
	There have been no material changes in accrued balances related to the charges, either as a result of revisions in the plan or changes in estimates. In addition, the savings anticipated as a result of the Company's restructuring plans have been or are expected to be achieved, primarily resulting in reduced salary and benefit costs principally impacting Selling, General and Administrative expenses, and to a lesser extent, Costs of Products Sold. However, to date, these savings have been more than offset by continued margin decline, principally as a result of product mix, and higher regulatory and compliance costs related to quality system improvements and reduced net sales volumes primarily related to mobility and seating products impacted by the consent decree, which are unrelated to the restructuring actions.
	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands):
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	December 31, 2010 Balance
	Total	$	—		$	—		$	—		$	—		$	—
	Charges
	NA/HME	4,755			—			—			4			4,759
	IPG	123			—			—			—			123
	Europe	3,288			277			1,788			113			5,466
	Asia/Pacific	186			—			—			—			186
	Total	8,352			277			1,788			117			10,534
	Payments
	NA/HME	(1,663		)	—			—			(4		)	(1,667		)
	IPG	(52		)	—			—			—			(52		)
	Europe	(1,546		)	(277		)	(1,714		)	(113		)	(3,650		)
	Asia/Pacific	(186		)	—			—			—			(186		)
	Total	(3,447		)	(277		)	(1,714		)	(117		)	(5,555		)
	December 31, 2011 Balance
	NA/HME	3,092			—			—			—			3,092
	IPG	71			—			—			—			71
	Europe	1,742			—			74			—			1,816
	Asia/Pacific	—			—			—			—			—
	Total	4,905			—			74			—			4,979
	Charges
	NA/HME	4,242			—			5			—			4,247
	IPG	35			—			—			—			35
	Europe	817			—			53			1,223			2,093
	Asia/Pacific	1,681			491			1,667			1,181			5,020
	Total	6,775			491			1,725			2,404			11,395
	Payments
	NA/HME	(3,587		)	—			(5		)	—			(3,592		)
	IPG	(106		)	—			—			—			(106		)
	Europe	(1,964		)	—			(127		)	(1,223		)	(3,314		)
	Asia/Pacific	(812		)	(340		)	(42		)	(1,175		)	(2,369		)
	Total	(6,469		)	(340		)	(174		)	(2,398		)	(9,381		)
	December 31, 2012 Balance
	NA/HME	3,747			—			—			—			3,747
	IPG	—			—			—			—			—
	Europe	595			—			—			—			595
	Asia/Pacific	869			151			1,625			6			2,651
	Total	5,211			151			1,625			6			6,993
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	Charges
	NA/HME	5,405			—			164			353			5,922
	IPG	267			—			—			—			267
	Europe	1,640			—			—			—			1,640
	Asia/Pacific	970			—			534			3			1,507
	Total	8,282			—			698			356			9,336
	Payments
	NA/HME	(6,347		)	—			(164		)	(353		)	(6,864		)
	IPG	(175		)	—			—			—			(175		)
	Europe	(1,146		)	—			—			—			(1,146		)
	Asia/Pacific	(1,839		)	(151		)	(1,660		)	(9		)	(3,659		)
	Total	(9,507		)	(151		)	(1,824		)	(362		)	(11,844		)
December 31, 2013 Balance
NA/HME	2,805			—			—			—			2,805
IPG	92			—			—			—			92
Europe	1,089			—			—			—			1,089
Asia/Pacific	—			—			499			—			499
	3,986			—			499			—			4,485
Charges
NA/HME	803			—			—			—			803
IPG	340			—			—			719			1,059
Europe	378			—			—			—			378
Asia/Pacific	—			—			—			—			—
Total	1,521			—			—			719			2,240
Payments
NA/HME	(1,120		)	—			—			—			(1,120		)
IPG	(35		)	—			—			(719		)	(754		)
Europe	(597		)	—			—			—			(597		)
Asia/Pacific	—			—			(154		)	—			(154		)
Total	(1,752		)	—			(154		)	(719		)	(2,625		)
March 31, 2014 Balance
NA/HME	2,488			—			—			—			2,488
IPG	397			—			—			—			397
Europe	870			—			—			—			870
Asia/Pacific	—			—			345			—			345
	$	3,755		$	—		$	345		$	—		$	4,100
Charges
NA/HME	$	845		$	—		$	—		$	—		$	845
IPG	394			—			—			264			658
Europe	58			—			—			525			583
Asia/Pacific	—			—			4			—			4
Total	1,297			—			4			789			2,090
	Severance			Product Line			Contract			Other			Total
				Discontinuance			Terminations
Payments
NA/HME	(1,303		)	—			—			—			(1,303		)
IPG	(32		)	—			—			(264		)	(296		)
Europe	(226		)	—			—			(525		)	(751		)
Asia/Pacific	—			—			—			—			—
Total	(1,561		)	—			—			(789		)	(2,350		)
June 30, 2014 Balance
NA/HME	2,030			—			—			—			2,030
IPG	759			—			—			—			759
Europe	702			—			—			—			702
Asia/Pacific	—			—			349			—			349
	$	3,491		$	—		$	349		$	—		$	3,840

Income_Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company had an effective tax rate provision of 29.2% and 20.2% on losses before tax from continuing operations for the three and six months ended June 30, 2014, respectively, compared to an expected benefit at the U.S. statutory rate of 35%. The Company's effective tax rate for the three and six months ended June 30, 2014 was higher than the beneficial U.S. federal statutory rate, principally due to the negative impact of the Company not being able to record tax benefits related to the significant losses in countries which had tax valuation allowances. The rate benefitted by taxes recognized outside the United States, excluding countries with tax valuation allowances, at an effective rate lower than the U.S. statutory rate.
	The Company had an effective tax rate provision of 76.6% and 11.6% on losses before tax from continuing operations for the three and six months ended June 30, 2013, respectively, compared to the expected benefit at the U.S. statutory rate of 35%. The Company's effective tax rate for the three and six months ended June 30, 2013 was higher than the beneficial U.S. federal statutory rate, principally due to losses overseas without tax benefit due to valuation allowances and an adjustment to the domestic intraperiod tax allocation due to the impact of a discrete tax expense of $9,702,000 ($0.30 per share) related to dividends for earnings previously deemed permanently reinvested overseas received in the U.S. during the second quarter. The rate benefitted by taxes recognized outside the United States, excluding countries with tax valuation allowances that were in losses in 2013, at an effective rate lower than the U.S. statutory rate.

Net_Earnings_Loss_Per_Common_S

Net Earnings (Loss) Per Common Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Earnings (Loss) Per Common Share	'
	Net Earnings (Loss) Per Common Share
	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated.
	(In thousands except per share data)	For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014			2013
	Basic
	Average common shares outstanding	32,017			31,902			32,015			31,902
	Net loss from continuing operations	$	(13,612	)	$	(24,489	)	$	(31,588	)	$	(30,197	)
	Net earnings from discontinued operations	$	—		$	12,028		$	—		$	52,917
	Net earnings (loss)	$	(13,612	)	$	(12,461	)	$	(31,588	)	$	22,720
	Net loss per common share from continuing operations	$	(0.43	)	$	(0.77	)	$	(0.99	)	$	(0.95	)
	Net earnings per common share from discontinued operations	$	—		$	0.38		$	—		$	1.66
	Net earnings (loss) per common share	$	(0.43	)	$	(0.39	)	$	(0.99	)	$	0.71
	Diluted
	Average common shares outstanding	32,017			31,902			32,015			31,902
	Shares related to convertible debt	—			—			—			—
	Stock options and awards	199			122			229			78
	Average common shares assuming dilution	32,216			32,024			32,244			31,980
	Net loss from continuing operations	$	(13,612	)	$	(24,489	)	$	(31,588	)	$	(30,197	)
	Net earnings from discontinued operations	$	—		$	12,028		$	—		$	52,917
	Net earnings (loss)	$	(13,612	)	$	(12,461	)	$	(31,588	)	$	22,720
	Net loss per common share from continuing operations *	$	(0.43	)	$	(0.77	)	$	(0.99	)	$	(0.95	)
	Net earnings per common share from discontinued operations	$	—		$	0.38		$	—		$	1.65
	Net earnings (loss) per common share *	$	(0.43	)	$	(0.39	)	$	(0.99	)	$	0.71
	* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.
	At June 30, 2014, 3,578,173 and 3,172,393 shares associated with stock options were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2014 as they were anti-dilutive. At June 30, 2014, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $16.98 and $18.74, respectively, for the three and six months ended June 30, 2014. At June 30, 2013, 4,929,913 and 4,861,512 shares associated with stock options were excluded from the average common shares assuming dilution for the three and six months ended June 30, 2013 as they were anti-dilutive. At June 30, 2013, the majority of the anti-dilutive shares were granted at an exercise price of $41.87, which was higher than the average fair market value prices of $13.85 and $14.60, respectively, for the three and six months ended June 30, 2013. For the six months ended June 30, 2014 and June 30, 2013, there were no shares necessary to settle a conversion spread on the convertible notes to be included in the common shares assuming dilution as the average market price of the Company stock for these periods did not exceed the conversion price.

Concentration_Of_Credit_Risk

Concentration Of Credit Risk	6 Months Ended
	Jun. 30, 2014
Risks and Uncertainties [Abstract]	'
Concentration Of Credit Risk	'
	Concentration of Credit Risk
	The Company manufactures and distributes durable medical equipment to the home health care, retail and extended care markets. The Company performs credit evaluations of its customers’ financial condition. The Company utilizes De Lage Landen, Inc. (“DLL”), a third party financing company, to provide the majority of future lease financing to the Company’s North America customers. The DLL agreement provides for direct leasing between DLL and the Invacare customer. The Company retains a recourse obligation of $4,897,000 at June 30, 2014 to DLL for events of default under the contracts, which total $36,824,000 at June 30, 2014. The Company's recourse is re-evaluated by DLL biannually, considers activity between the biannual dates and excludes any receivables repurchased by the Company from DLL. The Company monitors the collections status of these contracts and has provided amounts for estimated losses in its allowances for doubtful accounts in accordance with Receivables, ASC 310-10-05-4. Credit losses are provided for in the financial statements.
	Substantially all of the Company’s receivables are due from health care, medical equipment providers and long term care facilities located throughout the United States, Australia, Canada, New Zealand and Europe. A significant portion of products sold to dealers, both foreign and domestic, is ultimately funded through government reimbursement programs such as Medicare and Medicaid. The Company has also seen a significant shift in reimbursement to customers from managed care entities. As a consequence, changes in these programs can have an adverse impact on dealer liquidity and profitability. In addition, reimbursement guidelines in the home health care industry have a substantial impact on the nature and type of equipment an end user can obtain as well as the timing of reimbursement and, thus, affect the product mix, pricing and payment patterns of the Company’s customers.

Derivatives

Derivatives	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives	'
	Derivatives
	ASC 815 requires companies to recognize all derivative instruments in the consolidated balance sheet as either assets or liabilities at fair value. The accounting for changes in fair value of a derivative is dependent upon whether or not the derivative has been designated and qualifies for hedge accounting treatment and the type of hedging relationship. For derivatives designated and qualifying as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.
	Cash Flow Hedging Strategy
	The Company uses derivative instruments in an attempt to manage its exposure to foreign currency exchange risk and interest rate risk. Foreign forward exchange contracts are used to manage the price risk associated with forecasted sales denominated in foreign currencies and the price risk associated with forecasted purchases of inventory over the next twelve months. Interest rate swaps are, at times, utilized to manage interest rate risk associated with the Company’s fixed and floating-rate borrowings.
	The Company recognizes its derivative instruments as assets or liabilities in the consolidated balance sheet measured at fair value. A majority of the Company’s derivative instruments are designated and qualify as cash flow hedges. Accordingly, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income and reclassified into earnings in the same period or periods during which the hedged transaction affects earnings. The remaining gain or loss on the derivative instrument in excess of the cumulative change in the fair value of the hedged item, if any, is recognized in current earnings during the period of change.
	During a portion of 2014 and all of 2013, the Company was a party to interest rate swap agreements that qualified as cash flow hedges and effectively converted floating-rate debt to fixed-rate debt, so the Company could avoid the risk of changes in market interest rates. The gains or losses on interest rate swaps are reflected in interest expense on the consolidated statement of comprehensive income (loss).
	To protect against increases/decreases in forecasted foreign currency cash flows resulting from inventory purchases/sales over the next year, the Company utilizes foreign currency forward contracts to hedge portions of its forecasted purchases/sales denominated in foreign currencies. The gains and losses are included in cost of products sold and selling, general and administrative expenses on the consolidated statement of comprehensive income (loss). If it is later determined that a hedged forecasted transaction is unlikely to occur, any prospective gains or losses on the forward contracts would be recognized in earnings. The Company does not expect any material amount of hedge ineffectiveness related to forward contract cash flow hedges during the next twelve months.
	The Company has historically not recognized any material amount of ineffectiveness related to forward contract cash flow hedges because the Company generally limits its hedges to between 60% and 90% of total forecasted transactions for a given entity’s exposure to currency rate changes and the transactions hedged are recurring in nature. Furthermore, the majority of the hedged transactions are related to intercompany sales and purchases for which settlement occurs on a specific day each month. Forward contracts with a total notional amount in USD of $41,504,000 and $75,127,000 matured for the three and six months ended June 30, 2014 compared to forward contracts with a total notional amount in USD of $47,179,000 and $80,673,000 that matured for the three and six months ended June 30, 2013.
	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):
		June 30, 2014						December 31, 2013
		Notional			Unrealized			Notional			Unrealized
		Amount			Net Gain			Amount			Net Gain
					(Loss)						(Loss)
	USD / AUD	$	1,164		$	(63	)	$	—		$	—
	USD / CNY	6,437			(129		)	11,730			(66		)
	USD / CHF	207			(1		)	486			4
	USD / EUR	31,321			(5		)	51,106			(168		)
	USD / GBP	1,499			(59		)	2,686			(45		)
	USD / NZD	1,266			(25		)	—			—
	USD / SEK	979			37			2,485			58
	USD / MXP	5,730			191			5,960			102
	EUR / AUD	351			(20		)	—			—
	EUR / CAD	798			15			1,710			(1		)
	EUR / CHF	1,559			13			2,654			1
	EUR / DKK	647			(1		)	1,382			(5		)
	EUR / GBP	15,844			(643		)	29,614			(501		)
	EUR / SEK	1,807			88			3,432			75
	EUR / NOK	1,801			(13		)	3,135			66
	EUR / NZD	3,854			232			6,959			(111		)
	AUD / CAD	936			1			—			—
	AUD / NZD	586			(7		)	—			—
	GBP / CHF	448			(21		)	837			(26		)
	GBP / SEK	1,111			(103		)	2,078			(101		)
	DKK / SEK	2,525			(89		)	5,337			(94		)
	NOK / SEK	1,683			(66		)	3,418			31
		$	82,553		$	(668	)	$	135,009		$	(781	)
	Derivatives Not Qualifying or Designated for Hedge Accounting Treatment
	The Company also utilizes foreign currency forward contracts that are not designated as hedges in accordance with ASC 815. These contracts are entered into to eliminate the risk associated with the settlement of short-term intercompany trading receivables and payables between Invacare Corporation and its foreign subsidiaries. The currency forward contracts are entered into at the same time as the intercompany receivables or payables are created so that upon settlement, the gain/loss on the settlement is offset by the gain/loss on the foreign currency forward contract. No material net gain or loss was realized by the Company in 2014 or 2013 related to these contracts and the associated short-term intercompany trading receivables and payables.
	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2014 and 2013, respectively, and outstanding were as follows (in thousands USD):
		June 30, 2014						31-Dec-13
		Notional			Gain			Notional			Gain
		Amount			(Loss)			Amount			(Loss)
	AUD / USD	$	1,700		$	(16	)	$	225		$	(1	)
	CAD / USD	5,589			28			—			$	—
	CNY / USD	2,599			(43		)	—			—
	EUR / USD	19,157			14			14,867			250
	CHF / USD	—			—			1,645			35
	DKK / USD	5,533			(37		)	—			—
	NZD / USD	7,200			(10		)	3,824			(1		)
	EUR / AUD	—			—			2,039			80
	EUR / CAD	38			1			—			—
	EUR / DKK	68			—			5,470			(3		)
	AUD / CAD	—			—			5,989			10
	AUD / EUR	2,142			(81		)	—			—
	EUR / NOK	8			—			—			—
		$	44,034		$	(144	)	$	34,059		$	370
	The fair values of the Company’s derivative instruments were as follows (in thousands):
		June 30, 2014						December 31, 2013
		Assets			Liabilities			Assets			Liabilities
	Derivatives designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	$	685		$	1,353		$	414		$	1,195
	Interest rate swap contracts	—			—			—			12
	Derivatives not designated as hedging instruments under ASC 815
Foreign currency forward exchange contracts	95			239			375			5
Total derivatives	$	780		$	1,592		$	789		$	1,212
The fair values of the Company’s foreign currency forward exchange contract assets and liabilities are included in Other Current Assets and Accrued Expenses, respectively in the Consolidated Balance Sheets.
The effect of derivative instruments on Accumulated Other Comprehensive Income (OCI) and the Statement of Comprehensive Income (Loss) and was as follows (in thousands):
Derivatives in ASC 815 cash flow hedge	Amount of Gain			Amount of Gain  (Loss)			Amount of Gain (Loss)
relationships	(Loss) Recognized in Accumulated OCI on Derivatives			Reclassified from			Recognized in Income on
	(Effective Portion)			Accumulated  OCI into			Derivatives  (Ineffective Portion
				Income (Effective			and Amount Excluded from
				Portion)			Effectiveness Testing)
Three months ended June 30, 2014
Foreign currency forward exchange contracts	$	310		$	(328	)	$	(22	)
Interest rate swap contracts	(8		)	(12		)	—
	$	302		$	(340	)	$	(22	)
Six months ended June 30, 2014
Foreign currency forward exchange contracts	$	(324	)	$	(454	)	$	(22	)
Interest rate swap contracts	—			(12		)	—
	$	(324	)	$	(466	)	$	(22	)
Three months ended June, 2013
Foreign currency forward exchange contracts	$	(533	)	$	318		$	(22	)
Interest rate swap contracts	137			(59		)	—
	$	(396	)	$	259		$	(22	)
Six months ended June 30, 2013
Foreign currency forward exchange contracts	$	447		$	132		$	35
Interest rate swap contracts	400			(126		)	—
	$	847		$	6		$	35
Derivatives not designated as hedging							Amount of Gain (Loss)
instruments under ASC 815							Recognized in Income on Derivatives
Three months ended June 30, 2014
Foreign currency forward exchange contracts							$	201
Six months ended June 30, 2014
Foreign currency forward exchange contracts							$	(144	)
Three months ended June 30, 2013
Foreign currency forward exchange contracts							$	1,427
Six months ended June 30, 2013
Foreign currency forward exchange contracts							$	256
The gains or losses recognized as the result of the settlement of cash flow hedge foreign currency forward contracts are recognized in net sales for hedges of inventory sales and in cost of product sold for hedges of inventory purchases. For the three and six months ended June 30, 2014, net sales were decreased by $138,000 and $148,000 while cost of product sold was increased by $251,000 and $384,000 for net pre-tax realized losses of $389,000 and $532,000, respectively. For the three and six months ended June 30, 2013, net sales were increased by $306,000 and $442,000 while cost of product sold was decreased by $31,000 and increased by $325,000 for net realized pre-tax gains of $337,000 and $117,000, respectively.
The Company recognized pre-tax expense of $12,000 for both the three and six months ended June 30, 2014 compared to pre-tax expense of $59,000 and $126,000 for the three and six months ended June 30, 2013, respectively, related to interest rate swap agreements, which is reflected in interest expense on the consolidated statement of comprehensive income (loss).
A gain of $201,000 and a loss of $144,000 were recognized in selling, general and administrative (SG&A) expenses for the three and six months ended June 30, 2014, respectively, compared to gains of $1,427,000 and $256,000 for the three and six months ended June 30, 2013, respectively, on ineffective forward contracts and forward contracts not designated as hedging instruments that were entered into to offset gains/losses that were also recorded in SG&A expenses on intercompany trade receivables or payables. Any gains/losses on the non-designated hedging instruments were substantially offset by gains/losses also recorded in SG&A expenses on intercompany trade payables.
The Company has entered into foreign currency forward exchange contracts and, at times, interest rate swap contracts (the “agreements”) with various bank counterparties, each of which are subject to provisions which are similar to a master netting agreement. The agreements provide for a net settlement payment in a single currency upon a default by the Company. Furthermore, the agreements provide the counterparty with a right of set off in the event of a default that would enable the counterparty to offset any net payment due by the counterparty to the Company under the applicable agreement by any amount due by the Company to the counterparty under any other agreement. For example, the terms of the agreement would permit a counterparty to a derivative contract that is also a lender under the Company's Amended and Restated Credit Agreement to reduce any derivative settlement amounts owed to the Company under the derivative contract by any amounts owed to the counterparty by the Company under the Amended and Restated Credit Agreement. In addition, the agreements contain cross-default provisions that could trigger a default by the Company under the agreement in the event of a default by the Company under another agreement with the same counterparty. The Company does not present any derivatives on a net basis in its financial statements and all derivative balances presented are subject to provisions that are similar to master netting agreements.

Fair_Value_of_Financial_Instru

Fair Value of Financial Instruments	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Values
	Pursuant to ASC 820, the inputs used to derive the fair value of assets and liabilities are analyzed and assigned a level I, II or III priority, with level I being the highest and level III being the lowest in the hierarchy. Level I inputs are quoted prices in active markets for identical assets or liabilities. Level II inputs are quoted prices for similar assets or liabilities in active markets: quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets. Level III inputs are based on valuations derived from valuation techniques in which one or more significant inputs are unobservable.
	The following table provides a summary of the Company’s assets and liabilities that are measured on a recurring basis (in thousands).
					Basis for Fair Value Measurements at Reporting Date
					Quoted Prices in Active			Significant				Significant
					Markets for Identical			Other				Other
					Assets / (Liabilities)			Observable				Unobservable
								Inputs				Inputs
		Total			Level I			Level II				Level III
	30-Jun-14
	Forward Exchange Contracts—net	$	(812	)	—			$	(812	)		—
	31-Dec-13
	Forward Exchange Contracts—net	$	(411	)	—			$	(411	)		—
	Interest Rate Swap Agreements—net	(12		)	—			(12		)		—
	Forward Contracts: The Company operates internationally and as a result is exposed to foreign currency fluctuations. Specifically, the exposure includes intercompany loans and third party sales or payments. In an attempt to reduce this exposure, foreign currency forward contracts are utilized and accounted for as hedging instruments. The forward contracts are used to hedge the following currencies: AUD, CAD, CHF, CNY, DKK, EUR, GBP, MXP, NOK, NZD, SEK and USD. The Company does not use derivative financial instruments for speculative purposes. Fair values for the Company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities.
	The carrying values and fair values of the Company’s financial instruments are as follows (in thousands):
		June 30, 2014							December 31, 2013
		Carrying			Fair Value				Carrying				Fair Value
		Value							Value
	Cash and cash equivalents	$	23,001		$	23,001			$	29,785			$	29,785
	Other investments	799			799				998				998
	Installment receivables, net of reserves	2,751			2,751				2,819				2,819
	Long-term debt (including current maturities of long-term debt)	(56,116		)	(55,356		)		(45,286		)		(46,124		)
	Forward contracts in Other Current Assets	780			780				789				789
	Forward contracts in Accrued Expenses	(1,592		)	(1,592		)		(1,200		)		(1,200		)
	Interest rate swap agreements in Accrued Expenses	—			—				(12		)		(12		)
	The Company, in estimating its fair value disclosures for financial instruments, used the following methods and assumptions:
	Cash, cash equivalents: The carrying value reported in the balance sheet for cash, cash equivalents equals its fair value.
	Other investments: The Company has made other investments in limited partnerships and non-marketable equity securities, which are accounted for using the cost method, adjusted for any estimated declines in value. These investments were acquired in private placements and there are no quoted market prices or stated rates of return. The Company does not have the ability to easily sell these investments.
	Installment receivables: The carrying value reported in the balance sheet for installment receivables approximates its fair value. The interest rates associated with these receivables have not varied significantly since inception. Management believes that after consideration of the credit risk, the net book value of the installment receivables approximates market value.
	Long-term debt: Fair values for the Company’s convertible debt is based on quoted market-based estimates as of the end of the period, while the revolving credit facility fair values are based upon the Company’s estimate of the market for similar borrowing arrangements. The fair values are deemed to be categorized as Level 2 in the fair value hierarchy.
	Forward contracts and interest rate swaps: Fair values for the Company’s foreign exchange forward contracts are based on quoted market prices for contracts with similar maturities, while the fair values of the interest rate swaps are based on model-derived calculations using inputs that are observable in active markets.

Business_Segments

Business Segments	6 Months Ended
	Jun. 30, 2014
Segment Reporting [Abstract]	'
Business Segments	'
	Business Segments
	The Company operates in four primary business segments: North America/Home Medical Equipment (North America/HME), Institutional Products Group (IPG), Europe and Asia/Pacific.
	The North America/HME segment sells each of three primary product lines, which includes: lifestyle, mobility and seating and respiratory therapy products. IPG sells or rents long-term care medical equipment, health care furnishings and accessory products. Europe and Asia/Pacific sell product lines similar to North America/HME and IPG.
	The Company evaluates performance and allocates resources based on profit or loss from operations before income taxes for each reportable segment. The accounting policies of each segment are the same as those described in the summary of significant accounting policies for the Company’s consolidated financial statements. Intersegment sales and transfers are based on the costs to manufacture plus a reasonable profit element. Therefore, intercompany profit or loss on intersegment sales and transfers is not considered in evaluating segment performance except for Asia/Pacific due to its significant intercompany sales volume relative to the segment.
	The information by segment is as follows (in thousands):
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014			2013
	Revenues from external customers
	North America/HME	$	138,678		$	159,327		$	267,788		$	311,209
	Institutional Products Group	25,785			29,828			50,921			59,052
	Europe	153,990			141,751			296,758			279,385
	Asia/Pacific	12,859			13,854			24,914			26,551
	Consolidated	$	331,312		$	344,760		$	640,381		$	676,197
	Intersegment revenues
	North America/HME	$	20,872		$	20,398		$	39,545		$	39,234
	Institutional Products Group	2,853			1,882			4,426			2,989
	Europe	2,131			2,313			3,813			4,266
	Asia/Pacific	6,158			6,124			12,350			13,006
	Consolidated	$	32,014		$	30,717		$	60,134		$	59,495
	Restructuring charges before income taxes
	North America/HME	$	845		$	1,948		$	1,648		$	3,627
	Institutional Products Group	658			13			1,717			201
	Europe	583			65			961			180
	Asia/Pacific	4			566			4			1,106
	Consolidated	$	2,090		$	2,592		$	4,330		$	5,114
	Earnings (loss) before income taxes
	North America/HME	$	(13,292	)	$	(12,222	)	$	(30,091	)	$	(23,401	)
	Institutional Products Group	(110		)	471			(361		)	945
	Europe	11,763			8,365			21,009			14,208
	Asia/Pacific	(2,298		)	(5,377		)	(5,099		)	(7,638		)
	All Other (1)	(6,600		)	(5,101		)	(11,746		)	(11,161		)
	Consolidated	$	(10,537	)	$	(13,864	)	$	(26,288	)	$	(27,047	)
	________________________
	-1	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	General
	In the ordinary course of its business, the Company is a defendant in a number of lawsuits, primarily product liability actions in which various plaintiffs seek damages for injuries allegedly caused by defective products. All of the product liability lawsuits that the Company faces in the United States have been referred to the Company's captive insurance company and/or excess insurance carriers while all non-U.S. lawsuits have been referred to the Company's commercial insurance carriers. All such lawsuits are generally contested vigorously. The coverage territory of the Company's insurance is worldwide with the exception of those countries with respect to which, at the time the product is sold for use or at the time a claim is made, the U.S. government has suspended or prohibited diplomatic or trade relations. The amount recorded for identified contingent liabilities is based on estimates. Amounts recorded are reviewed periodically and adjusted to reflect additional technical and legal information that becomes available. Actual costs to be incurred in future periods may vary from the estimates, given the inherent uncertainties in evaluating certain exposures.
	As a medical device manufacturer, the Company is subject to extensive government regulation, including numerous laws directed at preventing fraud and abuse and laws regulating reimbursement under various government programs. The marketing, invoicing, documenting and other practices of health care suppliers and manufacturers are all subject to government scrutiny. Most of the Company's facilities are subject to periodic inspection by the FDA or similar agencies in other jurisdictions. Violations of law or regulations can result in administrative, civil and criminal penalties and sanctions, including disqualification from Medicare and other reimbursement programs, which could have a material adverse effect on the Company's business.
	On November 15, 2013, an amended complaint, in a lawsuit originally instituted on May 24, 2013, was filed against Invacare Corporation, Gerald B. Blouch and A. Malachi Mixon III in the U.S. District Court for the Northern District of Ohio, alleging that the defendants violated federal securities laws by failing to properly disclose the issues that the Company has faced with the FDA. The lawsuit seeks class certification and unspecified damages and attorneys' fees for purchasers of the Company's common shares between July 22, 2010 and December 7, 2011. This lawsuit has been referred to the Company's insurance carriers. The Company intends to vigorously defend this lawsuit.
	On February 14, 2014, an amended complaint, in a lawsuit originally instituted on August 26, 2013, was filed against Invacare Corporation, Gerald B. Blouch, A. Malachi Mixon III and Patricia Stumpp, as well as outside directors Dale C. LaPorte, Michael F. Delaney and Charles S. Robb, in the U.S. District Court for the Northern District of Ohio, alleging that the defendants breached their fiduciary duties and violated the Employment Retirement Security Act (ERISA) in the administration and maintenance of the Company stock fund in the Company’s Retirement Savings Plan (401(k) Plan). The lawsuit seeks class certification and unspecified damages and attorneys' fees for participants in the Company's stock fund of the 401(k) Plan between July 22, 2010 and the present. This lawsuit has been referred to the Company's insurance carriers. The Company intends to vigorously defend this lawsuit.
	Medical Device Regulatory Matters
	The FDA regulates virtually all aspects of the development, testing, manufacturing, labeling, promotion, distribution and marketing of a medical device. The Company and its products are subject to the laws and regulations of the FDA and other regulatory bodies in the various jurisdictions where the Company's products are manufactured or sold. The Company's failure to comply with the regulatory requirements of the FDA and other applicable medical device regulatory requirements can subject the Company to administrative or judicially imposed sanctions. These sanctions include injunctions, consent decrees, warning letters, civil penalties, criminal penalties, product seizure or detention, product recalls and total or partial suspension of production.
	In December 2012, the Company reached agreement with the FDA on the terms of the consent decree of injunction with respect to the Company's Corporate facility and its Taylor Street wheelchair manufacturing facility in Elyria, Ohio. A complaint and consent decree were filed in the U.S. District Court for the Northern District of Ohio, and on December 21, 2012, the Court approved the consent decree and it became effective. The consent decree limits the Company's manufacture and distribution of power and manual wheelchairs, wheelchair components and wheelchair sub-assemblies at or from its Taylor Street manufacturing facility. The decree also temporarily limited design activities related to wheelchairs and power beds that take place at the impacted Elyria, Ohio facilities. The Company is entitled to continue to produce from the Taylor Street manufacturing facility certain medically necessary wheelchairs provided that documentation and record-keeping requirements are followed, as well as ongoing replacement, service and repair of products already in use, under terms delineated in the consent decree. Under the terms of the consent decree, in order to resume full operations at the impacted facilities, the Company must successfully complete a third-party expert certification audit at the impacted Elyria facilities, which is comprised of three distinct reports that must be submitted to, and accepted by, the FDA. After the final certification report is submitted to the FDA, as well as the Company’s own report as to its compliance status together with its responses to any observations in the certification report, the FDA is expected to inspect the Company's Corporate and Taylor Street facilities to determine whether they are in compliance with the Quality System Regulation (QSR) governing the manufacture of medical devices and the terms of the consent decree. If the FDA is satisfied with the Company's compliance, the FDA will provide written notification that the Company is permitted to resume full operations at the impacted facilities.
	During 2013, the Company completed the first two of the expert certification audits, and the FDA found the results of both to be acceptable. In these reports, the third-party expert certified that the Company's equipment and process validation procedures and its design control systems are compliant with the FDA's QSR. As a result of the FDA's acceptance of the first certification report on May 13, 2013, the Taylor Street facility was able to resume supplying parts and components for the further manufacturing of medical devices at other Company facilities. The Company's receipt of the FDA's acceptance of the second certification report on July 15, 2013, resulted in the Company being able to resume design activities at the impacted facilities related to power wheelchairs and power beds.
	The third, most comprehensive expert certification audit is a comprehensive review of the Company's compliance with the FDA's QSR at the impacted Elyria facilities. At the time of filing this Quarterly Report on Form 10-Q, the Company is continuing its work with the third-party expert auditor on the final certification audit process. This audit is the most comprehensive and challenging of the three expert certification audits, and it encompasses all areas of the Company's Corporate and Taylor Street quality system. The Company needs to better demonstrate that its quality system is sustainably compliant and that each subsystem is properly integrated. In order to address these needs, the Company as engaged additional consultants to help improve the functionality and capabilities of certain of its quality subsystems. The Company respects the comprehensive nature of the audit process and is working diligently to be in a position to ultimately demonstrate compliance to the third-party expert auditor and subsequently, the FDA.
	The Company cannot predict the timing of the completion or the outcome of the third-party expert’s final certification report. However, after the expert's certification report is completed and submitted to the FDA, as well as the Company’s own report related to its compliance status together with its responses to any observations in the certification report, the FDA is expected to inspect the Company's Corporate and Taylor Street facilities to determine whether they are in compliance with the FDA's QSR and the consent decree. If the FDA is satisfied with the Company's compliance, the FDA will provide written notification that the Company is permitted to resume full operations at the impacted facilities.
	After resumption of full operations, the Company must undergo five years of audits by a third-party expert auditor to determine whether the facilities are in continuous compliance with FDA's QSR and the consent decree. The auditor will inspect the Corporate and Taylor Street facilities’ activities every six months during the first year following the resumption of full operations and then every 12 months for the next four years thereafter.
	As described above, because the limitations on production are expected to be temporary in nature, and partial production is allowed, the Company does not anticipate any major repair, replacement or scrapping of its fixed assets at the Taylor Street manufacturing facility. Based on the Company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the utilization of such raw material and with respect to expected future cash flows from production at the Taylor Street manufacturing facility, the Company concluded that there is no impairment in the value of the fixed assets related to the Taylor Street manufacturing facility at June 30, 2014.
	The majority of the production from the Taylor Street facility is "made to order" custom wheelchairs for customers and, as a result, there was not a significant amount of finished goods inventory on hand at June 30, 2014, and the inventory is expected to be fully utilized. Accordingly, the Company concluded that there was not an impairment of the work in process and finished goods at the Taylor Street facility at June 30, 2014. Further, based on its analysis of the raw material inventory at the Taylor Street facility and the Company's expectations at the time of filing of this Quarterly Report on Form 10-Q with respect to the time frame for completion of the third-party expert certification audits and FDA inspection, the Company concluded that the value of the inventory was not excessive or impaired at June 30, 2014. However, if the Company's expectations regarding the impacts of the limitations in the consent decree or the time frame for completion of the third-party expert certification audits and FDA inspection were to change, the Company may, in future periods, conclude that an impairment exists with respect to its fixed assets or inventory at the Taylor Street facility.
	Although the North America/HME segment is the segment primarily impacted by the limitations in the FDA consent decree, the Asia/Pacific segment also is negatively affected as a result of the consent decree due to the lower sales volume of microprocessor controllers. During 2012, before the effective date of the consent decree, the Company started to experience decreases in net sales in the North America/HME and Asia/Pacific segments. The Company believes that those decreases were driven in large part by the consent decree which has led to delays in new product introductions and to uncertainty regarding the timing of exiting the consent decree, which limited the Company's ability to renegotiate and bid on certain customer contracts and otherwise led to a decline in customer orders.  Separately, net sales in the North America/HME segment were likely impacted by uncertainty on the part of the Company's customers as they coped with prepayment reviews and post-payment audits by the Centers for Medicare and Medicaid Services ("CMS") and contemplated their participation in the next round of National Competitive Bidding ("NCB"). The negative effect of the consent decree on customer orders and net sales in these segments has been considerable, and the Company expects to experience continued low levels in net sales as a result of the limitations imposed by the consent decree. The Company expects to continue to experience lower levels of net sales in the North America/HME and Asia/Pacific segments at least until it has successfully completed the previously-described third-party expert certification audit and FDA inspection and has received written notification from the FDA that the Company may resume full operations at the Corporate and Taylor Street facilities. Even after the Company is permitted to resume full operations at the affected facilities, it is uncertain as to whether, or how quickly, the Company will be able to rebuild net sales to more typical historical levels, irrespective of market conditions. Accordingly, when compared to the Company's 2010 results, the limitations in the consent decree had, and likely will continue to have, a material adverse effect on the Company's business, financial condition and results of operations.
	For additional information regarding the consent decree, please see the following sections of the Company's Annual Report on Form 10-K for the year ending December 31, 2013: Item 1. Business - Government Regulation and Item 1A. Risk Factors and the following sections of this Quarterly Report on Form 10-Q: Item 1. Legal Proceedings; and Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations - Outlook and - Liquidity and Capital Resources.
	In the first quarter of 2014, the Company recorded additional warranty expense related to the power wheelchair joystick recall of $2,237,000 ($2,100,000 after-tax), which impacted the North America/HME segment by $1,171,000 after-tax and the Asia/Pacific segment by $929,000 after-tax. The increase in the Company's estimate of total cost related to this matter is attributable to higher than previously anticipated response rates from larger customers in United States and Canada. As previously indicated, the reserve is subject to adjustments as new developments change the Company's estimate of the total cost of this matter.
	In addition, in December 2010, the Company received a warning letter from the FDA related to quality system processes and procedures at the Company's Sanford, Florida facility. The Company has taken actions which it believes address all of the FDA's concerns in the warning letter. However, the results of regulatory claims, proceedings, investigations, or litigation are difficult to predict. An unfavorable resolution or outcome of the FDA warning letter could materially and adversely affect the Company's business, financial condition, and results of operations.
	Any of the above contingencies could have an adverse impact on the Company's financial condition or results of operations.

Supplemental_Guarantor_Informa

Supplemental Guarantor Information	6 Months Ended
	Jun. 30, 2014
Supplemental Guarantor Information [Abstract]	'
Guarantees [Text Block]	'
	Supplemental Guarantor Information
	Effective February 12, 2007, substantially all of the domestic subsidiaries (the “Guarantor Subsidiaries”) of the Company became guarantors of the indebtedness of Invacare Corporation under its 4.125% Convertible Senior Subordinated Debentures due 2027 (the “Debentures”) with an original aggregate principal amount of $135,000,000. The majority of the Company’s subsidiaries are not guaranteeing the indebtedness of the Debentures (the “Non-Guarantor Subsidiaries”). Each of the Guarantor Subsidiaries has fully and unconditionally guaranteed, on a joint and several basis, to pay principal, premium, and interest related to the Debentures and each of the Guarantor Subsidiaries are directly or indirectly 100%-owned subsidiaries of the Company. Specifically, the Debentures are guaranteed on an unsecured senior subordinated basis by all of the Company's existing domestic subsidiaries (other than the Company's captive insurance subsidiary and any receivables subsidiaries) and certain future direct and indirect 100% owned domestic subsidiaries. All of the guarantors are released and relieved of any liability under such guarantees upon the satisfaction and discharge of the indenture governing the debentures and the payment in full of the debentures. Additionally, in the event any subsidiary guarantor no longer guarantees any of the Company's existing or future senior debt incurred in a public or private U.S. capital markets transaction, such guarantor shall be released and relieved of any liability which it has under the indenture governing the debentures.
	Presented below are the consolidating condensed financial statements of Invacare Corporation (Parent), its combined Guarantor Subsidiaries and combined Non-Guarantor Subsidiaries with their investments in subsidiaries accounted for using the equity method. The Company does not believe that separate financial statements of the Guarantor Subsidiaries are material to investors and accordingly, separate financial statements and other disclosures related to the Guarantor Subsidiaries are not presented.
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Three month period ended June 30, 2014	(in thousands)
	Net sales	$	54,612		$	113,337		$	187,778		$	(24,415	)	$	331,312
	Cost of products sold	49,117			84,012			128,602			(24,352		)	237,379
	Gross Profit	5,495			29,325			59,176			(63		)	93,933
	Selling, general and administrative expenses	32,216			23,019			46,310			—			101,545
	Charge related to restructuring activities	890			—			1,200			—			2,090
	Income (loss) from equity investee	14,036			7,696			(28		)	(21,704		)	—
	Interest expense	—			626			209			—			835
	Earnings (Loss) from Continuing Operations before Income Taxes	(13,575		)	13,376			11,429			(21,767		)	(10,537		)
	Income taxes	37			—			3,038			—			3,075
	Net Earnings (loss)	$	(13,612	)	$	13,376		$	8,391		$	(21,767	)	$	(13,612	)
	Other Comprehensive Income (Loss), Net of Tax	(4,277		)	(2,502		)	11,432			(8,930		)	(4,277		)
	Comprehensive Income (Loss)	$	(17,889	)	$	10,874		$	19,823		$	(30,697	)	$	(17,889	)
	Three month period ended June 30, 2013
	Net sales	$	64,903		$	126,020		$	177,582		$	(23,745	)	$	344,760
	Cost of products sold	55,077			91,674			128,350			(23,898		)	251,203
	Gross Profit	9,826			34,346			49,232			153			93,557
	Selling, general and administrative expenses	35,407			23,978			43,353			1,350			104,088
	Charge related to restructuring activities	1,810			13			769			—			2,592
	Income (loss) from equity investee	25,370			6,729			(180		)	(31,919		)	—
	Interest expense (income)—net	(399		)	1,120			20			—			741
	Earnings (Loss) from Continuing Operations before Income Taxes	(1,622		)	15,964			4,910			(33,116		)	(13,864		)
	Income taxes (benefit)	10,839			(25		)	(189		)	—			10,625
	Net Earnings (Loss) from Continuing Operations	(12,461		)	15,989			5,099			(33,116		)	(24,489		)
	Net Earnings from Discontinued Operations	—			12,028			—			—			12,028
	Net Earnings (loss)	$	(12,461	)	$	28,017		$	5,099		$	(33,116	)	$	(12,461	)
	Other Comprehensive Income (Loss), Net of Tax	(8,163		)	1,551			(9,694		)	8,143			(8,163		)
	Comprehensive Income (Loss)	$	(20,624	)	$	29,568		$	(4,595	)	$	(24,973	)	$	(20,624	)
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Six month period ended June 30, 2014	(in thousands)
	Net sales	$	104,721		$	219,791		$	361,578		$	(45,709	)	$	640,381
	Cost of products sold	94,821			161,596			250,492			(45,709		)	461,200
	Gross Profit	9,900			58,195			111,086			—			179,181
	Selling, general and administrative expenses	63,866			45,287			90,413			—			199,566
	Charge related to restructuring activities	2,054			(95		)	2,371			—			4,330
	Income (loss) from equity investee	24,346			14,627			(64		)	(38,909		)	—
	Interest expense (income)—net	(284		)	1,491			366			—			1,573
	Earnings (Loss) from Continuing Operations before Income Taxes	(31,390		)	26,139			17,872			(38,909		)	(26,288		)
	Income taxes	198			—			5,102			—			5,300
	Net Earnings (loss)	$	(31,588	)	$	26,139		$	12,770		$	(38,909	)	$	(31,588	)
	Other Comprehensive Income (Loss), Net of Tax	2,413			(213		)	2,477			(2,264		)	2,413
	Comprehensive Income (Loss)	$	(29,175	)	$	25,926		$	15,247		$	(41,173	)	$	(29,175	)
	Six month period ended June 30, 2013
	Net sales	$	125,812		$	244,456		$	351,507		$	(45,578	)	$	676,197
	Cost of products sold	107,430			177,523			250,055			(45,952		)	489,056
	Gross Profit	18,382			66,933			101,452			374			187,141
	Selling, general and administrative expenses	70,270			47,029			87,330			2,694			207,323
	Charge related to restructuring activities	3,481			13			1,620			—			5,114
	Income (loss) from equity investee	73,388			12,537			(115		)	(85,810		)	—
	Interest expense (income)—net	(444		)	1,556			639			—			1,751
	Earnings (Loss) from Continuing Operations before Income Taxes	18,463			30,872			11,748			(88,130		)	(27,047		)
	Income taxes (benefit)	(4,257		)	(50		)	7,457			—			3,150
	Net Earnings (Loss) from Continuing Operations	22,720			30,922			4,291			(88,130		)	(30,197		)
Net Earnings from Discontinued Operations	—			52,917			—			—			52,917
Net Earnings (loss)	$	22,720		$	83,839		$	4,291		$	(88,130	)	$	22,720
Other Comprehensive Income (Loss), Net of Tax	(8,029		)	(635		)	(7,907		)	8,542			(8,029		)
Comprehensive Income (Loss)	$	14,691		$	83,204		$	(3,616	)	$	(79,588	)	$	14,691
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
June 30, 2014	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	3,222		$	247		$	19,532		$	—		$	23,001
Trade receivables, net	59,657			28,715			99,674			—			188,046
Installment receivables, net	—			482			1,026			—			1,508
Inventories, net	21,578			27,126			118,921			(2,612		)	165,013
Deferred income taxes	—			—			2,246			—			2,246
Intercompany advances, net	9,381			1,092			50,469			(60,942		)	—
Other current assets	6,516			514			33,381			(1,810		)	38,601
Total Current Assets	100,354			58,176			325,249			(65,364		)	418,415
Investment in subsidiaries	1,501,793			467,832			—			(1,969,625		)	—
Intercompany advances, net	999,265			1,676,731			181,680			(2,857,676		)	—
Other Assets	36,416			1,056			2,017			—			39,489
Other Intangibles	454			15,453			42,720			—			58,627
Property and Equipment, net	32,720			15,904			50,962			—			99,586
Goodwill	—			16,660			447,043			—			463,703
Total Assets	$	2,671,002		$	2,251,812		$	1,049,671		$	(4,892,665	)	$	1,079,820
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	52,271		$	9,517		$	61,276		$	—		$	123,064
Accrued expenses	28,961			16,869			84,716			(1,810		)	128,736
Current Taxes, payable and deferred	3,545			—			10,038			—			13,583
Intercompany advances, net	49,257			1,950			9,735			(60,942		)	—
Short-term debt and current maturities of long-term obligations	1,571			8			877			—			2,456
Total Current Liabilities	135,605			28,344			166,642			(62,752		)	267,839
Long-Term Debt	47,986			20			5,654			—			53,660
Other Long-Term Obligations	50,279			—			64,660			—			114,939
Intercompany advances, net	1,793,750			1,000,948			62,978			(2,857,676		)	—
Total Shareholders’ Equity	643,382			1,222,500			749,737			(1,972,237		)	643,382
Total Liabilities and Shareholders’ Equity	$	2,671,002		$	2,251,812		$	1,049,671		$	(4,892,665	)	$	1,079,820
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
December 31, 2013	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	1,401		$	313		$	28,071		$	—		$	29,785
Trade receivables, net	72,272			28,317			88,033			—			188,622
Installment receivables, net	—			452			1,110			—			1,562
Inventories, net	30,806			27,472			100,444			(3,085		)	155,637
Deferred income taxes	—			—			2,761			—			2,761
Intercompany advances, net	4,179			380			44,292			(48,851		)	—
Other current assets	9,970			568			35,461			(4,827		)	41,172
Total Current Assets	118,628			57,502			300,172			(56,763		)	419,539
Investment in subsidiaries	1,475,156			450,021			—			(1,925,177		)	—
Intercompany advances, net	959,071			1,620,683			179,451			(2,759,205		)	—
Other Assets	42,831			1,061			2,044			—			45,936
Other Intangibles	466			17,109			45,009			—			62,584
Property and Equipment, net	35,169			17,774			53,206			—			106,149
Goodwill	—			16,660			445,566			—			462,226
Total Assets	$	2,631,321		$	2,180,810		$	1,025,448		$	(4,741,145	)	$	1,096,434
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	42,521		$	7,237		$	66,946		$	—		$	116,704
Accrued expenses	30,314			17,228			90,385			(4,827		)	133,100
Current Taxes, payable and deferred	5,375			—			6,884			—			12,259
Intercompany advances, net	42,314			2,124			4,413			(48,851		)	—
Short-term debt and current maturities of long-term obligations	13,118			8			976			—			14,102
Total Current Liabilities	133,642			26,597			169,604			(53,678		)	276,165
Long-Term Debt	25,642			61			5,481			—			31,184
Other Long-Term Obligations	53,470			—			64,806			—			118,276
Intercompany advances, net	1,747,758			959,172			52,275			(2,759,205		)	—
Total Shareholders’ Equity	670,809			1,194,980			733,282			(1,928,262		)	670,809
Total Liabilities and Shareholders’ Equity	$	2,631,321		$	2,180,810		$	1,025,448		$	(4,741,145	)	$	1,096,434
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Six month period ended June 30, 2014	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	(11,663	)	$	1,192		$	(3,428	)	$	—		$	(13,899	)
Investing Activities
Purchases of property and equipment	(1,360		)	(1,005		)	(4,533		)	—			(6,898		)
Proceeds from sale of property and equipment	—			—			3			—			3
Other long-term assets	4,922			—			22			—			4,944
Other	46			—			(22		)	—			24
Net Cash Used for Investing Activities	3,608			(1,005		)	(4,530		)	—			(1,927		)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	135,734			—			—			—			135,734
Payments on revolving lines of credit and long-term borrowings	(125,198		)	(253		)	(1,951		)	—			(127,402		)
Proceeds from exercise of stock options	132			—			—			—			132
Payment of dividends	(792		)	—			—			—			(792		)
Net Cash Provided (Used) by Financing Activities	9,876			(253		)	(1,951		)	—			7,672
Effect of exchange rate changes on cash	—			—			1,370			—			1,370
Decrease in cash and cash equivalents	1,821			(66		)	(8,539		)	—			(6,784		)
Cash and cash equivalents at beginning of year	1,401			313			28,071			—			29,785
Cash and cash equivalents at end of period	$	3,222		$	247		$	19,532		$	—		$	23,001
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Six month period ended June 30, 2013	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	27,489		$	(78,678	)	$	(30,512	)	$	51,737		$	(29,964	)
Investing Activities
Purchases of property and equipment	(2,817		)	(2,338		)	(2,511		)	—			(7,666		)
Proceeds from sale of property and equipment	—			—			9			—			9
Proceeds from sale of business	—			144,681			—			—			144,681
Other long-term assets	(419		)	—			(3		)	—			(422		)
Other	117,937			(63,536		)	—			(54,431		)	(30		)
Net Cash Provided (Used) for Investing Activities	114,701			78,807			(2,505		)	(54,431		)	136,572
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	172,878			—			23,521			—			196,399
Payments on revolving lines of credit and long-term borrowings	(318,287		)	(676		)	—			—			(318,963		)
Payment of dividends	(791		)	—			(2,694		)	2,694			(791		)
Net Cash Provided (Used) by Financing Activities	(146,200		)	(676		)	20,827			2,694			(123,355		)
Effect of exchange rate changes on cash	—			—			(597		)	—			(597		)
Decrease in cash and cash equivalents	(4,010		)	(547		)	(12,787		)	—			(17,344		)
Cash and cash equivalents at beginning of year	5,774			1,018			31,999			—			38,791
Cash and cash equivalents at end of period	$	1,764		$	471		$	19,212		$	—		$	21,447

Accounting_Policies_Policies

Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation: The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries and include all adjustments, which were of a normal recurring nature, necessary to present fairly the financial position of the Company as of June 30, 2014, the results of its operations for the six months ended June 30, 2014 and changes in its cash flow for the six months ended June 30, 2014 and 2013, respectively. Certain foreign subsidiaries, represented by the European segment, are consolidated using a May 31 quarter end in order to meet filing deadlines. No material subsequent events have occurred related to the European segment, which would require disclosure or adjustment to the Company's financial statements. All significant intercompany transactions are eliminated.  The results of operations for the six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the full year.
Use of Estimates	'
	Use of Estimates: The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States, which require management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results may differ from these estimates.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recent Accounting Pronouncements: In February 2013, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2013-04, Liabilities (Topic 405), Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation is Fixed at the Reporting Date. This update requires an entity to measure obligations resulting from joint and several liability arrangements for which the total amount of the obligation is fixed at the reporting date, as the sum of a) the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and b) any additional amount the reporting entity expects to pay on behalf of its co-obligors. The update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. The Company adopted ASU No. 2013-04 in the first quarter of 2014 with no impact on the Company’s Condensed Consolidated Statement of Comprehensive Income (Loss), Balance Sheets or Statement of Cash Flows.
	In July 2013, the FASB issued ASU No. 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists." ASU 2013-11 requires an entity to present an unrecognized tax benefit in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss or a tax credit carryforward, with limited exceptions. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. ASU 2013-11 was adopted by the Company on January 1, 2014 and did not have a significant impact on the Company's financial statements.
	In April 2014, the FASB issued ASU 2014-08 changing the presentation of discontinued operations on the statements of income and other requirements for reporting discontinued operations. Under the new standard, a disposal of a component or a group of components of an entity is required to be reported in discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the component meets the criteria to be classified as held for sale or is disposed. The amendments in this update also require additional disclosures about discontinued operations and disposal of an individually significant component of an entity that does not qualify for discontinued operations. This standard must be prospectively applied to all reporting periods presented in financial reports issued after the effective date. Early adoption is permitted for disposals that have not been reported in financial statements previously issued or available for issuance. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2014. If applicable, this standard will change the presentation of the Company's financial statements but will not affect the calculation of net income, comprehensive income or earnings per share. The Company plans to adopt ASU 2014-08 effective January 1, 2015.
	In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers." ASU 2014-09 requires a company to recognize revenue when promised goods or services are transferred to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods and services. The guidance requires five steps to be applied: 1) identify the contract(s) with customers, 2) identify the performance obligations in the contract, 3) determine the transaction price, 4) allocated the transaction price to the performance obligation in the contract and 5) recognize revenue when (or as) the entity satisfies a performance obligation. The guidance also requires both quantitative and qualitative disclosures, which are more comprehensive than existing revenue standards. The disclosures are intended to enable financial statement users to understand the nature, timing and uncertainty of revenue and the related cash flow. An entity can apply the new revenue standard retrospectively to each prior reporting period presented or retrospective with the cumulative effect of initially applying the standard recognized at the date of initial application in retained earnings. The new accounting guidance is effective for annual periods beginning after December 15, 2016 and early adoption is not permitted. The Company is currently reviewing the impact of the adoption of ASU 2014-09 on the Company's financial statements.

Receivables_Tables

Receivables (Tables)	6 Months Ended
	Jun. 30, 2014
Receivables [Abstract]	'
Installment Receivables [Table Text Block]	'
	Installment receivables consist of the following (in thousands):
		June 30, 2014									December 31, 2013
		Current			Long-			Total			Current			Long-			Total
					Term									Term
	Installment receivables	$	3,184		$	6,104		$	9,288		$	3,242		$	5,677		$	8,919
	Less: Unearned interest	(58		)	—			(58		)	(61		)	—			(61		)
		3,126			6,104			9,230			3,181			5,677			8,858
	Allowance for doubtful accounts	(1,618		)	(4,861		)	(6,479		)	(1,619		)	(4,420		)	(6,039		)
		$	1,508		$	1,243		$	2,751		$	1,562		$	1,257		$	2,819
Schedule of Installment Receivables Allowance for Doubtful Accounts [Table Text Block]	'
	The movement in the installment receivables allowance for doubtful accounts was as follows (in thousands):
		Six Months Ended June 30, 2014			Year Ended December 31, 2013
	Balance as of beginning of period	$	6,039		$	3,823
	Current period provision	705			3,457
	Direct write-offs charged against the allowance	(265		)	(1,241		)
	Balance as of end of period	$	6,479		$	6,039
Schedule of Installment Receivables by Class [Table Text Block]	'
	Installment receivables by class as of June 30, 2014 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	7,918		$	7,918		$	6,380		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,271			1,213			—			41
	Impaired Installment receivables with a related allowance recorded	99			99			99			—
	Total Canadian Installment Receivables	$	1,370		$	1,312		$	99		$	41
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,271			1,213			—			41
	Impaired Installment receivables with a related allowance recorded	8,017			8,017			6,479			—
	Total Installment Receivables	$	9,288		$	9,230		$	6,479		$	41
	Installment receivables by class as of December 31, 2013 consist of the following (in thousands):
		Total			Unpaid			Related			Interest
		Installment			Principal			Allowance			Income
		Receivables			Balance			for			Recognized
								Doubtful
								Accounts
	U.S.
	Impaired Installment receivables with a related allowance recorded	$	7,464		$	7,464		$	5,951		$	—
	Canada
	Non-Impaired Installment receivables with no related allowance recorded	1,367			1,306			—			101
	Impaired Installment receivables with a related allowance recorded	88			88			88			—
	Total Canadian Installment Receivables	$	1,455		$	1,394		$	88		$	101
	Total
	Non-Impaired Installment receivables with no related allowance recorded	1,367			1,306			—			101
	Impaired Installment receivables with a related allowance recorded	7,552			7,552			6,039			—
	Total Installment Receivables	$	8,919		$	8,858		$	6,039		$	101
Schedule of Aging of Installment Receivables [Table Text Block]	'
	The aging of the Company’s installment receivables was as follows (in thousands):
		June 30, 2014									31-Dec-13
		Total			U.S.			Canada			Total			U.S.			Canada
	Current	$	1,235		$	—		$	1,235		$	1,338		$	—		$	1,338
	0-30 Days Past Due	4			—			4			7			—			7
	31-60 Days Past Due	5			—			5			—			—			—
	61-90 Days Past Due	—			—			—			—			—			—
	90+ Days Past Due	8,044			7,918			126			7,574			7,464			110
		$	9,288		$	7,918		$	1,370		$	8,919		$	7,464		$	1,455

Inventories_Tables

Inventories (Tables)	6 Months Ended
	Jun. 30, 2014
Inventory, Net [Abstract]	'
Inventories [Table Text Block]	'
	Inventories consist of the following (in thousands):
		30-Jun-14		31-Dec-13
	Finished goods	$	89,439	$	77,909
	Raw materials	62,635		63,123
	Work in process	12,939		14,605
		$	165,013	$	155,637

Other_Current_Assets_Tables

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Other Current Assets [Abstract]	'
Schedule of Other Assets [Table Text Block]	'
	Other current assets consist of the following (in thousands):
		June 30, 2014		December 31, 2013
	Value added tax receivables	$	19,044	$	19,699
	Recoverable income taxes	2,375		2,465
	Derivatives (foreign currency forward contracts)	780		789
	Prepaid insurance	1,258		4,556
	Prepaids and other current assets	15,144		13,663
		$	38,601	$	41,172

Other_LongTerm_Assets_Tables

Other Long-Term Assets (Tables)	6 Months Ended
	Jun. 30, 2014
Text Block [Abstract]	'
Schedule of Other Assets, Noncurrent [Table Text Block]	'
	Other long-term assets consist of the following (in thousands):
		June 30, 2014		December 31, 2013
	Cash surrender value of life insurance policies	$	31,861	$	36,522
	Deferred Financing Fees	451		1,096
	Investments	799		998
	Long-term installment receivables	1,243		1,257
	Long-term deferred taxes	3,894		4,741
	Other	1,241		1,322
		$	39,489	$	45,936

Property_And_Equipment_Tables

Property And Equipment (Tables)	6 Months Ended
	Jun. 30, 2014
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and Equipment
	Property and equipment consist of the following (in thousands):
		June 30, 2014			December 31, 2013
	Machinery and equipment	$	360,402		$	358,061
	Land, buildings and improvements	91,570			91,389
	Furniture and fixtures	13,013			12,774
	Leasehold improvements	15,616			14,931
		480,601			477,155
	Less allowance for depreciation	(381,015		)	(371,006		)
		$	99,586		$	106,149

Other_Intangibles_Tables

Other Intangibles (Tables)	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Definite and Indefinite Lived Intangible Assets [Table Text Block]	'
	The Company's intangibles consist of the following (in thousands):
		June 30, 2014				December 31, 2013
		Historical		Accumulated		Historical		Accumulated
		Cost		Amortization		Cost		Amortization
	Customer Lists	$	92,050	$	68,206	$	92,637	$	65,158
	Trademarks	31,783		—		31,649		—
	License Agreements	1,419		1,419		1,393		1,393
	Developed Technology	9,944		7,510		9,916		7,191
	Patents	6,286		5,781		6,107		5,568
	Other	7,541		7,480		7,702		7,510
		$	149,023	$	90,396	$	149,404	$	86,820

Current_Liabilities_Tables

Current Liabilities (Tables)	6 Months Ended
	Jun. 30, 2014
Payables and Accruals [Abstract]	'
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	'
	Accrued expenses consist of accruals for the following (in thousands):
		June 30, 2014		December 31, 2013
	Salaries and wages	$	34,778	$	40,252
	Taxes other than income taxes, primarily Value Added Taxes	24,863		24,525
	Warranty cost	26,084		27,393
	Freight	7,356		7,636
	Professional	8,166		6,516
	Product liability, current portion	3,410		3,183
	Rebates	2,133		1,681
	Insurance	2,502		2,549
	Interest	1,431		1,041
	Derivative liabilities	1,592		1,212
	Severance	3,491		3,986
	Other items, principally trade accruals	12,930		13,126
		$	128,736	$	133,100

Warrany_Costs_Tables

Warrany Costs (Tables)	6 Months Ended
	Jun. 30, 2014
Accrued Liabilities, Current [Abstract]	'
Accrued Warranty Costs [Table Text Block]	'
	The following is a reconciliation of the changes in accrued warranty costs for the reporting period (in thousands):
	Balance as of January 1, 2014	$	27,393
	Warranties provided during the period	6,964
	Settlements made during the period	(11,171		)
	Changes in liability for pre-existing warranties during the period, including expirations	2,898
	Balance as of June 30, 2014	$	26,084

LongTerm_Debt_Tables

Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2014
Line of Credit Facility [Line Items]	'
Schedule of Line of Credit Facilities [Table Text Block]	'
	An increase in the maximum leverage ratio for the first three quarters of 2014, with quarterly ratios as described in the following table:
	Fiscal Quarter Ending	Maximum Leverage Ratio
	31-Mar-14	4.75		to	1
	30-Jun-14	4.5		to	1
	30-Sep-14	4		to	1
	December 31, 2014 and thereafter	3.5		to	1
	The quarterly minimum interest coverage ratio remains 3.50 to 1.00 in the Amended and Restated Credit Agreement.
Schedule of Debt [Table Text Block]	'
	The liability components of the Company’s convertible debt consist of the following (in thousands):
		June 30, 2014				December 31, 2013
	Principal amount of liability component	$	13,350			$	13,350
	Unamortized discount	(2,364		)		(2,709		)
	Net carrying amount of liability component	$	10,986			$	10,641
Schedule of Long-term Debt Instruments [Table Text Block]	'
	Debt consists of the following (in thousands):
		June 30, 2014				December 31, 2013
	Senior secured revolving credit facility, due in October 2015	$	38,571			$	28,109
	Convertible senior subordinated debentures at 4.125%, due in February 2027	10,986				10,641
	Other notes and lease obligations	6,559				6,536
		56,116				45,286
	Less current maturities of long-term debt	(2,456		)		(14,102		)
		$	53,660			$	31,184

Other_LongTerm_Obligations_Tab

Other Long-Term Obligations (Tables)	6 Months Ended
	Jun. 30, 2014
Other Long-Term Obligations [Abstract]	'
Other Noncurrent Liabilities [Table Text Block]	'
	Other long-term obligations consist of the following (in thousands):
		June 30, 2014		December 31, 2013
	Supplemental Executive Retirement Plan liability	$	26,984	$	27,049
	Product liability	17,292		17,185
	Deferred income taxes	35,393		36,328
	Deferred compensation	9,664		11,679
	Uncertain tax obligation including interest	15,897		15,524
	Other	9,709		10,511
	Total long-term obligations	$	114,939	$	118,276

Shareholders_Equity_Transactio1

Shareholders' Equity Transactions (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The amount of amount of stock-based compensation expense recognized under the provisions of Compensation-Stock Compensation, ASC 718 was as follows (in thousands):
		For the Three Months Ended June 30,							For the Six Months Ended June 30,
		2014				2013			2014			2013
	Stock-based compensation expense recognized as part of selling, general and administrative expense	$	1,771			$	1,414		$	2,470		$	2,574
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes information about stock option activity for the six months ended June 30, 2014:
		June 30, 2014				Weighted
						Average
						Exercise
						Price
	Options outstanding at January 1, 2014	4,533,782				$	23.86
	Granted	8,977				16.71
	Exercised	(8,810		)		14.93
	Canceled	(179,241		)		19.98
	Options outstanding at June 30, 2014	4,354,708				$	24.02
	Options exercise price range at June 30, 2014	$ 12.42 to
		$	47.8
	Options exercisable at June 30, 2014	3,095,001
	Shares available for grant at June 30, 2014*	3,622,692
	________________________
	*	Shares available for grant as of June 30, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 387,068 shares and 440,600 shares, respectively during the quarter.
Schedule of Share-based Compensation, Stock Options Outstanding [Table Text Block]	'
	The following table summarizes information about stock options outstanding at June 30, 2014:
		Options Outstanding									Options Exercisable
	Exercise Prices	Number			Weighted Average		Weighted Average				Number		Weighted Average
		Outstanding			Remaining		Exercise Price				Exercisable		Exercise Price
		At 6/30/14			Contractual Life (Years)						At 6/30/14
	$ 12.42 – $15.00	1,222,011			8.4		$	13.95			307,617		$	13.97
	$ 15.01 – $25.00	1,548,349			4.9		22.47				1,314,501		22.2
	$ 25.01 – $35.00	898,383			5		25.72				786,918		25.77
	$ 35.01 – $47.80	685,965			0.7		43.23				685,965		43.23
	Total	4,354,708			5.2		$	24.02			3,095,001		$	26.95

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2014																Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Abstract]	'																'
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	'																'
	31-Dec-13	$	143,845		$	(12,566	)	$	(5,414	)	$	(709	)	$	125,156		December 31, 2012	$	117,465	$	2,845		$	(6,785	)	$	(782	)	$	112,743
	OCI before reclassifications	(6,493		)	8,205			436			(324		)	1,824			OCI before reclassifications	352		(9,588		)	485			847			(7,904		)
	Amount reclassified from accumulated OCI	—			—			123			466			589			Amount reclassified from accumulated OCI	—		—			(119		)	(6		)	(125		)
	Net current-period OCI	(6,493		)	8,205			559			142			2,413			Net current-period OCI	352		(9,588		)	366			841			(8,029		)
	30-Jun-14	$	137,352		$	(4,361	)	$	(4,855	)	$	(567	)	$	127,569		June 30, 2013	$	117,817	$	(6,743	)	$	(6,419	)	$	59		$	104,714
		Foreign Currency			Long-Term Notes			Defined Benefit Plans			Derivatives			Total			31-Mar-13	$	117,659	$	1,153		$	(6,649	)	$	714		$	112,877
	31-Mar-14	$	149,948		$	(12,021	)	$	(4,872	)	$	(1,209	)	$	131,846
																	OCI before reclassifications	158		(7,896		)	362			(396		)	(7,772		)
	OCI before reclassifications	(12,596		)	7,660			(48		)	302			(4,682		)
																	Amount reclassified from accumulated OCI	—		—			(132		)	(259		)	(391		)
	Amount reclassified from accumulated OCI	—			—			65			340			405
																	Net current-period OCI	158		(7,896		)	230			(655		)	(8,163		)
	Net current-period OCI	(12,596		)	7,660			17			642			(4,277		)
																	30-Jun-13	$	117,817	$	(6,743	)	$	(6,419	)	$	59		$	104,714
	30-Jun-14	$	137,352		$	(4,361	)	$	(4,855	)	$	(567	)	$	127,569
Schedule of Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]	'																'
	Reclassifications out of accumulated OCI for the six months ended June 30, 2014 and June 30, 2013 were as follows (in thousands):
		Amount reclassified from OCI												Affected line item in the Statement of Comprehensive (Income) Loss
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014			2013
	Defined Benefit Plans
	Service and interest costs	65			(138		)	$	123		$	(123	)	Selling, General and Administrative
	Tax	—			6			—			4			Income Taxes
	Total after tax	$	65		$	(132	)	$	123		$	(119	)
	Derivatives
	Foreign currency forward contracts hedging sales	$	138		$	(306	)	$	148		$	(442	)	Net Sales
	Foreign currency forward contracts hedging purchases	251			(31		)	384			325			Cost of Products Sold
	Interest rate swaps	12			59			12			126			Interest Expense
	Total before tax	401			(278		)	544			9
	Tax	(61		)	19			(78		)	(15		)	Income Taxes
	Total after tax	$	340		$	(259	)	$	466		$	(6	)

Charges_Related_To_Restructuri1

Charges Related To Restructuring Activities (Tables)	6 Months Ended
	Jun. 30, 2014
Restructuring and Related Activities [Abstract]	'
Schedule of Restructuring and Related Costs [Table Text Block]	'
	A progression by reporting segment of the accruals recorded as a result of the restructuring is as follows (in thousands):
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	December 31, 2010 Balance
	Total	$	—		$	—		$	—		$	—		$	—
	Charges
	NA/HME	4,755			—			—			4			4,759
	IPG	123			—			—			—			123
	Europe	3,288			277			1,788			113			5,466
	Asia/Pacific	186			—			—			—			186
	Total	8,352			277			1,788			117			10,534
	Payments
	NA/HME	(1,663		)	—			—			(4		)	(1,667		)
	IPG	(52		)	—			—			—			(52		)
	Europe	(1,546		)	(277		)	(1,714		)	(113		)	(3,650		)
	Asia/Pacific	(186		)	—			—			—			(186		)
	Total	(3,447		)	(277		)	(1,714		)	(117		)	(5,555		)
	December 31, 2011 Balance
	NA/HME	3,092			—			—			—			3,092
	IPG	71			—			—			—			71
	Europe	1,742			—			74			—			1,816
	Asia/Pacific	—			—			—			—			—
	Total	4,905			—			74			—			4,979
	Charges
	NA/HME	4,242			—			5			—			4,247
	IPG	35			—			—			—			35
	Europe	817			—			53			1,223			2,093
	Asia/Pacific	1,681			491			1,667			1,181			5,020
	Total	6,775			491			1,725			2,404			11,395
	Payments
	NA/HME	(3,587		)	—			(5		)	—			(3,592		)
	IPG	(106		)	—			—			—			(106		)
	Europe	(1,964		)	—			(127		)	(1,223		)	(3,314		)
	Asia/Pacific	(812		)	(340		)	(42		)	(1,175		)	(2,369		)
	Total	(6,469		)	(340		)	(174		)	(2,398		)	(9,381		)
	December 31, 2012 Balance
	NA/HME	3,747			—			—			—			3,747
	IPG	—			—			—			—			—
	Europe	595			—			—			—			595
	Asia/Pacific	869			151			1,625			6			2,651
	Total	5,211			151			1,625			6			6,993
		Severance			Product Line			Contract			Other			Total
					Discontinuance			Terminations
	Charges
	NA/HME	5,405			—			164			353			5,922
	IPG	267			—			—			—			267
	Europe	1,640			—			—			—			1,640
	Asia/Pacific	970			—			534			3			1,507
	Total	8,282			—			698			356			9,336
	Payments
	NA/HME	(6,347		)	—			(164		)	(353		)	(6,864		)
	IPG	(175		)	—			—			—			(175		)
	Europe	(1,146		)	—			—			—			(1,146		)
	Asia/Pacific	(1,839		)	(151		)	(1,660		)	(9		)	(3,659		)
	Total	(9,507		)	(151		)	(1,824		)	(362		)	(11,844		)
	December 31, 2013 Balance
	NA/HME	2,805			—			—			—			2,805
	IPG	92			—			—			—			92
	Europe	1,089			—			—			—			1,089
	Asia/Pacific	—			—			499			—			499
		3,986			—			499			—			4,485
	Charges
	NA/HME	803			—			—			—			803
IPG	340			—			—			719			1,059
Europe	378			—			—			—			378
Asia/Pacific	—			—			—			—			—
Total	1,521			—			—			719			2,240
Payments
NA/HME	(1,120		)	—			—			—			(1,120		)
IPG	(35		)	—			—			(719		)	(754		)
Europe	(597		)	—			—			—			(597		)
Asia/Pacific	—			—			(154		)	—			(154		)
Total	(1,752		)	—			(154		)	(719		)	(2,625		)
March 31, 2014 Balance
NA/HME	2,488			—			—			—			2,488
IPG	397			—			—			—			397
Europe	870			—			—			—			870
Asia/Pacific	—			—			345			—			345
	$	3,755		$	—		$	345		$	—		$	4,100
Charges
NA/HME	$	845		$	—		$	—		$	—		$	845
IPG	394			—			—			264			658
Europe	58			—			—			525			583
Asia/Pacific	—			—			4			—			4
Total	1,297			—			4			789			2,090
	Severance			Product Line			Contract			Other			Total
				Discontinuance			Terminations
Payments
NA/HME	(1,303		)	—			—			—			(1,303		)
IPG	(32		)	—			—			(264		)	(296		)
Europe	(226		)	—			—			(525		)	(751		)
Asia/Pacific	—			—			—			—			—
Total	(1,561		)	—			—			(789		)	(2,350		)
June 30, 2014 Balance
NA/HME	2,030			—			—			—			2,030
IPG	759			—			—			—			759
Europe	702			—			—			—			702
Asia/Pacific	—			—			349			—			349
	$	3,491		$	—		$	349		$	—		$	3,840

Net_Earnings_Loss_Per_Common_S1

Net Earnings (Loss) Per Common Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	'
	The following table sets forth the computation of basic and diluted net earnings (loss) per common share for the periods indicated.
	(In thousands except per share data)	For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014			2013
	Basic
	Average common shares outstanding	32,017			31,902			32,015			31,902
	Net loss from continuing operations	$	(13,612	)	$	(24,489	)	$	(31,588	)	$	(30,197	)
	Net earnings from discontinued operations	$	—		$	12,028		$	—		$	52,917
	Net earnings (loss)	$	(13,612	)	$	(12,461	)	$	(31,588	)	$	22,720
	Net loss per common share from continuing operations	$	(0.43	)	$	(0.77	)	$	(0.99	)	$	(0.95	)
	Net earnings per common share from discontinued operations	$	—		$	0.38		$	—		$	1.66
	Net earnings (loss) per common share	$	(0.43	)	$	(0.39	)	$	(0.99	)	$	0.71
	Diluted
	Average common shares outstanding	32,017			31,902			32,015			31,902
	Shares related to convertible debt	—			—			—			—
	Stock options and awards	199			122			229			78
	Average common shares assuming dilution	32,216			32,024			32,244			31,980
	Net loss from continuing operations	$	(13,612	)	$	(24,489	)	$	(31,588	)	$	(30,197	)
	Net earnings from discontinued operations	$	—		$	12,028		$	—		$	52,917
	Net earnings (loss)	$	(13,612	)	$	(12,461	)	$	(31,588	)	$	22,720
	Net loss per common share from continuing operations *	$	(0.43	)	$	(0.77	)	$	(0.99	)	$	(0.95	)
	Net earnings per common share from discontinued operations	$	—		$	0.38		$	—		$	1.65
	Net earnings (loss) per common share *	$	(0.43	)	$	(0.39	)	$	(0.99	)	$	0.71
	* Net loss per common share assuming dilution calculated utilizing weighted average shares outstanding-basic for the periods in which there was a net loss.

Derivatives_Tables

Derivatives (Tables)	6 Months Ended
	Jun. 30, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	'
	Outstanding foreign currency forward exchange contracts qualifying and designated for hedge accounting treatment were as follows (in thousands USD):
		June 30, 2014						December 31, 2013
		Notional			Unrealized			Notional			Unrealized
		Amount			Net Gain			Amount			Net Gain
					(Loss)						(Loss)
	USD / AUD	$	1,164		$	(63	)	$	—		$	—
	USD / CNY	6,437			(129		)	11,730			(66		)
	USD / CHF	207			(1		)	486			4
	USD / EUR	31,321			(5		)	51,106			(168		)
	USD / GBP	1,499			(59		)	2,686			(45		)
	USD / NZD	1,266			(25		)	—			—
	USD / SEK	979			37			2,485			58
	USD / MXP	5,730			191			5,960			102
	EUR / AUD	351			(20		)	—			—
	EUR / CAD	798			15			1,710			(1		)
	EUR / CHF	1,559			13			2,654			1
	EUR / DKK	647			(1		)	1,382			(5		)
	EUR / GBP	15,844			(643		)	29,614			(501		)
	EUR / SEK	1,807			88			3,432			75
	EUR / NOK	1,801			(13		)	3,135			66
	EUR / NZD	3,854			232			6,959			(111		)
	AUD / CAD	936			1			—			—
	AUD / NZD	586			(7		)	—			—
	GBP / CHF	448			(21		)	837			(26		)
	GBP / SEK	1,111			(103		)	2,078			(101		)
	DKK / SEK	2,525			(89		)	5,337			(94		)
	NOK / SEK	1,683			(66		)	3,418			31
		$	82,553		$	(668	)	$	135,009		$	(781	)
Schedule of Other Derivatives Not Designated as Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	Foreign currency forward exchange contracts not qualifying or designated for hedge accounting treatment entered into in 2014 and 2013, respectively, and outstanding were as follows (in thousands USD):
		June 30, 2014						31-Dec-13
		Notional			Gain			Notional			Gain
		Amount			(Loss)			Amount			(Loss)
	AUD / USD	$	1,700		$	(16	)	$	225		$	(1	)
	CAD / USD	5,589			28			—			$	—
	CNY / USD	2,599			(43		)	—			—
	EUR / USD	19,157			14			14,867			250
	CHF / USD	—			—			1,645			35
	DKK / USD	5,533			(37		)	—			—
	NZD / USD	7,200			(10		)	3,824			(1		)
	EUR / AUD	—			—			2,039			80
	EUR / CAD	38			1			—			—
	EUR / DKK	68			—			5,470			(3		)
	AUD / CAD	—			—			5,989			10
	AUD / EUR	2,142			(81		)	—			—
	EUR / NOK	8			—			—			—
		$	44,034		$	(144	)	$	34,059		$	370
Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]	'
	The fair values of the Company’s derivative instruments were as follows (in thousands):
		June 30, 2014						December 31, 2013
		Assets			Liabilities			Assets			Liabilities
	Derivatives designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	$	685		$	1,353		$	414		$	1,195
	Interest rate swap contracts	—			—			—			12
	Derivatives not designated as hedging instruments under ASC 815
	Foreign currency forward exchange contracts	95			239			375			5
	Total derivatives	$	780		$	1,592		$	789		$	1,212
Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]	'
	The effect of derivative instruments on Accumulated Other Comprehensive Income (OCI) and the Statement of Comprehensive Income (Loss) and was as follows (in thousands):
	Derivatives in ASC 815 cash flow hedge	Amount of Gain			Amount of Gain  (Loss)			Amount of Gain (Loss)
	relationships	(Loss) Recognized in Accumulated OCI on Derivatives			Reclassified from			Recognized in Income on
		(Effective Portion)			Accumulated  OCI into			Derivatives  (Ineffective Portion
					Income (Effective			and Amount Excluded from
					Portion)			Effectiveness Testing)
	Three months ended June 30, 2014
	Foreign currency forward exchange contracts	$	310		$	(328	)	$	(22	)
	Interest rate swap contracts	(8		)	(12		)	—
		$	302		$	(340	)	$	(22	)
	Six months ended June 30, 2014
	Foreign currency forward exchange contracts	$	(324	)	$	(454	)	$	(22	)
	Interest rate swap contracts	—			(12		)	—
		$	(324	)	$	(466	)	$	(22	)
	Three months ended June, 2013
	Foreign currency forward exchange contracts	$	(533	)	$	318		$	(22	)
	Interest rate swap contracts	137			(59		)	—
		$	(396	)	$	259		$	(22	)
	Six months ended June 30, 2013
	Foreign currency forward exchange contracts	$	447		$	132		$	35
	Interest rate swap contracts	400			(126		)	—
		$	847		$	6		$	35
	Derivatives not designated as hedging							Amount of Gain (Loss)
	instruments under ASC 815							Recognized in Income on Derivatives
	Three months ended June 30, 2014
	Foreign currency forward exchange contracts							$	201
	Six months ended June 30, 2014
	Foreign currency forward exchange contracts							$	(144	)
	Three months ended June 30, 2013
	Foreign currency forward exchange contracts							$	1,427
	Six months ended June 30, 2013
	Foreign currency forward exchange contracts							$	256

Fair_Values_of_Financial_Instr

Fair Values of Financial Instruments (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The following table provides a summary of the Company’s assets and liabilities that are measured on a recurring basis (in thousands).
					Basis for Fair Value Measurements at Reporting Date
					Quoted Prices in Active			Significant				Significant
					Markets for Identical			Other				Other
					Assets / (Liabilities)			Observable				Unobservable
								Inputs				Inputs
		Total			Level I			Level II				Level III
	30-Jun-14
	Forward Exchange Contracts—net	$	(812	)	—			$	(812	)		—
	31-Dec-13
	Forward Exchange Contracts—net	$	(411	)	—			$	(411	)		—
	Interest Rate Swap Agreements—net	(12		)	—			(12		)		—
Fair Value, by Balance Sheet Grouping [Table Text Block]	'
	The carrying values and fair values of the Company’s financial instruments are as follows (in thousands):
		June 30, 2014							December 31, 2013
		Carrying			Fair Value				Carrying				Fair Value
		Value							Value
	Cash and cash equivalents	$	23,001		$	23,001			$	29,785			$	29,785
	Other investments	799			799				998				998
	Installment receivables, net of reserves	2,751			2,751				2,819				2,819
	Long-term debt (including current maturities of long-term debt)	(56,116		)	(55,356		)		(45,286		)		(46,124		)
	Forward contracts in Other Current Assets	780			780				789				789
	Forward contracts in Accrued Expenses	(1,592		)	(1,592		)		(1,200		)		(1,200		)
	Interest rate swap agreements in Accrued Expenses	—			—				(12		)		(12		)

Business_Segments_Tables

Business Segments (Tables)	6 Months Ended
	Jun. 30, 2014
Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The information by segment is as follows (in thousands):
		For the Three Months Ended June 30,						For the Six Months Ended June 30,
		2014			2013			2014			2013
	Revenues from external customers
	North America/HME	$	138,678		$	159,327		$	267,788		$	311,209
	Institutional Products Group	25,785			29,828			50,921			59,052
	Europe	153,990			141,751			296,758			279,385
	Asia/Pacific	12,859			13,854			24,914			26,551
	Consolidated	$	331,312		$	344,760		$	640,381		$	676,197
	Intersegment revenues
	North America/HME	$	20,872		$	20,398		$	39,545		$	39,234
	Institutional Products Group	2,853			1,882			4,426			2,989
	Europe	2,131			2,313			3,813			4,266
	Asia/Pacific	6,158			6,124			12,350			13,006
	Consolidated	$	32,014		$	30,717		$	60,134		$	59,495
	Restructuring charges before income taxes
	North America/HME	$	845		$	1,948		$	1,648		$	3,627
	Institutional Products Group	658			13			1,717			201
	Europe	583			65			961			180
	Asia/Pacific	4			566			4			1,106
	Consolidated	$	2,090		$	2,592		$	4,330		$	5,114
	Earnings (loss) before income taxes
	North America/HME	$	(13,292	)	$	(12,222	)	$	(30,091	)	$	(23,401	)
	Institutional Products Group	(110		)	471			(361		)	945
	Europe	11,763			8,365			21,009			14,208
	Asia/Pacific	(2,298		)	(5,377		)	(5,099		)	(7,638		)
	All Other (1)	(6,600		)	(5,101		)	(11,746		)	(11,161		)
	Consolidated	$	(10,537	)	$	(13,864	)	$	(26,288	)	$	(27,047	)
	________________________
	-1	Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Supplemental_Guarantor_Informa1

Supplemental Guarantor Information Supplemental Guarantor Information (Tables)	6 Months Ended
	Jun. 30, 2014
Supplemental Guarantor Information [Abstract]	'
Condensed Financial Statements [Table Text Block]	'
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Three month period ended June 30, 2014	(in thousands)
	Net sales	$	54,612		$	113,337		$	187,778		$	(24,415	)	$	331,312
	Cost of products sold	49,117			84,012			128,602			(24,352		)	237,379
	Gross Profit	5,495			29,325			59,176			(63		)	93,933
	Selling, general and administrative expenses	32,216			23,019			46,310			—			101,545
	Charge related to restructuring activities	890			—			1,200			—			2,090
	Income (loss) from equity investee	14,036			7,696			(28		)	(21,704		)	—
	Interest expense	—			626			209			—			835
	Earnings (Loss) from Continuing Operations before Income Taxes	(13,575		)	13,376			11,429			(21,767		)	(10,537		)
	Income taxes	37			—			3,038			—			3,075
	Net Earnings (loss)	$	(13,612	)	$	13,376		$	8,391		$	(21,767	)	$	(13,612	)
	Other Comprehensive Income (Loss), Net of Tax	(4,277		)	(2,502		)	11,432			(8,930		)	(4,277		)
	Comprehensive Income (Loss)	$	(17,889	)	$	10,874		$	19,823		$	(30,697	)	$	(17,889	)
	Three month period ended June 30, 2013
	Net sales	$	64,903		$	126,020		$	177,582		$	(23,745	)	$	344,760
	Cost of products sold	55,077			91,674			128,350			(23,898		)	251,203
	Gross Profit	9,826			34,346			49,232			153			93,557
	Selling, general and administrative expenses	35,407			23,978			43,353			1,350			104,088
	Charge related to restructuring activities	1,810			13			769			—			2,592
	Income (loss) from equity investee	25,370			6,729			(180		)	(31,919		)	—
	Interest expense (income)—net	(399		)	1,120			20			—			741
	Earnings (Loss) from Continuing Operations before Income Taxes	(1,622		)	15,964			4,910			(33,116		)	(13,864		)
	Income taxes (benefit)	10,839			(25		)	(189		)	—			10,625
	Net Earnings (Loss) from Continuing Operations	(12,461		)	15,989			5,099			(33,116		)	(24,489		)
	Net Earnings from Discontinued Operations	—			12,028			—			—			12,028
	Net Earnings (loss)	$	(12,461	)	$	28,017		$	5,099		$	(33,116	)	$	(12,461	)
	Other Comprehensive Income (Loss), Net of Tax	(8,163		)	1,551			(9,694		)	8,143			(8,163		)
	Comprehensive Income (Loss)	$	(20,624	)	$	29,568		$	(4,595	)	$	(24,973	)	$	(20,624	)
	CONSOLIDATING CONDENSED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
		The			Combined			Combined			Eliminations			Total
		Company			Guarantor			Non-Guarantor
		(Parent)			Subsidiaries			Subsidiaries
	Six month period ended June 30, 2014	(in thousands)
	Net sales	$	104,721		$	219,791		$	361,578		$	(45,709	)	$	640,381
	Cost of products sold	94,821			161,596			250,492			(45,709		)	461,200
	Gross Profit	9,900			58,195			111,086			—			179,181
	Selling, general and administrative expenses	63,866			45,287			90,413			—			199,566
	Charge related to restructuring activities	2,054			(95		)	2,371			—			4,330
	Income (loss) from equity investee	24,346			14,627			(64		)	(38,909		)	—
	Interest expense (income)—net	(284		)	1,491			366			—			1,573
	Earnings (Loss) from Continuing Operations before Income Taxes	(31,390		)	26,139			17,872			(38,909		)	(26,288		)
	Income taxes	198			—			5,102			—			5,300
	Net Earnings (loss)	$	(31,588	)	$	26,139		$	12,770		$	(38,909	)	$	(31,588	)
	Other Comprehensive Income (Loss), Net of Tax	2,413			(213		)	2,477			(2,264		)	2,413
	Comprehensive Income (Loss)	$	(29,175	)	$	25,926		$	15,247		$	(41,173	)	$	(29,175	)
	Six month period ended June 30, 2013
	Net sales	$	125,812		$	244,456		$	351,507		$	(45,578	)	$	676,197
	Cost of products sold	107,430			177,523			250,055			(45,952		)	489,056
	Gross Profit	18,382			66,933			101,452			374			187,141
	Selling, general and administrative expenses	70,270			47,029			87,330			2,694			207,323
	Charge related to restructuring activities	3,481			13			1,620			—			5,114
	Income (loss) from equity investee	73,388			12,537			(115		)	(85,810		)	—
	Interest expense (income)—net	(444		)	1,556			639			—			1,751
	Earnings (Loss) from Continuing Operations before Income Taxes	18,463			30,872			11,748			(88,130		)	(27,047		)
	Income taxes (benefit)	(4,257		)	(50		)	7,457			—			3,150
	Net Earnings (Loss) from Continuing Operations	22,720			30,922			4,291			(88,130		)	(30,197		)
	Net Earnings from Discontinued Operations	—			52,917			—			—			52,917
	Net Earnings (loss)	$	22,720		$	83,839		$	4,291		$	(88,130	)	$	22,720
	Other Comprehensive Income (Loss), Net of Tax	(8,029		)	(635		)	(7,907		)	8,542			(8,029		)
Comprehensive Income (Loss)	$	14,691		$	83,204		$	(3,616	)	$	(79,588	)	$	14,691
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
June 30, 2014	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	3,222		$	247		$	19,532		$	—		$	23,001
Trade receivables, net	59,657			28,715			99,674			—			188,046
Installment receivables, net	—			482			1,026			—			1,508
Inventories, net	21,578			27,126			118,921			(2,612		)	165,013
Deferred income taxes	—			—			2,246			—			2,246
Intercompany advances, net	9,381			1,092			50,469			(60,942		)	—
Other current assets	6,516			514			33,381			(1,810		)	38,601
Total Current Assets	100,354			58,176			325,249			(65,364		)	418,415
Investment in subsidiaries	1,501,793			467,832			—			(1,969,625		)	—
Intercompany advances, net	999,265			1,676,731			181,680			(2,857,676		)	—
Other Assets	36,416			1,056			2,017			—			39,489
Other Intangibles	454			15,453			42,720			—			58,627
Property and Equipment, net	32,720			15,904			50,962			—			99,586
Goodwill	—			16,660			447,043			—			463,703
Total Assets	$	2,671,002		$	2,251,812		$	1,049,671		$	(4,892,665	)	$	1,079,820
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	52,271		$	9,517		$	61,276		$	—		$	123,064
Accrued expenses	28,961			16,869			84,716			(1,810		)	128,736
Current Taxes, payable and deferred	3,545			—			10,038			—			13,583
Intercompany advances, net	49,257			1,950			9,735			(60,942		)	—
Short-term debt and current maturities of long-term obligations	1,571			8			877			—			2,456
Total Current Liabilities	135,605			28,344			166,642			(62,752		)	267,839
Long-Term Debt	47,986			20			5,654			—			53,660
Other Long-Term Obligations	50,279			—			64,660			—			114,939
Intercompany advances, net	1,793,750			1,000,948			62,978			(2,857,676		)	—
Total Shareholders’ Equity	643,382			1,222,500			749,737			(1,972,237		)	643,382
Total Liabilities and Shareholders’ Equity	$	2,671,002		$	2,251,812		$	1,049,671		$	(4,892,665	)	$	1,079,820
CONSOLIDATING CONDENSED BALANCE SHEETS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
December 31, 2013	(in thousands)
Assets
Current Assets
Cash and cash equivalents	$	1,401		$	313		$	28,071		$	—		$	29,785
Trade receivables, net	72,272			28,317			88,033			—			188,622
Installment receivables, net	—			452			1,110			—			1,562
Inventories, net	30,806			27,472			100,444			(3,085		)	155,637
Deferred income taxes	—			—			2,761			—			2,761
Intercompany advances, net	4,179			380			44,292			(48,851		)	—
Other current assets	9,970			568			35,461			(4,827		)	41,172
Total Current Assets	118,628			57,502			300,172			(56,763		)	419,539
Investment in subsidiaries	1,475,156			450,021			—			(1,925,177		)	—
Intercompany advances, net	959,071			1,620,683			179,451			(2,759,205		)	—
Other Assets	42,831			1,061			2,044			—			45,936
Other Intangibles	466			17,109			45,009			—			62,584
Property and Equipment, net	35,169			17,774			53,206			—			106,149
Goodwill	—			16,660			445,566			—			462,226
Total Assets	$	2,631,321		$	2,180,810		$	1,025,448		$	(4,741,145	)	$	1,096,434
Liabilities and Shareholders’ Equity
Current Liabilities
Accounts payable	$	42,521		$	7,237		$	66,946		$	—		$	116,704
Accrued expenses	30,314			17,228			90,385			(4,827		)	133,100
Current Taxes, payable and deferred	5,375			—			6,884			—			12,259
Intercompany advances, net	42,314			2,124			4,413			(48,851		)	—
Short-term debt and current maturities of long-term obligations	13,118			8			976			—			14,102
Total Current Liabilities	133,642			26,597			169,604			(53,678		)	276,165
Long-Term Debt	25,642			61			5,481			—			31,184
Other Long-Term Obligations	53,470			—			64,806			—			118,276
Intercompany advances, net	1,747,758			959,172			52,275			(2,759,205		)	—
Total Shareholders’ Equity	670,809			1,194,980			733,282			(1,928,262		)	670,809
Total Liabilities and Shareholders’ Equity	$	2,631,321		$	2,180,810		$	1,025,448		$	(4,741,145	)	$	1,096,434
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Six month period ended June 30, 2014	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	(11,663	)	$	1,192		$	(3,428	)	$	—		$	(13,899	)
Investing Activities
Purchases of property and equipment	(1,360		)	(1,005		)	(4,533		)	—			(6,898		)
Proceeds from sale of property and equipment	—			—			3			—			3
Other long-term assets	4,922			—			22			—			4,944
Other	46			—			(22		)	—			24
Net Cash Used for Investing Activities	3,608			(1,005		)	(4,530		)	—			(1,927		)
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	135,734			—			—			—			135,734
Payments on revolving lines of credit and long-term borrowings	(125,198		)	(253		)	(1,951		)	—			(127,402		)
Proceeds from exercise of stock options	132			—			—			—			132
Payment of dividends	(792		)	—			—			—			(792		)
Net Cash Provided (Used) by Financing Activities	9,876			(253		)	(1,951		)	—			7,672
Effect of exchange rate changes on cash	—			—			1,370			—			1,370
Decrease in cash and cash equivalents	1,821			(66		)	(8,539		)	—			(6,784		)
Cash and cash equivalents at beginning of year	1,401			313			28,071			—			29,785
Cash and cash equivalents at end of period	$	3,222		$	247		$	19,532		$	—		$	23,001
CONSOLIDATING CONDENSED STATEMENTS OF CASH FLOWS
	The			Combined			Combined			Eliminations			Total
	Company			Guarantor			Non-Guarantor
	(Parent)			Subsidiaries			Subsidiaries
Six month period ended June 30, 2013	(in thousands)
Net Cash Provided (Used) by Operating Activities	$	27,489		$	(78,678	)	$	(30,512	)	$	51,737		$	(29,964	)
Investing Activities
Purchases of property and equipment	(2,817		)	(2,338		)	(2,511		)	—			(7,666		)
Proceeds from sale of property and equipment	—			—			9			—			9
Proceeds from sale of business	—			144,681			—			—			144,681
Other long-term assets	(419		)	—			(3		)	—			(422		)
Other	117,937			(63,536		)	—			(54,431		)	(30		)
Net Cash Provided (Used) for Investing Activities	114,701			78,807			(2,505		)	(54,431		)	136,572
Financing Activities
Proceeds from revolving lines of credit and long-term borrowings	172,878			—			23,521			—			196,399
Payments on revolving lines of credit and long-term borrowings	(318,287		)	(676		)	—			—			(318,963		)
Payment of dividends	(791		)	—			(2,694		)	2,694			(791		)
Net Cash Provided (Used) by Financing Activities	(146,200		)	(676		)	20,827			2,694			(123,355		)
Effect of exchange rate changes on cash	—			—			(597		)	—			(597		)
Decrease in cash and cash equivalents	(4,010		)	(547		)	(12,787		)	—			(17,344		)
Cash and cash equivalents at beginning of year	5,774			1,018			31,999			—			38,791
Cash and cash equivalents at end of period	$	1,764		$	471		$	19,212		$	—		$	21,447

Discontinued_Operations_Detail

Discontinued Operations (Details) (USD $)	6 Months Ended		0 Months Ended		3 Months Ended	6 Months Ended		0 Months Ended	3 Months Ended	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jan. 18, 2013	Dec. 21, 2012	Mar. 31, 2013	Jun. 30, 2014	Jun. 30, 2013	Aug. 06, 2013	Sep. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
			ISG [Member]	ISG [Member]	ISG [Member]	ISG [Member]	ISG [Member]	Champion [Member]	Champion [Member]	Champion [Member]	Champion [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Agreement to Sell Operations Date	'	'	'	21-Dec-12	'	'	'	'	'	'	'
Disposal Date	'	'	18-Jan-13	'	'	'	'	6-Aug-13	'	'	'
Proceeds from Divestiture of Businesses	'	'	$150,800,000	'	'	'	'	$45,000,000	'	'	'
Gain on sale of businesses (pre-tax)	0	59,402,000	'	'	-59,402,000	'	'	'	-22,761,000	'	'
Disposal Group, Expenses Related to Sale of Business	'	'	'	'	'	5,350,000	'	'	'	2,130,000	'
Disposal Group, Expenses Related to Sale of Business, cash paid	'	'	'	'	'	5,227,000	'	'	'	1,542,000	'
Net Sales from Discontinued Operations	'	'	'	'	'	'	18,498,000	'	'	'	13,214,000
Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax	'	'	'	'	'	'	402,000	'	'	'	2,672,000
Interest Expense Allocation from Continuing to Discontinuing Operations	'	'	'	'	'	'	'	'	'	'	$371,000

Receivables_Narrative_Details

Receivables Narrative (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Allowance for Doubtful Accounts Receivable	$16,022,000	$17,715,000
Number of Missed Payments before Delinquent	3	'
Typical Financing Period	'12 months	'
Credit amount requiring additional analysis	250,000	'
Average Period of Adjudication	'18 months	'
Installment receivable purchased from DLL	$1,688,000	'

Receivables_Details

Receivables (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Total Installment Receivables	$9,288	$8,919	'
Installment Receivables, Net of Unearned Interest	9,230	8,858	'
Allowance for doubtful accounts	6,479	6,039	'
Installment receivables, net	1,508	1,562	'
Installment receivables, net, long-term	1,243	1,257	'
Installment Receivables [Member]	'	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'	'
Installment Receivables, Current	3,184	3,242	'
Installment Receivables, Long-Term	6,104	5,677	'
Total Installment Receivables	9,288	8,919	'
Unearned Interest, Current	-58	-61	'
Unearned Interest, Noncurrent	0	0	'
Total Unearned Interest	58	61	'
Installment Receivables Net of Unearned Interest Current	3,126	3,181	'
Installment Receivables Net of Unearned Interest Noncurrent	6,104	5,677	'
Installment Receivables, Net of Unearned Interest	9,230	8,858	'
Allowance for doubtful accounts, current	-1,618	-1,619	'
Allowance for doubtful accounts, long-term	-4,861	-4,420	'
Allowance for doubtful accounts	6,479	6,039	3,823
Installment receivables, net	1,508	1,562	'
Installment receivables, net, long-term	1,243	1,257	'
Installment receivables, net	$2,751	$2,819	'

Receivables_Rollforward_of_All

Receivables Rollforward of Allowance for Doubtful Accounts (Details) (USD $)	6 Months Ended			12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Dec. 31, 2013
			Installment Receivables [Member]	Installment Receivables [Member]
Allowance for Doubtful Accounts [Roll Forward]	'	'	'	'
Balance as of January 1	$6,039	'	$6,039	$3,823
Current period provision	1,143	1,603	705	3,457
Direct write-offs charged against the allowance	'	'	-265	-1,241
Balance as of December 31	$6,479	'	$6,479	$6,039

Receivables_Installment_Receiv

Receivables Installment Receivables by Class (Details) (USD $)	6 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Dec. 31, 2013
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	$9,288	$8,919
Unpaid Principal Balance	9,230	8,858
Related Allowance for Doubtful Accounts	6,479	6,039
Interest Income Recognized	41	101
CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,370	1,455
Unpaid Principal Balance	1,312	1,394
Related Allowance for Doubtful Accounts	99	88
Interest Income Recognized	41	101
Impaired Installment Receivables with Related Allowance [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	8,017	7,552
Unpaid Principal Balance	8,017	7,552
Related Allowance for Doubtful Accounts	6,479	6,039
Interest Income Recognized	0	0
Impaired Installment Receivables with Related Allowance [Member] | U.S.	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	7,918	7,464
Unpaid Principal Balance	7,918	7,464
Related Allowance for Doubtful Accounts	6,380	5,951
Interest Income Recognized	0	0
Impaired Installment Receivables with Related Allowance [Member] | CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	99	88
Unpaid Principal Balance	99	88
Related Allowance for Doubtful Accounts	99	88
Interest Income Recognized	0	0
Installment Receivables [Member]	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,271	1,367
Unpaid Principal Balance	1,213	1,306
Related Allowance for Doubtful Accounts	0	0
Interest Income Recognized	41	101
Installment Receivables [Member] | CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Total Installment Receivables	1,271	1,367
Unpaid Principal Balance	1,213	1,306
Related Allowance for Doubtful Accounts	0	0
Interest Income Recognized	$41	$101

Receivables_Aging_of_Installme

Receivables Aging of Installment Receivables (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	$1,235	$1,338
0-30 Days Past Due	4	7
31-60 Days Past Due	5	0
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	8,044	7,574
Total Installment Receivables Past Due	9,288	8,919
U.S.	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	0	0
0-30 Days Past Due	0	0
31-60 Days Past Due	0	0
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	7,918	7,464
Total Installment Receivables Past Due	7,918	7,464
CANADA	'	'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'	'
Current	1,235	1,338
0-30 Days Past Due	4	7
31-60 Days Past Due	5	0
61-90 Days Past Due	0	0
Greater than 90 Days Past Due	126	110
Total Installment Receivables Past Due	$1,370	$1,455

Inventories_Details

Inventories (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net [Abstract]	'	'
Finished goods	$89,439	$77,909
Raw materials	62,635	63,123
Work in process	12,939	14,605
Inventory, Net	$165,013	$155,637

Other_Current_Assets_Details

Other Current Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Other Current Assets [Abstract]	'	'
Value Added Tax Receivables	$19,044	$19,699
Recoverable Income Taxes	2,375	2,465
Derivative Assets	780	789
Prepaid Insurance	1,258	4,556
Prepaid Expense and Other Current Assets	15,144	13,663
Other current assets	$38,601	$41,172

Other_LongTerm_Assets_Details

Other Long-Term Assets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Text Block [Abstract]	'	'
Cash Surrender Value of Life Insurance	$31,861	$36,522
Deferred Financing Fees	451	1,096
Investments	799	998
Installment receivables, net, long-term	1,243	1,257
Long-term Deferred Taxes	3,894	4,741
Prepaid Expense and Other Assets, Noncurrent	1,241	1,322
Other Assets	$39,489	$45,936

Property_And_Equipment_Details

Property And Equipment (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$480,601	$477,155
Less allowance for depreciation	-381,015	-371,006
Property and Equipment, net	99,586	106,149
Machinery and Equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	360,402	358,061
Land, Buildings and Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	91,570	91,389
Furniture and Fixtures [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	13,013	12,774
Leasehold Improvements [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property, Plant and Equipment, Gross	$15,616	$14,931

Other_Intangibles_Narrative_De

Other Intangibles Narrative (Details) (USD $)	6 Months Ended			6 Months Ended
	Jun. 30, 2014	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2014	Jun. 30, 2014
		Trademarks [Member]	Trademarks [Member]	Minimum [Member]	Maximum [Member]
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'
Indefinite-lived Intangible Assets	'	$31,783,000	$31,649,000	'	'
Finite-Lived Intangible Assets, Useful Life, Minimum	'	'	'	'1 year	'11 years
Finite-Lived Intangible Assets, Average Useful Life	'6 years	'	'	'	'
Finite-Lived Intangible Assets, Amortization Expense	$4,353,000	'	'	'	'

Other_Intangibles_Details

Other Intangibles (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	$149,023,000	$149,404,000
Finite-Lived Intangible Assets, Accumulated Amortization	90,396,000	86,820,000
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	92,050,000	92,637,000
Finite-Lived Intangible Assets, Accumulated Amortization	68,206,000	65,158,000
Licensing Agreements [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	1,419,000	1,393,000
Finite-Lived Intangible Assets, Accumulated Amortization	1,419,000	1,393,000
Developed Technology Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	9,944,000	9,916,000
Finite-Lived Intangible Assets, Accumulated Amortization	7,510,000	7,191,000
Patents [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	6,286,000	6,107,000
Finite-Lived Intangible Assets, Accumulated Amortization	5,781,000	5,568,000
Other Intangible Assets [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Intangible Assets, Gross	7,541,000	7,702,000
Finite-Lived Intangible Assets, Accumulated Amortization	7,480,000	7,510,000
Trademarks [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Indefinite-lived Intangible Assets	$31,783,000	$31,649,000

Other_Intangibles_FiniteLived_

Other Intangibles Finite-Lived Intangible Asset Future Amortization Expense (Details) (USD $)	Jun. 30, 2014
Finite-Lived Intangible Assets [Line Items]	'
Future Amortization Expense, Entire Fiscal Year	$8,519,000
Future Amortization Expense, Year One	7,091,000
Future Amortization Expense, Year Two	5,682,000
Future Amortization Expense, Year Three	2,289,000
Future Amortization Expense, Year Four	2,276,000
Future Amortization Expense, Year Five	$2,266,000

Current_Liabilities_Details

Current Liabilities (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]	'	'
Salaries and Wages	$34,778	$40,252
Taxes other than income taxes, primarily Value Added Taxes	24,863	24,525
Product Warranty Accrual, Current	26,084	27,393
Freight	7,356	7,636
Professional	8,166	6,516
Product Liability, Current Portion	3,410	3,183
Rebates	2,133	1,681
Insurance	2,502	2,549
Interest	1,431	1,041
Derivative Liabilities	1,592	1,212
Severance	3,491	3,986
Other items, principally trade accruals	12,930	13,126
Accrued expenses	$128,736	$133,100

Warrany_Costs_Warranty_Schedul

Warrany Costs Warranty Schedule (Details) (USD $)	6 Months Ended
	Jun. 30, 2014
Product Liability Contingency [Line Items]	'
Loss Contingency Accrual, at Carrying Value	$2,237,000
Balance at Beginning of Period	27,393,000
Warranties provided during the period	6,964,000
Settlements made during the period	-11,171,000
Changes in liability for pre-existing warranties during the period, including expirations	2,898,000
Balance at of End of Period	26,084,000
Loss Contingency Accrual Carrying Value, Net of Tax	2,100,000
NA/HME [Member]	'
Product Liability Contingency [Line Items]	'
Loss Contingency Accrual, at Carrying Value	1,171,000
Asia Pacific [Member]	'
Product Liability Contingency [Line Items]	'
Loss Contingency Accrual, at Carrying Value	$929,000

LongTerm_Debt_Details

Long-Term Debt (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Jan. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]	'	'	'
Increase in Basis Points in the Margin Applicable to Determing the Interest Rate on New Debt	'	25	'
Payments of Debt Issuance Costs	$351,000	'	'
Future One-Time Cash Restructuring Charges Added Back to EBITDA	20,000,000	'	'
Incremental Increase to Future One-Time Cash Restructuring Charges Added Back to EBITDA	5,000,000	'	'
Long-term Debt	56,116,000	'	45,286,000
Long-term Debt, Current Maturities	-2,456,000	'	-14,102,000
Long-term Debt, Excluding Current Maturities	53,660,000	'	31,184,000
Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity	100,000,000	250,000,000	'
Long-term Debt	38,571,000	'	28,109,000
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term Debt	10,986,000	'	10,641,000
Write off of Deferred Debt Issuance Cost	1,070,000	'	'
Notes Payable, Other Payables [Member] | Other Notes and Lease Obligations [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term Debt	6,559,000	'	6,536,000
Maximum [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Reductions in Capital Expenditures	$25,000,000	'	'
Minimum [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Ratio of Earnings before Interest Taxes Depreciation and Amortization to Interest Expense	3.5	'	'
Minimum [Member] | Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	1	'	'
Q1 Current Year [Member] | Maximum [Member] | Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	4.75	'	'
Q2 Current Year [Member] | Maximum [Member] | Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	4.5	'	'
Q3 Current Year [Member] | Maximum [Member] | Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	4	'	'
Q4 Current Year [Member] | Maximum [Member] | Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	3.5	'	'

LongTerm_Debt_Line_of_Credit_D

Long-Term Debt Line of Credit (Details) (USD $)	1 Months Ended	6 Months Ended
	Jan. 31, 2014	Jun. 30, 2014
Debt Instrument [Line Items]	'	'
Debt Amendment Date	31-Jan-14	'
Future One-Time Cash Restructuring Charges Added Back to EBITDA	'	$20,000,000
Increase in Basis Points in the Margin Applicable to Determing the Interest Rate on New Debt	25	'
Payments of Debt Issuance Costs	'	351,000
Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Line of Credit Facility, Maximum Borrowing Capacity	250,000,000	100,000,000
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'
Debt Instrument [Line Items]	'	'
Write off of Deferred Debt Issuance Cost	'	$1,070,000
Minimum [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Ratio of Earnings before Interest Taxes Depreciation and Amortization to Interest Expense	'	3.5
Minimum [Member] | Line of Credit [Member] | Senior Secured Revolving Credit Facility October 2015 [Member]	'	'
Debt Instrument [Line Items]	'	'
Ratio of Indebtedness to Earnings Before Interest Taxes Depreciation and Amortization	'	1

LongTerm_Debt_Convertible_Debt

Long-Term Debt Convertible Debt (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Feb. 17, 2007
Debt Instrument [Line Items]	'	'	'
Long-term Debt	$56,116,000	$45,286,000	'
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Long-term Debt	10,986,000	10,641,000	'
Debt Instrument, Convertible, Principal amount of Liability Component	13,350,000	13,350,000	'
Debt Instrument, Unamortized Discount	-2,364,000	-2,709,000	'
Principal Amount	'	'	$135,000,000
Interest Rate	4.13%	'	'

LongTerm_Debt_Interest_Rate_Sw

Long-Term Debt Interest Rate Swaps (Details)	Jun. 30, 2014	Dec. 31, 2013
Derivative [Line Items]	'	'
Long-term Debt, Weighted Average Interest Rate	2.28%	2.39%

LongTerm_Debt_Components_of_Co

Long-Term Debt Components of Convertible Debt (Details) (Convertible Subordinated Debt [Member], Convertible Senior Subordinated Debentures February 2027 [Member], USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Convertible Subordinated Debt [Member] | Convertible Senior Subordinated Debentures February 2027 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Convertible, Principal amount of Liability Component	$13,350	$13,350
Debt Instrument, Unamortized Discount	-2,364	-2,709
Convertible Debt	$10,986	$10,641

Other_LongTerm_Obligations_Det

Other Long-Term Obligations (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013
Other Long-Term Obligations [Abstract]	'	'	'
Defined Benefit Pension Plan, Liabilities, Noncurrent	$26,984,000	$27,049,000	'
Product Liability, Noncurrent	17,292,000	17,185,000	'
Deferred Income Taxes and Other Tax Liabilities, Noncurrent	35,393,000	36,328,000	'
Deferred Compensation Liability, Classified, Noncurrent	9,664,000	11,679,000	'
Liability for Uncertain Tax Positions, Noncurrent	15,897,000	15,524,000	9,702,000
Other Liabilities	9,709,000	10,511,000	'
Other Liabilities, Noncurrent	$114,939,000	$118,276,000	'

Shareholders_Equity_Transactio2

Shareholders' Equity Transactions Narrative (Details) (USD $)	0 Months Ended			3 Months Ended			6 Months Ended
	21-May-13	16-May-13	Mar. 27, 2013	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	4,460,337	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	'	'	'	'		'	8,977		'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number	'	'	'	27,925		'	27,925		'
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations	'	'	'	'		'	7,400		'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	21-May-13	'	'	'		'	'		'
Annual Shareholder Meeting Date	'	16-May-13	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Adoption date	'	'	27-Mar-13	'		'	'		'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	'	$15,415,000		'	$15,415,000		'
Allocated Share-based Compensation Expense	'	'	'	1,771,000		1,414,000	2,470,000		2,574,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'	'		'	'2 years		'
Restricted Stock [Member]	'	'	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'	'		'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	'	'	'	'		'	387,068		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'		'	'3 years		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	'	'	'	558,271		'	558,271		'
Allocated Share Based Compensation Expense Recognized Weighted Average Period	'	'	'	'		'	'1 year 6 months		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	'		'	193,534		'
Stock Issued During Period, Shares, Restricted Stock Award, Forfeited	'	'	'	'		'	25,016		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vesting Entirety Date	'	'	'	'		'	15-May-17		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	'	'		'	$20.01		'
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	'	'	'	6,490,000		'	6,490,000		'
Allocated Share-based Compensation Expense	'	'	'	'		'	867,000		'
Stock Options [Member]	'	'	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'		'	'4 years		'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	'	3,622,692	[1]	'	3,622,692	[1]	'
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award	'	'	'	'		'	'P10Y		'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	'	'	'	6,148,000		'	6,148,000		'
Allocated Share-based Compensation Expense	'	'	'	'		'	1,356,000		'
Performance Shares [Member]	'	'	'	'		'	'		'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'		'	'		'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	'	'	'	'		'	440,600		'
Allocated Share Based Compensation Expense Recognized Weighted Average Period	'	'	'	'		'	'3 years 0 months		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'	'	'	'		'	152,800		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	'	'	'	'		'	$20.05		'
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period	'	'	'	'		'	'3 years		'
Period of Performance Award Measurement, Beginning	'	'	'	'		'	1-Jan-16		'
Period of Performance Award Measurement, Ending	'	'	'	'		'	31-Dec-16		'
Level of Performance Award Achievement, Minimum	'	'	'	'		'	0.00%		'
Level of Performance Award Achievement, Maximum	'	'	'	'		'	150.00%		'
Level of Performance Award Achievement, Target	'	'	'	'		'	100.00%		'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested	'	'	'	2,777,000		'	2,777,000		'
Allocated Share-based Compensation Expense	'	'	'	'		'	$247,000		'
[1]	*Shares available for grant as of JuneB 30, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 387,068 shares and 440,600

Shareholders_Equity_Transactio3

Shareholders' Equity Transactions Options Activity (Details) (USD $)	3 Months Ended			6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013	Jun. 30, 2014		Jun. 30, 2013	16-May-13
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'		'	'
Allocated Share-based Compensation Expense	$1,771,000		$1,414,000	$2,470,000		$2,574,000	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'	'		'	'
Options outstanding at beginning of period	'		'	4,533,782		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	'		'	8,977		'	'
Excercised	'		'	-8,810		'	'
Canceled	'		'	-179,241		'	'
Options outstanding at end of period	4,354,708		'	4,354,708		'	'
Granted Weighted Average Exercise Price	'		'	$16.71		'	'
Options outstanding at beginning of period Weighted Average Exercise Price	'		'	$23.86		'	'
Excercised Weighted Average Exercise Price	'		'	$0		'	'
Canceled Weighted Average Exercise Price	'		'	$19.98		'	'
Options outstanding at end of period Weighted Average Exercise Price	$24.02		'	$24.02		'	'
Options exercise price range at end of period, Lower Limit	'		'	$12.42		'	'
Options exercise price range at end of period, Upper Limit	'		'	$47.80		'	'
Options exercisable at end of period	3,095,001		'	3,095,001		'	'
Options available for grant at end of period	'		'	'		'	4,460,337
Stock Options [Member]	'		'	'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'		'	'
Allocated Share-based Compensation Expense	'		'	1,356,000		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]	'		'	'		'	'
Options available for grant at end of period	3,622,692	[1]	'	3,622,692	[1]	'	'
Restricted Stock [Member]	'		'	'		'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'		'	'		'	'
Allocated Share-based Compensation Expense	'		'	$867,000		'	'
Share Based Compensation Arrangement By Share Based Payment Award Net Restricted Stock Award Activity	'		'	387,068		'	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	'		'	193,534		'	'
[1]	*Shares available for grant as of JuneB 30, 2014 reduced by net restricted stock and restricted stock unit award and performance share and performance share unit award activity of 387,068 shares and 440,600

Shareholders_Equity_Transactio4

Shareholders' Equity Transactions Stock Options Outstanding by Exercise Price (Details) (USD $)	6 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	8,977	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'2 years	'
Range of Exercise Price, Lower Limit	$12.42	'
Range of Exercise Price, Upper Limit	$47.80	'
Number Outstanding at end of period	4,354,708	'
Weighted Average Remaining Contractual Life	'5 years 2 months 13 days	'
Weighted Average Exercise Price	$24.02	$23.86
Number Exercisable At end of period	3,095,001	'
Weighted Average Exercise Price	$26.95	'
Range of Exercise Price 12.42 to 15.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$12.42	'
Range of Exercise Price, Upper Limit	$15	'
Number Outstanding at end of period	1,222,011	'
Weighted Average Remaining Contractual Life	'8 years 4 months 13 days	'
Weighted Average Exercise Price	$13.95	'
Number Exercisable At end of period	307,617	'
Weighted Average Exercise Price	$13.97	'
Range of Exercise Price 15.01 to 25.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$15.01	'
Range of Exercise Price, Upper Limit	$25	'
Number Outstanding at end of period	1,548,349	'
Weighted Average Remaining Contractual Life	'4 years 10 months 13 days	'
Weighted Average Exercise Price	$22.47	'
Number Exercisable At end of period	1,314,501	'
Weighted Average Exercise Price	$22.20	'
Range of Exercise Price 25.01 to 35.00 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$25.01	'
Range of Exercise Price, Upper Limit	$35	'
Number Outstanding at end of period	898,383	'
Weighted Average Remaining Contractual Life	'5 years 0 months 13 days	'
Weighted Average Exercise Price	$25.72	'
Number Exercisable At end of period	786,918	'
Weighted Average Exercise Price	$25.77	'
Range of Exercise Price 35.01 to 47.80 [Member]	'	'
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]	'	'
Range of Exercise Price, Lower Limit	$35.01	'
Range of Exercise Price, Upper Limit	$47.80	'
Number Outstanding at end of period	685,965	'
Weighted Average Remaining Contractual Life	'0 years 8 months 13 days	'
Weighted Average Exercise Price	$43.23	'
Number Exercisable At end of period	685,965	'
Weighted Average Exercise Price	$43.23	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	$131,846	$112,877	$125,156	$112,743
OCI before reclassifications	-4,682	-7,772	1,824	-7,904
Amount reclassified from accumulated OCI	405	-391	589	-125
Other Comprehensive Income (Loss)	-4,277	-8,163	2,413	-8,029
Ending Balance	127,569	104,714	127,569	104,714
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Net Sales	331,312	344,760	640,381	676,197
Cost of Products Sold	237,379	251,203	461,200	489,056
Amortization of prior service costs and unrecognized gains (losses)	15	236	723	536
Interest Expense	-835	-741	-1,573	-1,751
Income tax provision	-3,075	-10,625	-5,300	-3,150
Accumulated Translation Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	149,948	117,659	143,845	117,465
OCI before reclassifications	-12,596	158	-6,493	352
Amount reclassified from accumulated OCI	0	0	0	0
Other Comprehensive Income (Loss)	-12,596	158	-6,493	352
Ending Balance	137,352	117,817	137,352	117,817
Accumulated Long-Term Notes Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	-12,021	1,153	-12,566	2,845
OCI before reclassifications	7,660	-7,896	8,205	-9,588
Amount reclassified from accumulated OCI	0	0	0	0
Other Comprehensive Income (Loss)	7,660	-7,896	8,205	-9,588
Ending Balance	-4,361	-6,743	-4,361	-6,743
Accumulated Defined Benefit Plans Adjustment [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	-4,872	-6,649	-5,414	-6,785
OCI before reclassifications	-48	362	436	485
Amount reclassified from accumulated OCI	65	-132	123	-119
Other Comprehensive Income (Loss)	17	230	559	366
Ending Balance	-4,855	-6,419	-4,855	-6,419
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Amortization of prior service costs and unrecognized gains (losses)	65	-138	123	-123
Income tax provision	0	6	0	4
Total after tax	65	-132	123	-119
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Beginning Balance	-1,209	714	-709	-782
OCI before reclassifications	302	-396	-324	847
Amount reclassified from accumulated OCI	340	-259	466	-6
Other Comprehensive Income (Loss)	642	-655	142	841
Ending Balance	-567	59	-567	59
Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Total before tax	401	-278	544	9
Income tax provision	-61	19	-78	-15
Total after tax	340	-259	466	-6
Foreign Exchange Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Net Sales	138	-306	148	-442
Commodity Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Cost of Products Sold	251	-31	384	325
Interest Rate Contract [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]	'	'	'	'
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Abstract]	'	'	'	'
Interest Expense	$12	$59	$12	$126

Charges_Related_To_Restructuri2

Charges Related To Restructuring Activities (Details) (USD $)	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	$4,100,000	$4,485,000	$4,485,000	$6,993,000	$4,979,000	$0
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	10,534,000
Restructuring Reserve, Settled with Cash	-2,350,000	-2,625,000	-4,975,000	-11,844,000	-9,381,000	-5,555,000
Restructuring Reserve, Ending Balance	3,840,000	4,100,000	3,840,000	4,485,000	6,993,000	4,979,000
Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	3,755,000	3,986,000	3,986,000	5,211,000	4,905,000	0
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	8,352,000
Restructuring Reserve, Settled with Cash	-1,561,000	-1,752,000	'	-9,507,000	-6,469,000	-3,447,000
Restructuring Reserve, Ending Balance	3,491,000	3,755,000	3,491,000	3,986,000	5,211,000	4,905,000
Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	151,000	0	0
Restructuring Reserve, Settled with Cash	0	0	'	-151,000	-340,000	-277,000
Restructuring Reserve, Ending Balance	0	0	0	0	151,000	0
Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	345,000	499,000	499,000	1,625,000	74,000	0
Restructuring Reserve, Settled with Cash	0	-154,000	'	-1,824,000	-174,000	-1,714,000
Restructuring Reserve, Ending Balance	349,000	345,000	349,000	499,000	1,625,000	74,000
Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	6,000	0	0
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	117,000
Restructuring Reserve, Settled with Cash	-789,000	-719,000	'	-362,000	-2,398,000	-117,000
Restructuring Reserve, Ending Balance	0	0	0	0	6,000	0
NA/HME [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	2,488,000	2,805,000	2,805,000	3,747,000	3,092,000	'
Restructuring Reserve, Settled with Cash	-1,303,000	-1,120,000	'	-6,864,000	-3,592,000	-1,667,000
Restructuring Reserve, Ending Balance	2,030,000	2,488,000	2,030,000	2,805,000	3,747,000	3,092,000
NA/HME [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	2,488,000	2,805,000	2,805,000	3,747,000	3,092,000	'
Restructuring Reserve, Settled with Cash	-1,303,000	-1,120,000	'	-6,347,000	-3,587,000	-1,663,000
Restructuring Reserve, Ending Balance	2,030,000	2,488,000	2,030,000	2,805,000	3,747,000	3,092,000
NA/HME [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	0	0	'	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
NA/HME [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	0	0	'	-164,000	-5,000	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
NA/HME [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	0	0	'	-353,000	0	-4,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
IPG [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	397,000	92,000	92,000	0	71,000	'
Restructuring Reserve, Settled with Cash	-296,000	-754,000	'	-175,000	-106,000	-52,000
Restructuring Reserve, Ending Balance	759,000	397,000	759,000	92,000	0	71,000
IPG [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	397,000	92,000	92,000	0	71,000	'
Restructuring Reserve, Settled with Cash	-32,000	-35,000	'	-175,000	-106,000	-52,000
Restructuring Reserve, Ending Balance	759,000	397,000	759,000	92,000	0	71,000
IPG [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	0	0	'	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
IPG [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	0	0	'	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
IPG [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	-264,000	-719,000	'	0	0	0
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
Europe [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	870,000	1,089,000	1,089,000	595,000	1,816,000	'
Restructuring Reserve, Settled with Cash	-751,000	-597,000	'	-1,146,000	-3,314,000	-3,650,000
Restructuring Reserve, Ending Balance	702,000	870,000	702,000	1,089,000	595,000	1,816,000
Europe [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	870,000	1,089,000	1,089,000	595,000	1,742,000	'
Restructuring Reserve, Settled with Cash	-226,000	-597,000	'	-1,146,000	-1,964,000	-1,546,000
Restructuring Reserve, Ending Balance	702,000	870,000	702,000	1,089,000	595,000	1,742,000
Europe [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	277,000
Restructuring Reserve, Settled with Cash	0	0	'	0	0	-277,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
Europe [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	74,000	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	1,788,000
Restructuring Reserve, Settled with Cash	0	0	'	0	-127,000	-1,714,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	74,000
Europe [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	0	0	'
Restructuring Reserve, Settled with Cash	-525,000	0	'	0	-1,223,000	-113,000
Restructuring Reserve, Ending Balance	0	0	0	0	0	0
Asia/Pacific [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	345,000	499,000	499,000	2,651,000	0	'
Restructuring Reserve, Settled with Cash	0	-154,000	'	-3,659,000	-2,369,000	-186,000
Restructuring Reserve, Ending Balance	349,000	345,000	349,000	499,000	2,651,000	0
Asia/Pacific [Member] | Severance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	869,000	0	'
Restructuring Reserve, Settled with Cash	0	0	'	-1,839,000	-812,000	-186,000
Restructuring Reserve, Ending Balance	0	0	0	0	869,000	0
Asia/Pacific [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	151,000	0	'
Restructuring Reserve, Settled with Cash	0	0	'	-151,000	-340,000	0
Restructuring Reserve, Ending Balance	0	0	0	0	151,000	0
Asia/Pacific [Member] | Contract Termination [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	345,000	499,000	499,000	1,625,000	0	'
Restructuring Reserve, Settled with Cash	0	-154,000	'	-1,660,000	-42,000	0
Restructuring Reserve, Ending Balance	349,000	345,000	349,000	499,000	1,625,000	0
Asia/Pacific [Member] | Other [Member]	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'
Restructuring Reserve, Beginning Balance	0	0	0	6,000	0	'
Restructuring Reserve, Settled with Cash	0	0	'	-9,000	-1,175,000	0
Restructuring Reserve, Ending Balance	$0	$0	$0	$0	$6,000	$0

Charges_Related_To_Restructuri3

Charges Related To Restructuring Activities Narrative (Details) (USD $)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	'	'	$10,534,000
Restructuring Charges	2,090,000	2,240,000	2,592,000	4,330,000	5,114,000	9,336,000	11,395,000	10,534,000
Restructuring Reserve, Settled with Cash	2,350,000	2,625,000	'	4,975,000	'	11,844,000	9,381,000	5,555,000
Restructuring and Related Activities, Expected Payout Period	'	'	'	'12 months	'	'	'	'
Severance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	'	'	8,352,000
Restructuring Charges	1,297,000	1,521,000	'	2,818,000	'	8,282,000	6,775,000	8,352,000
Restructuring Reserve, Settled with Cash	1,561,000	1,752,000	'	'	'	9,507,000	6,469,000	3,447,000
Contract Termination [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	4,000	0	'	'	'	698,000	1,725,000	1,788,000
Restructuring Reserve, Settled with Cash	0	154,000	'	'	'	1,824,000	174,000	1,714,000
Product Line Discontinuance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	0	491,000	277,000
Restructuring Reserve, Settled with Cash	0	0	'	'	'	151,000	340,000	277,000
Other [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	'	'	117,000
Restructuring Charges	789,000	719,000	'	'	'	356,000	2,404,000	117,000
Restructuring Reserve, Settled with Cash	789,000	719,000	'	'	'	362,000	2,398,000	117,000
Europe [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	583,000	378,000	65,000	961,000	180,000	1,640,000	2,093,000	5,466,000
Restructuring Reserve, Settled with Cash	751,000	597,000	'	'	'	1,146,000	3,314,000	3,650,000
Europe [Member] | Severance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	58,000	378,000	'	'	'	1,640,000	817,000	3,288,000
Restructuring Reserve, Settled with Cash	226,000	597,000	'	'	'	1,146,000	1,964,000	1,546,000
Europe [Member] | Contract Termination [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	'	'	1,788,000
Restructuring Charges	0	0	'	'	'	0	53,000	1,788,000
Restructuring Reserve, Settled with Cash	0	0	'	'	'	0	127,000	1,714,000
Europe [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges including Inventory Markdowns	'	'	'	'	'	'	'	277,000
Restructuring Charges	0	0	'	'	'	0	0	277,000
Restructuring Reserve, Settled with Cash	0	0	'	'	'	0	0	277,000
Europe [Member] | Other [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	525,000	0	'	'	'	0	1,223,000	113,000
Restructuring Reserve, Settled with Cash	525,000	0	'	'	'	0	1,223,000	113,000
Asia Pacific [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	4,000	0	566,000	4,000	1,106,000	1,507,000	5,020,000	186,000
Restructuring Reserve, Settled with Cash	0	154,000	'	'	'	3,659,000	2,369,000	186,000
Asia Pacific [Member] | Severance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	970,000	1,681,000	186,000
Restructuring Reserve, Settled with Cash	0	0	'	'	'	1,839,000	812,000	186,000
Asia Pacific [Member] | Contract Termination [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	4,000	0	'	'	'	534,000	1,667,000	0
Restructuring Reserve, Settled with Cash	0	154,000	'	'	'	1,660,000	42,000	0
Asia Pacific [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	0	491,000	0
Restructuring Reserve, Settled with Cash	0	0	'	'	'	151,000	340,000	0
Asia Pacific [Member] | Other [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	3,000	1,181,000	0
Restructuring Reserve, Settled with Cash	0	0	'	'	'	9,000	1,175,000	0
NA/HME [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	845,000	803,000	'	'	'	5,922,000	4,247,000	4,759,000
Restructuring Reserve, Settled with Cash	1,303,000	1,120,000	'	'	'	6,864,000	3,592,000	1,667,000
NA/HME [Member] | Severance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	845,000	803,000	'	'	'	5,405,000	4,242,000	4,755,000
Restructuring Reserve, Settled with Cash	1,303,000	1,120,000	'	'	'	6,347,000	3,587,000	1,663,000
NA/HME [Member] | Contract Termination [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	164,000	5,000	0
Restructuring Reserve, Settled with Cash	0	0	'	'	'	164,000	5,000	0
NA/HME [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	0	0	0
Restructuring Reserve, Settled with Cash	0	0	'	'	'	0	0	0
NA/HME [Member] | Other [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	353,000	0	4,000
Restructuring Reserve, Settled with Cash	0	0	'	'	'	353,000	0	4,000
IPG [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	658,000	1,059,000	'	'	'	267,000	35,000	123,000
Restructuring Reserve, Settled with Cash	296,000	754,000	'	'	'	175,000	106,000	52,000
IPG [Member] | Severance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	394,000	340,000	'	'	'	267,000	35,000	123,000
Restructuring Reserve, Settled with Cash	32,000	35,000	'	'	'	175,000	106,000	52,000
IPG [Member] | Contract Termination [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	0	0	0
Restructuring Reserve, Settled with Cash	0	0	'	'	'	0	0	0
IPG [Member] | Product Line Discontinuance [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	0	0	'	'	'	0	0	0
Restructuring Reserve, Settled with Cash	0	0	'	'	'	0	0	0
IPG [Member] | Other [Member]	'	'	'	'	'	'	'	'
Restructuring Cost and Reserve [Line Items]	'	'	'	'	'	'	'	'
Restructuring Charges	264,000	719,000	'	1,512,000	'	0	0	0
Restructuring Reserve, Settled with Cash	$264,000	$719,000	'	'	'	$0	$0	$0

Income_Taxes_Narrative_Details

Income Taxes (Narrative) (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Effective Income Tax Rate, Continuing Operations	-29.20%	-76.60%	-20.20%	-11.60%	'
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	'	'	35.00%	35.00%	'
Liability for Uncertain Tax Positions, Noncurrent	$15,897,000	$9,702,000	$15,897,000	$9,702,000	$15,524,000
Income Tax Examination, Foreign Tax Expense (Benefit), Per Share	'	'	'	$0.30	'

Net_Earnings_Loss_Per_Common_S2

Net Earnings (Loss) Per Common Share Computation of Basic and Diluted Net Earnings (Loss) Per Common Share (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Basic	'	'	'	'
Average common shares outstanding	32,017	31,902	32,015	31,902
Net Earnings (loss)	($13,612)	($12,461)	($31,588)	$22,720
Net earnings (loss) per common share	($0.43)	($0.39)	($0.99)	$0.71
Income (Loss) from Continuing Operations	-13,612	-24,489	-31,588	-30,197
Total Net Earnings from Discontinued Operations	0	12,028	0	52,917
Income (Loss) from Continuing Operations	($0.43)	($0.77)	($0.99)	($0.95)
Income (Loss) from Discontinued Operations	$0	$0.38	$0	$1.66
Diluted	'	'	'	'
Average common shares outstanding	32,017	31,902	32,015	31,902
Shares related to convertible debt	0	0	0	0
Stock options and awards	199	122	229	78
Average common shares assuming dilution	32,216	32,024	32,244	31,980
Net Earnings (loss)	($13,612)	($12,461)	($31,588)	$22,720
Net Earnings (loss) per Share - Assuming Dilution	($0.43)	($0.39)	($0.99)	$0.71
Income (Loss) from Continuing Operations	($0.43)	($0.77)	($0.99)	($0.95)
Income (Loss) from Discontinued Operations	$0	$0.38	$0	$1.65

Net_Earnings_Loss_Per_Common_S3

Net Earnings (Loss) Per Common Share Textuals (Details) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount	3,578,173	4,929,913	3,172,393	4,861,512
Antidilutive Share Granted, Average Exercise Price	$41.87	$41.87	$41.87	$41.87
Fair value stock price	$16.98	$13.85	$18.74	$14.60

Concentration_Of_Credit_Risk_D

Concentration Of Credit Risk (Details) (USD $)	Jun. 30, 2014
Concentration Risk [Line Items]	'
Retained Recourse Obligation For Events Of Default Under Contracts	$4,897,000
Events of Default Under Contract by Third Party	$36,824,000

Derivatives_Notional_Amounts_D

Derivatives Notional Amounts (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Mar. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Minimum [Member]

Maximum [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

EUR / AUD [Member]

EUR / AUD [Member]

EUR / AUD [Member]

EUR / CAD [Member]

EUR / CAD [Member]

EUR / DKK [Member]

EUR / DKK [Member]

AUD / EUR [Member]

AUD / EUR [Member]

AUD / CAD [Member]

AUD / CAD [Member]

EUR / NOK [Member]

EUR / NOK [Member]

EUR / AUD [Member]

EUR / AUD [Member]

EUR / DKK [Member]

EUR / DKK [Member]

DKK / SEK [Member]

DKK / SEK [Member]

EUR / CAD [Member]

EUR / CAD [Member]

EUR / CHF [Member]

EUR / CHF [Member]

EUR / GBP [Member]

EUR / GBP [Member]

EUR / SEK [Member]

EUR / SEK [Member]

AUD / CAD [Member]

AUD / CAD [Member]

EUR / NZD [Member]

EUR / NZD [Member]

GBP / CHF [Member]

GBP / CHF [Member]

GBP / SEK [Member]

GBP / SEK [Member]

NOK / CHF [Member]

NOK / CHF [Member]

AUD / NZD [Member]

AUD / NZD [Member]

EUR / NOK [Member]

EUR / NOK [Member]

Derivative [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative, Percentage of Forcasted Transactions With Currency Rate Exposure

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

60.00%

90.00%

Notional Amount

'

'

'

'

$44,034,000

$34,059,000

$1,700,000

$225,000

$0

'

$2,039,000

$38,000

$0

$68,000

$5,470,000

$2,142,000

$0

$5,589,000

$0

$2,599,000

$0

$19,157,000

$14,867,000

$0

'

$1,645,000

$7,200,000

$3,824,000

$0

$5,989,000

$5,533,000

$0

$8,000

$0

$82,553,000

$135,009,000

$351,000

$0

$647,000

$1,382,000

$2,525,000

$5,337,000

$1,164,000

$0

$6,437,000

$11,730,000

$207,000

$486,000

$31,321,000

$51,106,000

$1,499,000

$2,686,000

$1,266,000

$0

$979,000

$2,485,000

$5,730,000

$5,960,000

$798,000

$1,710,000

$1,559,000

$2,654,000

$15,844,000

$29,614,000

$1,807,000

$3,432,000

$936,000

$0

$3,854,000

$6,959,000

$448,000

$837,000

$1,111,000

$2,078,000

$1,683,000

$3,418,000

$586,000

$0

$1,801,000

$3,135,000

'

'

Unrealized Gain (Loss)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-668,000

-781,000

-20,000

0

-1,000

-5,000

-89,000

-94,000

-63,000

0

-129,000

-66,000

-1,000

4,000

-5,000

-168,000

-59,000

-45,000

-25,000

0

37,000

58,000

191,000

102,000

15,000

-1,000

13,000

1,000

-643,000

-501,000

88,000

75,000

1,000

0

232,000

-111,000

-21,000

-26,000

-103,000

-101,000

-66,000

31,000

-7,000

0

-13,000

66,000

'

'

Amount of Gain (Loss) Recognized in Income on Derivatives

201,000

1,427,000

-144,000

256,000

-144,000

370,000

-16,000

-1,000

0

80,000

'

1,000

0

0

-3,000

-81,000

0

28,000

0

-43,000

0

14,000

250,000

0

35,000

'

-10,000

-1,000

0

10,000

-37,000

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount of Derivatives, Matured During Period

$41,504,000

$47,179,000

$75,127,000

$80,673,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivatives_Balance_Sheet_Loca

Derivatives Balance Sheet Location (Details) (USD $)

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Designated as Hedging Instrument [Member]

Derivatives, Fair Value [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Notional Amount of Derivatives, Matured During Period

'

'

$41,504,000

$47,179,000

$75,127,000

$80,673,000

'

'

'

'

'

'

Derivative Assets

780,000

789,000

'

'

'

'

685,000

414,000

95,000

375,000

0

0

Interest Rate Derivative Liabilities, at Fair Value

$1,592,000

$1,212,000

'

'

'

'

$1,353,000

$1,195,000

$239,000

$5,000

$0

$12,000

Derivatives_Gain_Loss_in_State

Derivatives Gain (Loss) in Statement of Finacial Position (Details) (USD $)

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Dec. 31, 2013

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Cost of Sales [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Interest Rate Swap [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

EUR / AUD [Member]

EUR / AUD [Member]

EUR / NOK [Member]

EUR / NOK [Member]

EUR / CAD [Member]

EUR / CAD [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Selling General and Administrative Expense [Member]

Selling General and Administrative Expense [Member]

Selling General and Administrative Expense [Member]

Selling General and Administrative Expense [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Cash Flow Hedging [Member]

Interest Expense [Member]

Interest Expense [Member]

Interest Expense [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Not Designated as Hedging Instrument [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Foreign Exchange Forward [Member]

Derivative Instruments, Gain (Loss) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in OCI on Derivatives (Effective Portion)

$302,000

($396,000)

($324,000)

$847,000

'

'

'

'

'

'

'

'

'

'

'

'

$310,000

($533,000)

($324,000)

$447,000

'

'

'

'

($8,000)

$137,000

$0

$400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Reclassified from Accumulated OCI into Income (Effective Portion)

-340,000

259,000

-466,000

6,000

'

'

'

'

'

'

'

'

'

'

'

'

-328,000

318,000

-454,000

132,000

'

'

'

'

-12,000

-59,000

-12,000

-126,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Derivative Instruments, Gain (Loss) Recognized in Income

'

'

'

'

-138,000

306,000

-148,000

442,000

'

31,000

'

-325,000

'

'

'

'

'

'

'

'

201,000

'

-144,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in Income on Derivatives (Ineffective Portion and Amount Excluded from Effectiveness Testing)

-22,000

-22,000

-22,000

35,000

'

'

'

'

'

'

'

'

'

'

'

'

-22,000

-22,000

-22,000

35,000

'

'

'

'

0

0

0

0

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of Gain (Loss) Recognized in Income on Derivatives

-389,000

337,000

-532,000

117,000

'

'

'

'

'

'

'

'

201,000

1,427,000

-144,000

256,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

-144,000

370,000

0

35,000

0

80,000

0

0

1,000

0

Derivative Instruments, Gain (Loss) Recognized in Income

'

'

'

'

'

'

'

'

($251,000)

'

($384,000)

'

'

'

'

'

'

'

'

'

'

$1,427,000

'

$256,000

'

'

'

'

($12,000)

($59,000)

($126,000)

'

'

'

'

'

'

'

'

'

'

Fair_Values_of_Financial_Instr1

Fair Values of Financial Instruments Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Interest Rate Derivative Liabilities, at Fair Value	$1,592	$1,212
Fair Value, Measurements, Recurring [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	-812	-411
Interest Rate Derivative Liabilities, at Fair Value	0	-12
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Liabilities, at Fair Value	0	0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	-812	-411
Interest Rate Derivative Liabilities, at Fair Value	0	-12
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Foreign Currency Contract, Asset, Fair Value Disclosure	0	0
Interest Rate Derivative Liabilities, at Fair Value	$0	$0

Fair_Values_of_Financial_Instr2

Fair Values of Financial Instruments Details of Book Value and Fair Value of Financial Instruments (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	$23,001	$29,785	$21,447	$38,791
Installment receivables, net	1,508	1,562	'	'
Other current assets	38,601	41,172	'	'
Cash and Cash Equivalents [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value	23,001	29,785	'	'
Cash and Cash Equivalents [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Cash and Cash Equivalents	23,001	29,785	'	'
Other Assets [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other Investments	799	998	'	'
Other Assets [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other Investments	799	998	'	'
Accounts and Notes Receivable, Net [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Installment receivables, net	2,751	2,819	'	'
Accounts and Notes Receivable, Net [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Installment receivables, net	2,751	2,819	'	'
Debt [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Long-term debt (including current maturities of long-term debt)	-56,116	-45,286	'	'
Debt [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Long-term debt (including current maturities of long-term debt)	-55,356	-46,124	'	'
Foreign Exchange Forward [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other current assets	780	789	'	'
Accrued Expenses	-1,592	-1,200	'	'
Foreign Exchange Forward [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Other current assets	780	789	'	'
Accrued Expenses	-1,592	-1,200	'	'
Interest Rate Swap [Member] | Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Accrued Expenses	0	-12	'	'
Interest Rate Swap [Member] | Estimate of Fair Value, Fair Value Disclosure [Member]	'	'	'	'
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]	'	'	'	'
Accrued Expenses	$0	($12)	'	'

Business_Segments_Information_

Business Segments (Information by Segment) (Details) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

$331,312,000

'

$344,760,000

$640,381,000

$676,197,000

'

'

'

'

Related Party Transaction, Other Revenues from Transactions with Related Party

32,014,000

'

30,717,000

60,134,000

59,495,000

'

'

'

'

Restructuring Charges

2,090,000

2,240,000

2,592,000

4,330,000

5,114,000

9,336,000

11,395,000

10,534,000

'

Earnings (loss) before income taxes

-10,537,000

'

-13,864,000

-26,288,000

-27,047,000

'

'

'

'

Restructuring Reserve, Settled with Cash

-2,350,000

-2,625,000

'

-4,975,000

'

-11,844,000

-9,381,000

-5,555,000

'

Restructuring Reserve

3,840,000

4,100,000

'

3,840,000

'

4,485,000

6,993,000

4,979,000

0

North America/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

138,678,000

'

159,327,000

267,788,000

311,209,000

'

'

'

'

Related Party Transaction, Other Revenues from Transactions with Related Party

20,872,000

'

20,398,000

39,545,000

39,234,000

'

'

'

'

Restructuring Charges

845,000

'

1,948,000

1,648,000

3,627,000

'

'

'

'

Earnings (loss) before income taxes

-13,292,000

'

-12,222,000

-30,091,000

-23,401,000

'

'

'

'

Institutional Products Group [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

25,785,000

'

29,828,000

50,921,000

59,052,000

'

'

'

'

Related Party Transaction, Other Revenues from Transactions with Related Party

2,853,000

'

1,882,000

4,426,000

2,989,000

'

'

'

'

Restructuring Charges

658,000

'

13,000

1,717,000

201,000

'

'

'

'

Earnings (loss) before income taxes

-110,000

'

471,000

-361,000

945,000

'

'

'

'

Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

153,990,000

'

141,751,000

296,758,000

279,385,000

'

'

'

'

Related Party Transaction, Other Revenues from Transactions with Related Party

2,131,000

'

2,313,000

3,813,000

4,266,000

'

'

'

'

Restructuring Charges

583,000

378,000

65,000

961,000

180,000

1,640,000

2,093,000

5,466,000

'

Earnings (loss) before income taxes

11,763,000

'

8,365,000

21,009,000

14,208,000

'

'

'

'

Restructuring Reserve, Settled with Cash

-751,000

-597,000

'

'

'

-1,146,000

-3,314,000

-3,650,000

'

Restructuring Reserve

702,000

870,000

'

702,000

'

1,089,000

595,000

1,816,000

'

Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Revenue from external customers

12,859,000

'

13,854,000

24,914,000

26,551,000

'

'

'

'

Related Party Transaction, Other Revenues from Transactions with Related Party

6,158,000

'

6,124,000

12,350,000

13,006,000

'

'

'

'

Restructuring Charges

4,000

0

566,000

4,000

1,106,000

1,507,000

5,020,000

186,000

'

Earnings (loss) before income taxes

-2,298,000

'

-5,377,000

-5,099,000

-7,638,000

'

'

'

'

Restructuring Reserve, Settled with Cash

0

-154,000

'

'

'

-3,659,000

-2,369,000

-186,000

'

Restructuring Reserve

349,000

345,000

'

349,000

'

499,000

2,651,000

0

'

All Other Segments [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Earnings (loss) before income taxes

-6,600,000

[1]

'

-5,101,000

[1]

-11,746,000

[1]

-11,161,000

[1]

'

'

'

'

NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

845,000

803,000

'

'

'

5,922,000

4,247,000

4,759,000

'

Restructuring Reserve, Settled with Cash

-1,303,000

-1,120,000

'

'

'

-6,864,000

-3,592,000

-1,667,000

'

Restructuring Reserve

2,030,000

2,488,000

'

2,030,000

'

2,805,000

3,747,000

3,092,000

'

IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

658,000

1,059,000

'

'

'

267,000

35,000

123,000

'

Restructuring Reserve, Settled with Cash

-296,000

-754,000

'

'

'

-175,000

-106,000

-52,000

'

Restructuring Reserve

759,000

397,000

'

759,000

'

92,000

0

71,000

'

Severance [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

1,297,000

1,521,000

'

2,818,000

'

8,282,000

6,775,000

8,352,000

'

Restructuring Reserve, Settled with Cash

-1,561,000

-1,752,000

'

'

'

-9,507,000

-6,469,000

-3,447,000

'

Restructuring Reserve

3,491,000

3,755,000

'

3,491,000

'

3,986,000

5,211,000

4,905,000

0

Severance [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

58,000

378,000

'

'

'

1,640,000

817,000

3,288,000

'

Restructuring Reserve, Settled with Cash

-226,000

-597,000

'

'

'

-1,146,000

-1,964,000

-1,546,000

'

Restructuring Reserve

702,000

870,000

'

702,000

'

1,089,000

595,000

1,742,000

'

Severance [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

970,000

1,681,000

186,000

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

-1,839,000

-812,000

-186,000

'

Restructuring Reserve

0

0

'

0

'

0

869,000

0

'

Severance [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

845,000

803,000

'

'

'

5,405,000

4,242,000

4,755,000

'

Restructuring Reserve, Settled with Cash

-1,303,000

-1,120,000

'

'

'

-6,347,000

-3,587,000

-1,663,000

'

Restructuring Reserve

2,030,000

2,488,000

'

2,030,000

'

2,805,000

3,747,000

3,092,000

'

Severance [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

394,000

340,000

'

'

'

267,000

35,000

123,000

'

Restructuring Reserve, Settled with Cash

-32,000

-35,000

'

'

'

-175,000

-106,000

-52,000

'

Restructuring Reserve

759,000

397,000

'

759,000

'

92,000

0

71,000

'

Product Line Discontinuance [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

491,000

277,000

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

-151,000

-340,000

-277,000

'

Restructuring Reserve

0

0

'

0

'

0

151,000

0

0

Product Line Discontinuance [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

0

277,000

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

0

0

-277,000

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Product Line Discontinuance [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

491,000

0

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

-151,000

-340,000

0

'

Restructuring Reserve

0

0

'

0

'

0

151,000

0

'

Product Line Discontinuance [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

0

0

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

0

0

0

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Product Line Discontinuance [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

0

0

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

0

0

0

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Contract Termination [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

4,000

0

'

'

'

698,000

1,725,000

1,788,000

'

Restructuring Reserve, Settled with Cash

0

-154,000

'

'

'

-1,824,000

-174,000

-1,714,000

'

Restructuring Reserve

349,000

345,000

'

349,000

'

499,000

1,625,000

74,000

0

Contract Termination [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

53,000

1,788,000

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

0

-127,000

-1,714,000

'

Restructuring Reserve

0

0

'

0

'

0

0

74,000

'

Contract Termination [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

4,000

0

'

'

'

534,000

1,667,000

0

'

Restructuring Reserve, Settled with Cash

0

-154,000

'

'

'

-1,660,000

-42,000

0

'

Restructuring Reserve

349,000

345,000

'

349,000

'

499,000

1,625,000

0

'

Contract Termination [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

164,000

5,000

0

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

-164,000

-5,000

0

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Contract Termination [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

0

0

0

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

0

0

0

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Other [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

789,000

719,000

'

'

'

356,000

2,404,000

117,000

'

Restructuring Reserve, Settled with Cash

-789,000

-719,000

'

'

'

-362,000

-2,398,000

-117,000

'

Restructuring Reserve

0

0

'

0

'

0

6,000

0

0

Other [Member] | Europe [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

525,000

0

'

'

'

0

1,223,000

113,000

'

Restructuring Reserve, Settled with Cash

-525,000

0

'

'

'

0

-1,223,000

-113,000

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Other [Member] | Asia Pacific [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

3,000

1,181,000

0

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

-9,000

-1,175,000

0

'

Restructuring Reserve

0

0

'

0

'

0

6,000

0

'

Other [Member] | NA/HME [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

0

0

'

'

'

353,000

0

4,000

'

Restructuring Reserve, Settled with Cash

0

0

'

'

'

-353,000

0

-4,000

'

Restructuring Reserve

0

0

'

0

'

0

0

0

'

Other [Member] | IPG [Member]

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

Restructuring Charges

264,000

719,000

'

1,512,000

'

0

0

0

'

Restructuring Reserve, Settled with Cash

-264,000

-719,000

'

'

'

0

0

0

'

Restructuring Reserve

$0

$0

'

$0

'

$0

$0

$0

'

[1]

The information by segment is as follows (in thousands): For the Three Months Ended June 30,B For the Six Months Ended June 30,B 2014B 2013B 2014B 2013Revenues from external customers North America/HME$138,678B $159,327B $267,788B $311,209Institutional Products Group25,785B 29,828B 50,921B 59,052Europe153,990B 141,751B 296,758B 279,385Asia/Pacific12,859B 13,854B 24,914B 26,551Consolidated$331,312B $344,760B $640,381B $676,197Intersegment revenues North America/HME$20,872B $20,398B $39,545B $39,234Institutional Products Group2,853B 1,882B 4,426B 2,989Europe2,131B 2,313B 3,813B 4,266Asia/Pacific6,158B 6,124B 12,350B 13,006Consolidated$32,014B $30,717B $60,134B $59,495Restructuring charges before income taxes North America/HME$845B $1,948B $1,648B $3,627Institutional Products Group658B 13B 1,717B 201Europe583B 65B 961B 180Asia/Pacific4B 566B 4B 1,106Consolidated$2,090B $2,592B $4,330B $5,114Earnings (loss) before income taxes North America/HME$(13,292)B $(12,222)B $(30,091)B $(23,401)Institutional Products Group(110)B 471B (361)B 945Europe11,763B 8,365B 21,009B 14,208Asia/Pacific(2,298)B (5,377)B (5,099)B (7,638)All Other (1)(6,600)B (5,101)B (11,746)B (11,161)Consolidated$(10,537)B $(13,864)B $(26,288)B $(27,047) ________________________(1)Consists of un-allocated corporate SG&A costs and intercompany profits, which do not meet the quantitative criteria for determining reportable segments.

Contingencies_Contingencies_De

Contingencies Contingencies (Details) (USD $)	0 Months Ended
	Dec. 21, 2012	Jun. 30, 2014
Loss Contingencies [Line Items]	'	'
Consent Decree Court Approval Date	21-Dec-12	'
Loss Contingency Accrual, at Carrying Value	'	$2,237,000
Loss Contingency Accrual Carrying Value, Net of Tax	'	2,100,000
NA/HME [Member]	'	'
Loss Contingencies [Line Items]	'	'
Loss Contingency Accrual, at Carrying Value	'	1,171,000
Asia Pacific [Member]	'	'
Loss Contingencies [Line Items]	'	'
Loss Contingency Accrual, at Carrying Value	'	$929,000

Supplemental_Guarantor_Informa2

Supplemental Guarantor Information Consolidating Condensed Statements of Operations (Details) (USD $)	3 Months Ended			6 Months Ended		12 Months Ended			3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Feb. 17, 2007
									The Company (Parent) [Member]	The Company (Parent) [Member]	The Company (Parent) [Member]	The Company (Parent) [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Combined Non-Guarantor Subsidiaries [Member]	Eliminations [Member]	Eliminations [Member]	Eliminations [Member]	Eliminations [Member]	Convertible Senior Subordinated Debentures February 2027 [Member]	Convertible Senior Subordinated Debentures February 2027 [Member]
																									Convertible Subordinated Debt [Member]	Convertible Subordinated Debt [Member]
Condensed Financial Statements, Captions [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Net sales	$331,312,000	'	$344,760,000	$640,381,000	$676,197,000	'	'	'	$54,612,000	$64,903,000	$104,721,000	$125,812,000	$113,337,000	$126,020,000	$219,791,000	$244,456,000	$187,778,000	$177,582,000	$361,578,000	$351,507,000	($24,415,000)	($23,745,000)	($45,709,000)	($45,578,000)	'	'
Interest Rate	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	4.13%	'
Debt Instrument, Face Amount	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	135,000,000
Cost of Goods Sold	237,379,000	'	251,203,000	461,200,000	489,056,000	'	'	'	49,117,000	55,077,000	94,821,000	107,430,000	84,012,000	91,674,000	161,596,000	177,523,000	128,602,000	128,350,000	250,492,000	250,055,000	-24,352,000	-23,898,000	-45,709,000	-45,952,000	'	'
Gross Profit	93,933,000	'	93,557,000	179,181,000	187,141,000	'	'	'	5,495,000	9,826,000	9,900,000	18,382,000	29,325,000	34,346,000	58,195,000	66,933,000	59,176,000	49,232,000	111,086,000	101,452,000	-63,000	153,000	0	374,000	'	'
Selling, general and administrative expense	101,545,000	'	104,088,000	199,566,000	207,323,000	'	'	'	32,216,000	35,407,000	63,866,000	70,270,000	23,019,000	23,978,000	45,287,000	47,029,000	46,310,000	43,353,000	90,413,000	87,330,000	0	1,350,000	0	2,694,000	'	'
Restructuring Charges	2,090,000	2,240,000	2,592,000	4,330,000	5,114,000	9,336,000	11,395,000	10,534,000	890,000	1,810,000	2,054,000	3,481,000	0	13,000	-95,000	13,000	1,200,000	769,000	2,371,000	1,620,000	0	0	0	0	'	'
Asset write-downs related to restructuring activities	'	'	'	1,163,000	0	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Income (Loss) from Equity Method Investments	0	'	0	0	0	'	'	'	14,036,000	25,370,000	24,346,000	73,388,000	7,696,000	6,729,000	14,627,000	12,537,000	-28,000	-180,000	-64,000	-115,000	-21,704,000	-31,919,000	-38,909,000	-85,810,000	'	'
Interest Income (Expense), Net	835,000	'	741,000	1,573,000	1,751,000	'	'	'	0	-399,000	-284,000	-444,000	626,000	1,120,000	1,491,000	1,556,000	209,000	20,000	366,000	639,000	0	0	0	0	'	'
Income (Loss) from Continuing Operations before Income Taxes	-10,537,000	'	-13,864,000	-26,288,000	-27,047,000	'	'	'	-13,575,000	-1,622,000	-31,390,000	18,463,000	13,376,000	15,964,000	26,139,000	30,872,000	11,429,000	4,910,000	17,872,000	11,748,000	-21,767,000	-33,116,000	-38,909,000	-88,130,000	'	'
Income tax provision	3,075,000	'	10,625,000	5,300,000	3,150,000	'	'	'	37,000	10,839,000	198,000	-4,257,000	0	-25,000	0	-50,000	3,038,000	-189,000	5,102,000	7,457,000	0	0	0	0	'	'
Income (Loss) from Continuing Operations	-13,612,000	'	-24,489,000	-31,588,000	-30,197,000	'	'	'	'	-12,461,000	'	22,720,000	'	15,989,000	'	30,922,000	'	5,099,000	'	4,291,000	'	-33,116,000	'	-88,130,000	'	'
Total Net Earnings from Discontinued Operations	0	'	12,028,000	0	52,917,000	'	'	'	'	0	'	0	'	12,028,000	'	52,917,000	'	0	'	0	'	0	'	0	'	'
Net Earnings (loss)	-13,612,000	'	-12,461,000	-31,588,000	22,720,000	'	'	'	-13,612,000	-12,461,000	-31,588,000	22,720,000	13,376,000	28,017,000	26,139,000	83,839,000	8,391,000	5,099,000	12,770,000	4,291,000	-21,767,000	-33,116,000	-38,909,000	-88,130,000	'	'
Other Comprehensive Income (Loss)	-4,277,000	'	-8,163,000	2,413,000	-8,029,000	'	'	'	-4,277,000	-8,163,000	2,413,000	-8,029,000	-2,502,000	1,551,000	-213,000	-635,000	11,432,000	-9,694,000	2,477,000	-7,907,000	-8,930,000	8,143,000	-2,264,000	8,542,000	'	'
Comprehensive Income (Loss)	($17,889,000)	'	($20,624,000)	($29,175,000)	$14,691,000	'	'	'	($17,889,000)	($20,624,000)	($29,175,000)	$14,691,000	$10,874,000	$29,568,000	$25,926,000	$83,204,000	$19,823,000	($4,595,000)	$15,247,000	($3,616,000)	($30,697,000)	($24,973,000)	($41,173,000)	($79,588,000)	'	'

Supplemental_Guarantor_Informa3

Supplemental Guarantor Information Consolidating Condensed Balance Sheets (Details) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current Assets	'	'	'	'
Cash and cash equivalents	$23,001	$29,785	$21,447	$38,791
Trade receivables, net	188,046	188,622	'	'
Installment receivables, net	1,508	1,562	'	'
Inventories, net	165,013	155,637	'	'
Deferred income taxes	2,246	2,761	'	'
Due from Affiliate, Current	0	0	'	'
Other current assets	38,601	41,172	'	'
Total Current Assets	418,415	419,539	'	'
Investment in subsidiaries	0	0	'	'
Intercompany advances, net	0	0	'	'
Other Assets	39,489	45,936	'	'
Other Intangibles	58,627	62,584	'	'
Property and Equipment, net	99,586	106,149	'	'
Goodwill	463,703	462,226	'	'
Total Assets	1,079,820	1,096,434	'	'
Current Liabilities	'	'	'	'
Accounts payable	123,064	116,704	'	'
Accrued expenses	128,736	133,100	'	'
Accrued income taxes	13,583	12,259	'	'
Due to Affiliate, Current	0	0	'	'
Short-term debt and current maturities of long-term obligations	2,456	14,102	'	'
Total Current Liabilities	267,839	276,165	'	'
Long-Term Debt	53,660	31,184	'	'
Other Long-Term Obligations	114,939	118,276	'	'
Inercompany advances, net	0	0	'	'
Total Shareholders' Equity	643,382	670,809	'	'
Total Liabilities and Shareholders' Equity	1,079,820	1,096,434	'	'
The Company (Parent) [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	3,222	1,401	1,764	5,774
Trade receivables, net	59,657	72,272	'	'
Installment receivables, net	0	0	'	'
Inventories, net	21,578	30,806	'	'
Deferred income taxes	0	0	'	'
Due from Affiliate, Current	9,381	4,179	'	'
Other current assets	6,516	9,970	'	'
Total Current Assets	100,354	118,628	'	'
Investment in subsidiaries	1,501,793	1,475,156	'	'
Intercompany advances, net	999,265	959,071	'	'
Other Assets	36,416	42,831	'	'
Other Intangibles	454	466	'	'
Property and Equipment, net	32,720	35,169	'	'
Goodwill	0	0	'	'
Total Assets	2,671,002	2,631,321	'	'
Current Liabilities	'	'	'	'
Accounts payable	52,271	42,521	'	'
Accrued expenses	28,961	30,314	'	'
Accrued income taxes	3,545	5,375	'	'
Due to Affiliate, Current	49,257	42,314	'	'
Short-term debt and current maturities of long-term obligations	1,571	13,118	'	'
Total Current Liabilities	135,605	133,642	'	'
Long-Term Debt	47,986	25,642	'	'
Other Long-Term Obligations	50,279	53,470	'	'
Inercompany advances, net	1,793,750	1,747,758	'	'
Total Shareholders' Equity	643,382	670,809	'	'
Total Liabilities and Shareholders' Equity	2,671,002	2,631,321	'	'
Combined Guarantor Subsidiaries [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	247	313	471	1,018
Trade receivables, net	28,715	28,317	'	'
Installment receivables, net	482	452	'	'
Inventories, net	27,126	27,472	'	'
Deferred income taxes	0	0	'	'
Due from Affiliate, Current	1,092	380	'	'
Other current assets	514	568	'	'
Total Current Assets	58,176	57,502	'	'
Investment in subsidiaries	467,832	450,021	'	'
Intercompany advances, net	1,676,731	1,620,683	'	'
Other Assets	1,056	1,061	'	'
Other Intangibles	15,453	17,109	'	'
Property and Equipment, net	15,904	17,774	'	'
Goodwill	16,660	16,660	'	'
Total Assets	2,251,812	2,180,810	'	'
Current Liabilities	'	'	'	'
Accounts payable	9,517	7,237	'	'
Accrued expenses	16,869	17,228	'	'
Accrued income taxes	0	0	'	'
Due to Affiliate, Current	1,950	2,124	'	'
Short-term debt and current maturities of long-term obligations	8	8	'	'
Total Current Liabilities	28,344	26,597	'	'
Long-Term Debt	20	61	'	'
Other Long-Term Obligations	0	0	'	'
Inercompany advances, net	1,000,948	959,172	'	'
Total Shareholders' Equity	1,222,500	1,194,980	'	'
Total Liabilities and Shareholders' Equity	2,251,812	2,180,810	'	'
Combined Non-Guarantor Subsidiaries [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	19,532	28,071	19,212	31,999
Trade receivables, net	99,674	88,033	'	'
Installment receivables, net	1,026	1,110	'	'
Inventories, net	118,921	100,444	'	'
Deferred income taxes	2,246	2,761	'	'
Due from Affiliate, Current	50,469	44,292	'	'
Other current assets	33,381	35,461	'	'
Total Current Assets	325,249	300,172	'	'
Investment in subsidiaries	0	0	'	'
Intercompany advances, net	181,680	179,451	'	'
Other Assets	2,017	2,044	'	'
Other Intangibles	42,720	45,009	'	'
Property and Equipment, net	50,962	53,206	'	'
Goodwill	447,043	445,566	'	'
Total Assets	1,049,671	1,025,448	'	'
Current Liabilities	'	'	'	'
Accounts payable	61,276	66,946	'	'
Accrued expenses	84,716	90,385	'	'
Accrued income taxes	10,038	6,884	'	'
Due to Affiliate, Current	9,735	4,413	'	'
Short-term debt and current maturities of long-term obligations	877	976	'	'
Total Current Liabilities	166,642	169,604	'	'
Long-Term Debt	5,654	5,481	'	'
Other Long-Term Obligations	64,660	64,806	'	'
Inercompany advances, net	62,978	52,275	'	'
Total Shareholders' Equity	749,737	733,282	'	'
Total Liabilities and Shareholders' Equity	1,049,671	1,025,448	'	'
Eliminations [Member]	'	'	'	'
Current Assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Trade receivables, net	0	0	'	'
Installment receivables, net	0	0	'	'
Inventories, net	-2,612	-3,085	'	'
Deferred income taxes	0	0	'	'
Due from Affiliate, Current	-60,942	-48,851	'	'
Other current assets	-1,810	-4,827	'	'
Total Current Assets	-65,364	-56,763	'	'
Investment in subsidiaries	-1,969,625	-1,925,177	'	'
Intercompany advances, net	-2,857,676	-2,759,205	'	'
Other Assets	0	0	'	'
Other Intangibles	0	0	'	'
Property and Equipment, net	0	0	'	'
Goodwill	0	0	'	'
Total Assets	-4,892,665	-4,741,145	'	'
Current Liabilities	'	'	'	'
Accounts payable	0	0	'	'
Accrued expenses	-1,810	-4,827	'	'
Accrued income taxes	0	0	'	'
Due to Affiliate, Current	-60,942	-48,851	'	'
Short-term debt and current maturities of long-term obligations	0	0	'	'
Total Current Liabilities	-62,752	-53,678	'	'
Long-Term Debt	0	0	'	'
Other Long-Term Obligations	0	0	'	'
Inercompany advances, net	-2,857,676	-2,759,205	'	'
Total Shareholders' Equity	-1,972,237	-1,928,262	'	'
Total Liabilities and Shareholders' Equity	($4,892,665)	($4,741,145)	'	'

Supplemental_Guarantor_Informa4

Supplemental Guarantor Information Consolidating Condensed Statement of Cash Flows (Details) (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	($13,899)	($29,964)
Investing Activities	'	'
Purchases of property and equipment	-6,898	-7,666
Proceeds from sale of property and equipment	3	9
Proceeds from Divestiture of Business, net	0	144,681
Other long-term assets	4,944	-422
Other	24	-30
Net Cash Used for Investing Activities	-1,927	136,572
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	135,734	196,399
Payments on revolving lines of credit and long-term borrowings	-127,402	-318,963
Proceeds from Stock Options Exercised	132	0
Payment of dividends	-792	-791
Net Cash Provided (Used) by Financing Activities	7,672	-123,355
Effect of exchange rate changes on cash	1,370	-597
Increase (decrease) in cash and cash equivalents	-6,784	-17,344
Cash and cash equivalents at beginning of year	29,785	38,791
Cash and cash equivalents at end of year	23,001	21,447
The Company (Parent) [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	-11,663	27,489
Investing Activities	'	'
Purchases of property and equipment	-1,360	-2,817
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	'	0
Other long-term assets	4,922	-419
Other	46	117,937
Net Cash Used for Investing Activities	3,608	114,701
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	135,734	172,878
Payments on revolving lines of credit and long-term borrowings	-125,198	-318,287
Proceeds from Stock Options Exercised	132	'
Payment of dividends	-792	-791
Net Cash Provided (Used) by Financing Activities	9,876	-146,200
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	1,821	-4,010
Cash and cash equivalents at beginning of year	1,401	5,774
Cash and cash equivalents at end of year	3,222	1,764
Combined Guarantor Subsidiaries [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	1,192	-78,678
Investing Activities	'	'
Purchases of property and equipment	-1,005	-2,338
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	'	144,681
Other long-term assets	0	0
Other	0	-63,536
Net Cash Used for Investing Activities	-1,005	78,807
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	0
Payments on revolving lines of credit and long-term borrowings	-253	-676
Proceeds from Stock Options Exercised	0	'
Payment of dividends	0	0
Net Cash Provided (Used) by Financing Activities	-253	-676
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	-66	-547
Cash and cash equivalents at beginning of year	313	1,018
Cash and cash equivalents at end of year	247	471
Combined Non-Guarantor Subsidiaries [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	-3,428	-30,512
Investing Activities	'	'
Purchases of property and equipment	-4,533	-2,511
Proceeds from sale of property and equipment	3	9
Proceeds from Divestiture of Business, net	'	0
Other long-term assets	22	-3
Other	-22	0
Net Cash Used for Investing Activities	-4,530	-2,505
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	23,521
Payments on revolving lines of credit and long-term borrowings	-1,951	0
Proceeds from Stock Options Exercised	0	'
Payment of dividends	0	-2,694
Net Cash Provided (Used) by Financing Activities	-1,951	20,827
Effect of exchange rate changes on cash	1,370	-597
Increase (decrease) in cash and cash equivalents	-8,539	-12,787
Cash and cash equivalents at beginning of year	28,071	31,999
Cash and cash equivalents at end of year	19,532	19,212
Eliminations [Member]	'	'
Condensed Financial Statements, Captions [Line Items]	'	'
Net Cash Provided (Used) by Operating Activities	0	51,737
Investing Activities	'	'
Purchases of property and equipment	0	0
Proceeds from sale of property and equipment	0	0
Proceeds from Divestiture of Business, net	'	0
Other long-term assets	0	0
Other	0	-54,431
Net Cash Used for Investing Activities	0	-54,431
Financing Activities	'	'
Proceeds from revolving lines of credit and long-term borrowings	0	0
Payments on revolving lines of credit and long-term borrowings	0	0
Proceeds from Stock Options Exercised	0	'
Payment of dividends	0	2,694
Net Cash Provided (Used) by Financing Activities	0	2,694
Effect of exchange rate changes on cash	0	0
Increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of year	0	0
Cash and cash equivalents at end of year	$0	$0